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2 Abstract 
Abstract 
This thesis presents novel investigations of three common ageing phenotypes in human 
population studies, using microarray technology to assess ‘transcriptome-wide’ expression in 
whole blood to identify mechanisms and biomarkers. 
Muscle strength is related to frailty and is predictive of disability in older persons. I assessed 
the association between transcript abundance in the InCHIANTI peripheral blood samples 
(N=695) and muscle strength. One gene (CEBPB) passed the multiple testing criteria, and is 
involved in macrophage-mediated repair of damaged muscle. I extended this work with a 
meta-analysis of over 7,781 individuals in four collaborating cohorts; expression of over 222 
genes were significantly associated with strength, less than half of which have previously 
been linked to muscle in the literature. CEBPB did not replicate in these younger cohorts. 
I then performed the first human analysis of gene expression and cognitive function (and 
separately with decline in cognitive ability over nine years) in the InCHIANTI cohort (N=681), 
and one gene was identified; CCR2, a chemokine receptor. Evidence in mice has implicated 
this gene in the accumulation of β-amyloid and cognitive impairment.  
Finally, in a collaborative project with the Framingham Heart Study I studied age-related 
inflammation – another hallmark of ageing - using a novel approach to ‘transcriptome-wide’ 
analysis; each transcript was assessed for the proportion of the association between age and 
interleukin-6 (IL6) that it statistically mediated. Very few of the genes associated with IL6 
alone also mediated the relationship with age. Findings include; SLC4A10, the strongest 
mediator, not previously linked to inflammation, and interleukin-1 beta and perforin, a 
cytokine and cytotoxic protein, respectively. 
These novel analyses highlight key molecular pathways associated with age-related 
phenotypes in whole blood and provide links between mouse models and humans. They 
provide biological insight and directions for future research. 
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Chapter 1 – Introduction 
 
Ageing is described as declining intrinsic physiological functioning over time, corresponding 
with increased mortality [1]. Tissues experience progressively decreased functioning over 
time, which manifest as age-related phenotypes and diseases including neurodegeneration, 
weakness and cardiovascular disease [2]. Experiments on rodents have shown that soluble 
factors found in the blood affect traits of ageing; rejuvenation of injured muscle, normally 
impaired in ageing, is improved by injecting mice with GDF11 (growth and differentiation 
factor 11) [3], and age-related cognitive decline can be ameliorated by countering the age-
associated increase in systemic CCL11 (chemokine C-C motif ligand 11) [4], [5]. The 
implications for anti-ageing research are profound; circulating factors can promote or inhibit 
ageing phenotypes by influencing the resident tissues, which must therefore have the 
inherent potential to regenerate and function akin to youthful tissues. However, we lack 
understanding of comparable mechanisms in humans [6], [7]. 
In this thesis I will describe epidemiological projects that investigated gene expression data 
from human whole blood to identify molecular mechanisms and biomarkers related to three 
common and well-measured traits related to ageing; muscle strength, cognitive function and 
inflammation. To introduce the projects I have carried out and to place them in context I will 
give an overview of ageing and the known risk factors of age-related diseases, and move on 
to introduce three key age-related phenotypes prominent in this thesis. Chapter 2 will give a 
detailed cohort description and methods that were used throughout the separate projects. 
Chapters 3-6 are four studies presented as scientific papers investigating the three 
phenotypes. Finally Chapter 7 summarises and discusses the findings of the studies and 
draws several conclusions. 
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1.1 Ageing and age-related diseases 
Substantial variation exists in the ageing process; although most people in the U.K. die 
between the ages of 60 and 80, individual members of the population die at strikingly 
different ages (Figure 1.1). It is common for older people to have one or more age-related 
disease, with corresponding increases in risk of mortality [8], yet there are those who “age 
well”: the “successful agers” who live beyond middle age in good health and with freedom 
from impairment [9]. Therefore although ageing is associated with frailty and illness, the 
variability inherent in ageing provides hope of interventions [10].  
The aim of most “anti-ageing” research is to decrease the proportion of one’s life that is 
encumbered with age-related diseases; to increase peoples “healthspan” (as opposed to 
lifespan), the benefits of which are numerous and include, not least, improved quality of life 
for the individual and their family, increased productivity, and decreased burden on 
healthcare systems [11]. Considerable research effort is now focused on overcoming ageing 
entirely, with some proponents (notably Dr Aubrey de Grey) even claiming that the first 1000 
year old human has already been born [12], although this view is not held by all. 
In this thesis I will present original studies of age-related phenotypes and molecular 
mechanisms in an aged human population. This work is grounded in gerontology and 
epidemiology, and focuses on identifying biochemical factors (primarily expression of genes) 
that are related to ageing phenotypes, rather than “regenerative medicine” explicitly.  
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Figure 1.1 | Number of male survivors by age in England and Wales 
 
Survival curves showing the number of male survivors by age for selected years between 
1850 and 2010. Although average lifespan has increased, there is substantial individual 
variability in “age at death” as people experience ageing in different ways.  
Data from the Office of National Statistics [13]. 
 
The “process” of ageing manifests in different ways; for instance two individuals born in the 
same hospital on the same day are unlikely to die on the same day from the same cause. 
Causes of variation in ‘rate of ageing’ can be broadly categorised into the intrinsic biology 
specific to each individual, and the environment in which they live [14]. Each individual has a 
unique genome (aside from twins; discussed later), and are exposed to different risk factors. 
Some “environmental” factors increase the rate of ageing (i.e. increase risk of death from an 
age-related disease), including exposure to pollutants [15] and smoking [16], whereas others 
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can decrease the rate of ageing, such as exercise [17] and diet [18]; the interaction between 
an individual’s nature and their environment ultimately determines their rate of ageing (i.e. 
how quickly they are likely to succumb to age-related morbidity/mortality). Finally there is an 
element of randomness to the process that is most starkly presented in genetically identical 
model organisms, where a “normal” survival curve can be observed despite identical 
genetics and environment (illustrated in Figure 1.2). The curve is very similar to those in 
Figure 1.1, despite a controlled environment and identical genomes within the control mice. 
Random factors influence individual longevity, despite there being correlations between 
genetics, environment, and population average lifespan. 
In humans, a recent meta-analysis found a relationship between age and DNA-damage [19] 
and thus, assuming that damage to DNA is related to reduced fitness, lifespan is inherently 
limited by the trade-off between the effectiveness of maintenance mechanisms and the 
accumulation of damage, which is highly dependent on environmental exposure and lifestyle. 
This is highlighted by the imperfect correlation in lifespan between twins: despite being 
genetically identical at conception their exposures and random damage differ – including 
divergence in genetics as mutations accumulate - leading to different disease risks [20]. This, 
at least in part, explains the existence of a normal survival curve in genetically identical mice 
under controlled conditions (Figure 1.2). 
However, DNA damage is not the only cellular alteration associated with ageing; nine 
“hallmarks of ageing” were recently described in a review: genomic instability, telomere 
attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular 
communication [2]. These are not mutually exclusive and are related to one another, but are 
characteristic cellular phenotypes of ageing. That ageing of peripheral tissues can to a 
degree be ameliorated in old mice by exposure to blood from young mice [6] is very 
intriguing, as it suggests that many of these hallmarks are potentially reversible. 
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Figure 1.2 | Survival curves of mice in laboratory conditions 
 
The data shows three survival curves for genetically identical mice under 3 conditions. The 
purpose of this figure is to illustrate that even genetically identical organisms in a controlled 
environment do not have a fixed lifespan; in the control group the first mouse dies around 20 
weeks of age, and the last is nearly 120 weeks. The trend in survival is altered by changing 
the environment (the exposures), yet the shape of the curve remains unchanged; there is still 
large variability (and unpredictability) in survival for individual mice. Figure from Navarro et al 
2007 [21]. 
 
 
In nature there are evolutionarily conserved genetic pathways associated with longevity 
between related species [22]. Major differences between species are in the use of these 
pathways; for instance humans, chimpanzees and mice are closely related in the protein-
coding regions of the genome, but have drastically different maximum lifespans (~90 years 
for humans, ~60 for chimps, ~3 for mice). Given the close genetic relatedness of the species 
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in the protein-coding regions the differences in rate of ageing could be in the use of the 
genes (i.e. when, where, and by how much the genes are expressed, rather than in their 
exact sequence per se) [23].  
The research presented in this thesis examines gene expression data from whole blood 
samples drawn from human population study participants to examine the difference in use of 
genes between individuals with diverse phenotypes. These studies are exploratory and 
hypothesis generating, and sought to identify molecular biomarkers and elucidate 
mechanisms associated with ageing that may in the future help predict individuals at higher 
risk of age-related disease (who could be interpreted as “fast agers”) and may also highlight 
plausible mechanisms for future research. Before commencing an epidemiological study on 
age-related phenotypes it is important to understand the known factors that could influence 
or confound the relationship under examination; the following section describes some of the 
current known risk factors of ageing, health, and frailty. 
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1.2 Traditional risk factors and biomarkers 
Determining predictive and modifiable risk factors of disease are central goals of 
epidemiological studies. Some are well known (tobacco exposure is the single largest 
modifiable risk factor for age-related diseases [24]), whereas others may have more subtle 
effects. Biochemical risk factors predictive of age-related disease include, but are not limited 
to; interleukin-6 (IL-6) and other immune markers [25]; uric acid [26]; and vitamin D [27]. 
However, this is not an exhaustive list (see the recent review by Sorrentino et al describing 
“gerontogens;” toxicants that accelerate ageing [28]), and there is much variation in longevity 
beyond the known biomarkers yet to be accounted for.  
Social status is associated with health and can be predictive of disease [29]. It is typically 
measured as “income”, “highest education level attained”, or some similar definition. Social 
status encompasses many related exposures and behaviours, from “living conditions” to 
“availability to healthcare” to “physical activity/labour at work”, which could all impact on 
exposure to risk factors and lifestyle. 
Lifestyle factors often have large effects on health and longevity, many of which – including 
smoking as already mentioned – are easily modifiable, but require people to take a physically 
or mentally active role in ‘administering’ the treatment, be it giving up smoking, or being more 
physically active. The beneficial effects of exercise or physical activity are still debated in 
some areas; a recent systematic review and meta-analysis of randomised controlled trials 
(RCT’s) found large inconsistencies in associations between resistance training, aerobic 
exercise, and Tai Chi, and indicators of cognitive performance/decline [30]. The 
inconsistencies could be due to differences in study design or the administration of exercise, 
as epidemiological studies have previously reported a protective effect of physical activity on 
cognitive function both in mid- and late-life [31], [32], as well as other age-related traits, such 
as cardiovascular function [33]. 
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Many of the above quantifiable traits relate qualitatively to a one’s physiological reserve, 
which affects the body’s vulnerability to diseases and morbidities, and ultimately to mortality 
at older ages [34]. This relates quantitatively to ‘frailty’, recognised as more than simply the 
most severe disease an individual presents clinically, but instead is expressed as increased 
vulnerability over time and reduced ability to recover after a serious destabilising event [35]. 
Three traits in particular can be predictive (epidemiologically) of morbidity or mortality in later 
life by contributing to older peoples frailty, and will be the focus of this thesis; declining 
muscle strength [36], declining cognitive function [37], and increased (chronic) levels of 
peripheral inflammatory cytokines [38]. These traits are correlated cross-sectionally in the 
InCHIANTI cohort (Table 1.1). 
 
Table 1.1 | Pearson correlations between age and three ageing traits 
 
 
 
 
 
 
 
 
 
 
1.2.1 Muscle Strength 
Low mid-life muscle strength (measured using grip strength) is strongly associated with 
reduced physical function and higher risk of mortality in later life [39], independent of 
adiposity (although other studies have found their relationship dependent in older persons 
[40]). Grip strength is a marker for overall strength and frailty [41], is commonly measured in 
population studies, correlates with overall body strength in older individuals [42], and is 
therefore utilised in the projects in this thesis. The definition of sarcopenia [43] also includes 
decreasing muscle mass with age, however changes to the composition of muscle tissue (for 
instance infiltration of intramuscular adipose and connective tissues) also contribute to 
  Age Strength MMSE 
Age 1   
Strength -0.579 1  
MMSE -0.462 0.447 1 
IL-6 0.422 -0.307 -0.251 
 
Strength: hand grip strength (kg),  
MMSE: mini-mental state examination, 
IL-6: interleukin-6 (pg/dL). 
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reduced strength [44], therefore strength can be lost without any apparent change in mass. 
The reasons for this are unclear, but impairment in the regeneration/homeostasis of muscle 
tissue could be due to reduced numbers of functional muscle stem cells available, or the 
aged muscle providing a non-favourable environment [45]. Evidence in mouse-models shows 
that muscle tissue from aged mice has the capacity to regenerate when transplanted into 
younger mice, and that muscle from young mice regenerates poorly in older mice [46]. This, 
coupled with the knowledge that the immune system plays a critical role in muscle 
maintenance [47] and is also impaired by ageing [48], suggests that one mechanism 
determining the success of muscle regeneration and maintenance is the circulating 
environment, which is known to change with age. Again, the implication is that aged tissues 
have the capacity to regenerate under normal (young) biological conditions, but the aged 
systemic milieu inhibits (or does not promote) this process. In Chapter 3 a study of 
peripheral gene expression associations with muscle strength is reported, and in Chapter 4 
this is extended to a meta-analysis of multiple independent cohorts. 
 
1.2.2 Cognitive Function 
Declines in cognitive function are common in ageing; the prevalence of dementia – a 
syndrome which encompasses a range of symptoms from declines in memory to impaired 
reasoning and judgment [49] – increases dramatically with age (Table 1.2). Alzheimer’s 
disease (AD) is the most common form and is pathologically characterised by neuronal loss, 
β-amyloid plaques, and neurofibrillary tangles [50]. Inflammation – both in the brain and 
outside the central nervous system (CNS) - is recognised as a key feature of cognitive 
dysfunction and dementia [51]. In particular there is evidence that with ageing there is a 
progressive decline in the effectiveness of the blood-brain-barrier (which separates the CNS 
from the peripheral blood) [52], although to what extent age-related chronic peripheral 
inflammation is involved is unclear. Mouse-model parabiosis experiments (where two 
organisms are attached allowing sharing of their blood) have shown that neurological and 
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cognitive declines with age could be due to changes in blood-borne factors [4]. Following 
publication of Chapter 5 of this thesis (a study of peripheral gene expression associations 
with cognitive function) in 2012 evidence is increasing for an interplay between resident 
immune cells in the brain and the peripheral immune system [53], [54]. 
 
Table 1.2 | Prevalence rates of dementia in the UK 
In 2014 an estimated 850,000 
people in the UK had dementia, 
with the prevalence increasing 
dramatically with age. Data from 
the Alzheimer’s Society [55]. 
 
 
 
1.2.3 Chronic inflammation 
Sustained low-level (chronic) systemic inflammation is common in ageing [56]. Inflammatory 
biomarkers IL-6 and C-reactive protein (CRP) are commonly used in such studies to indicate 
inflammation; both are associated with increased risk of numerous diseases including 
cognitive decline [57], and clinically relevant cut-points have been identified that are 
associated with poor physical performance and muscle strength in older people [58]. This 
age-related pro-inflammatory state is hypothesised to be detrimental by damageing tissues 
“directly” (with continued production of cytotoxic compounds by immune cells), “indirectly” (by 
altering the phenotype of peripheral tissues, for instance by promoting cellular senescence 
[59]), or by another means, such as disrupted insulin signalling [60]. In Chapter 6 the results 
of the first study into the gene expression mediators of the association between age and 
inflammation in humans is reported; this is distinct to our study of gene expression 
associations with circulating IL-6 levels independent of age [61], published separately and 
does not form part of this thesis.  
Age group, years Male Female 
60-64 0.1% 0.2% 
65-69 1.0% 1.5% 
70-74 2.4% 3.1% 
75-79 6.5% 5.1% 
80-84 13.3% 10.2% 
85-89 22.2% 16.7% 
90-94 29.6% 27.5% 
95+ 34.4% 30.0% 
 PhD Thesis | Luke Pilling 
23 Chapter 1 – Introduction 
1.3 Molecular mechanisms 
In this section I will review the genetic (and other molecular) risk factors of diseases, leading 
on to introduce the work included in this thesis. 
 
1.3.1 Genetic risk factors 
Many ageing traits are highly heritable, including muscle strength (30-85% heritability) [62], 
IL-6 levels (29-49% in an African population) [63], and cognitive function (35-74% depending 
on the specific domain of cognition studied) [64], suggesting that inherited genetic variation 
between people have a large impact on these traits. Studies of common genetic variation 
associated with disease predominantly focus on single-nucleotide polymorphisms (SNPs), 
which are single base-pair substitutions in the DNA (which account for 88% of the variants in 
dbSNP (build 135), the database of known genetic variation between individuals [65]). So far 
studies of associations with longevity have found very few replicable variants; the APOE 
locus is a notable exception [66], [67], although some promising candidates, including a 
variant previously associated with blood-pressure in region 5q33, have recently been 
identified [67]. There doesn’t seem to be a single gene or pathway that confers longevity, 
with many plausible candidates identified in model organisms not translating to human 
populations [68]. I will here summarise the known genetic contributors to longevity in 
humans. 
The United States National Human Genome Research Institute provides an up-to-date 
catalogue of published Genome-Wide Association Studies (GWAS), known as the “GWAS 
catalog” [69]. On 29th July 2014 this contained (after excluding associations with p-value’s 
greater than 5x10-8, an often used cut-off for GWAS) 7609 records pertaining to 5005 unique 
SNPs associated with 684 diseases and/or traits. Just assessing age-related diseases/traits 
(81 at the time of writing, everything from Alzheimer’s disease through cardiovascular 
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disease, diabetes and cancer) there are 789 unique SNPs. Although there are many variants 
that increase the risk of individual age-related diseases, the APOE locus is the only robust 
GWAS result associated with longevity specifically (though other candidates exist). DNA 
variants in APOE are implicated in a variety of age-related diseases including Alzheimer’s 
disease (AD) and cardiovascular disease (CVD) [17] (this paper puts forward an interesting 
argument for the evolution of the e4 allele; that the negative effects of inheriting the risk allele 
may be ameliorated by exercise, and it is only recently that activity levels in the general 
population have dropped sufficiently for the negative effects of the e4 allele to manifest [17]). 
p16INK4a (9p21.3 locus) is also associated with a number of age-related diseases [70], but is 
not prominent in GWAS of longevity. No other genetic variant or gene in the catalogue has 
been robustly (i.e. with multiple replication studies) associated with >1 age-related disease or 
longevity itself (although there are some interesting candidates including FOXO3a and 
LMNA), so there is little evidence for common “ageing” (or longevity) variants in humans at 
the genetic level, albeit using current techniques which do not assess every nucleotide, and 
may rely on imputed variants that require further validation.  
The above observations agree with a publication by the Leiden group (a study of long-lived 
individuals in the Netherlands) that long-lived individuals are not enriched with the protective 
alleles of GWAS-identified disease risk variants compared to controls [71]. Thus to achieve 
longevity you may need more than just not inheriting disease-associated genetic variants. 
Reports that offspring of long-lived parents have reduced risk of age-related diseases 
(including cancer and cardiovascular disease) compared to age-matched controls, 
independent of socio-economic status and a number of other factors [72], have a profound 
implication; that there may be “longevity alleles” yet to be discovered (APOE is the best 
candidate yet) that do more than just protect against disease, but actually extend lifespan. 
That these have not yet been identified may highlight the heterogeneity of the ageing 
process, lack of clear “phenotype” in studies of longevity, limited sample sizes available, 
inadequate analysis methods to take into account the additive effects of many small-effect or 
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rare variants, or that other factors such as epigenetics (introduced in section 1.3.3) play a 
more important role. 
Of note are several rare monogenic diseases that present accelerated ageing (progeria) 
phenotypes, including Werner’s syndrome and Hutchinson-Gilford Progeria Syndrome 
(HGPS) [73], the latter of which is caused by a mutation in the LMNA gene noted earlier as a 
candidate for longevity identified by GWAS. HGPS to some degree replicates phenotypes 
associated with normal ageing, in particular hair loss, skin problems and atherosclerosis, but 
also premature death due to stroke and coronary dysfunction [74] (mean age at death was 
12.6 years in this study). Efforts have been made to study accelerated ageing phenotypes for 
clues to “normal” ageing mechanisms; lamin A (the protein product of LMNA, also called 
progerin) is expressed at high levels in individuals with HGPS-causing mutations and 
promotes atherosclerosis in vascular cells [75]; in individuals without a HGPS-causing 
mutation expression increases with age [76] suggesting that there may be a causal link.  
 
1.3.2 Gene expression 
The central dogma of molecular biology (Figure 1.3) is that information in the genome needs 
to be transcribed to RNA (a functional molecule, as well as an intermediate to proteins [77]) 
in order to be “used” by the cell – messenger RNAs are translated by ribosomes into 
proteins, and non-coding RNAs may function to regulate transcription of other genes. 
However, despite all cells in an organism containing the same genetic information (with the 
exception of a small few, e.g. B-lymphocytes have a hypervariable region to increase 
antibody diversity) the phenotypes can be drastically different. The temporal and spatial 
variation in expression (and processing) of gene transcripts – as the information in the DNA 
is transcribed to RNA in different cells and tissues at various time points – gives rise to the 
multitude of cellular phenotypes possible from the single genome available to organisms. By 
measuring levels of specific transcripts and asking which transcripts are related to diseases 
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or phenotypes we can gain insight into mechanism and pathways, as well as potentially 
identify biomarkers of disease [23].  
 
 
Figure 1.3 | The central dogma of molecular biology 
 
The central dogma of molecular biology is that “DNA makes RNA makes Protein”. This is 
over simplified but demonstrates that all functional molecules (RNA and proteins; RNA 
molecules can have many functions beyond simply “messenger” RNA) are derived from 
information in the DNA. Cellular and tissue specificity is dependent upon the exact product 
that is produced (when, where, how much, what form), which is reliant on not just the 
“coding” sequence that makes the final product, but the extensive regulatory elements that 
can be many kilobases away (only 64% of enhancers have at least one transcriptional-start-
site within 500 kilobases [78]) and are regulated by epigenetic mechanisms. Figure from 
Pilling et al 2012 [23]. 
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Large scale peripheral (blood-derived) gene expression studies in humans are now feasible 
due to the rapid expansion of methods such as microarray technology (described in the 
methods) in cohort studies, that assay the expression of many thousands of transcripts 
simultaneously. Studies by colleagues in our group which I have been involved in found that 
many gene expression profiles are associated with age and that the ratio of isoforms of some 
genes is age-related [79], and that RNA processing itself is related to ageing [80]. This 
suggests that regulation and “fine tuning” of gene expression transcripts and isoforms may 
be age-related, which is further supported by a study showing that common disease-
associated variants are localised to regulatory DNA [81].  
The whole blood transcriptome of an individual is stable over a time period of several months 
[82]. Although this study had a small sample size (n=22) the authors found that there was 
high within-subject correlation (>0.94 Spearman correlations) for all probes, while some 
differed seasonally. This re-enforces the suggestion that blood-based gene expression has 
the potential to become robust biomarkers, for example in the diagnosis of diseases such as 
Alzheimer’s, where a panel of expression markers can identify cases and controls with 
reasonable (>75%) accuracy [83], [84]. Mechanistically, the blood-brain-barrier (that under 
normal conditions keeps the milieu in the brain separate from that in blood) degenerates in 
ageing and is correlated with cognitive decline [52]; therefore observing markers correlating 
with neurodegeneration in the blood is plausible. Gene expression has also been analysed in 
cancer cells (for instance in gastric cancer [85]) and can differentiate between different types 
and grades of cancer; this is typically done by measuring a panel (from tens to hundreds) of 
genes from the cancerous tissue. In breast cancer there are studies showing that using 
expression of just 30 ion channel genes has prognostic value [86]. 
The relevance of studying blood in relation to age-related diseases and phenotypes is clear; 
not only is chronic inflammation (immunosenescence) a widely accepted hallmark of ageing 
[87] but evidence from mouse-models of both age-related sarcopenia (loss of muscle 
function) and neurodegeneration (cognitive impairment) show that circulating factors drive 
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some of the changes, and that the tissues have the inherent capability to regenerate given 
the correct signal [4], [46]. Additionally, it is possible to estimate people’s biological age (an 
individual’s relative functioning to chronologically age-matched peers) using whole-blood 
gene expression only, and identify those who are biologically older than their age-matched 
peers [88], admittedly with limited precision. These individuals have lower muscle strength 
and higher levels of inflammation, consistent with the ageing phenotype. So the use of 
peripheral (whole blood) gene expression for observational analyses is logical and provides a 
novel avenue for research into biomarkers and molecular mechanisms of common diseases 
and traits in humans. 
Two of the studies (Chapter 3 and Chapter 5) described in this thesis were performed at a 
time when relatively few population cohorts had gene expression measures on many 
samples, so replication at the time was not possible. For Chapter 4 a meta-analysis 
including over 7000 participants is presented, and in Chapter 6 collaboration with the 
Framingham Heart Study was possible. At the time of writing in 2014 we are now in the 
position to participate in a number of these large meta-analyses, in particular in the CHARGE 
(Cohorts for Heart and Ageing Research in Genomic Epidemiology) consortium. The seminal 
CHARGE gene expression analysis of age included more than 15,000 participants in >12 
studies [76], and many age-related phenotypes and diseases are currently under 
examination. 
 
1.3.3 Epigenetics 
In order to achieve the breadth of cellular phenotypes possible from a single genome, with 
huge amounts of adaptability and plasticity, there are numerous regulatory systems that 
tightly control when and by how much transcripts are expressed (substantially simplified in 
Figure 1.3), which ultimately regulate RNA polymerase II [89]. Epigenetics refers to the 
ability of various cells to maintain stable gene activity over time and through many replication 
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events without any change to the sequence of the DNA [90]. There are a variety of 
mechanisms used by cells to control whether genes are transcribed including, but not limited 
to; DNA methylation (DNAm), histone modifications, chromatin structure, and even non-
coding RNA molecules that affect translation post-transcriptionally [91]. 
DNAm is the addition of a methyl group to the 5th carbon of a cytosine in DNA, making 5-
methylcytosine (5mC). There are other modifications (such as 5-hydroxymethylcytosine, 
5hmC) that could have distinct functions [92], but currently research is limited as to the 
importance of this modification. DNAm occurs at cytosine-guanine dinucleotides (abbreviated 
to CpG; cytosine-phosphate-guanine), and is part of the developmental process 
distinguishing lineages of cells. There are growing bodies of evidence linking methylation of 
specific CpG’s with diseases and phenotypes, for instance in cancer (albeit with small 
sample sizes) [93], type-2 diabetes (T2D) [94] and age itself [95].  
Chromatin (and histones) provide the three-dimensional scaffold around which DNA is 
wound, which not only allows compression of DNA but also regulates “accessibility” of DNA 
to translational machinery, which in turn affects expression [96]. Studies have shown that 
ageing is associated with reduced chromatin “organisation”, possibly as a result of molecular 
damage [97], [98]. 
Although epigenetic data is not incorporated into these studies it remains entirely relevant to 
future work, as gene expression associations observed in the studies may be causally linked 
to specific epigenetic mechanisms. 
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1.4 Advancements in model organisms 
“Model organism” is a term used to encompass any organism studied in a laboratory 
environment to dissect biological mechanisms [99]. There are several strengths to this 
approach, not least that model organisms live much shorter lives than humans (so 
experiments take less time), but also experiments not ethically viable in a human population 
can be performed on model organisms, and the experimental environment can be controlled 
and manipulated. Additionally, the genetics of the organisms can be controlled and 
manipulated, and access to samples from multiple tissues and time points are relatively easy 
to acquire and study. However, weaknesses include inconsistent translation to human data, 
at least partly due to the genetically homogeneous populations used as models that are not 
representative of the complex interactions present in wild populations, but also due to 
intrinsic inter-species biological differences [68]. 
 
1.4.1 Blood-borne factors affect ageing phenotypes 
One of the most critical discoveries made possible by rodent models is that rejuvenation of 
tissues (particularly muscle, liver and brain) of aged animals can be achieved by exposure to 
blood from a younger animal, first discovered in 1972 [100]. This is possible using a 
technique known as parabiosis, where two organisms are surgically attached so they share a 
circulatory system, and are therefore exposed to the soluble factors therein [101]. By 
attaching an old mouse to a young mouse (“heterochronic parabiosis”) it is possible to 
observe the physiological effects of exposing aged tissues to a young circulating 
environment [6]. There are a number of beneficial effects on the old mouse, including 
improved regenerative capacity of muscle stem cells [102], and negative effects on the 
young mouse, such as decreased synaptic plasticity and cognitive function [4]. These 
experiments in the genomic era now provide an unprecedented opportunity to discover the 
 PhD Thesis | Luke Pilling 
31 Chapter 1 – Introduction 
exact factors in the circulatory system that rejuvenate old mice, and conversely which factors 
from old mice inhibit young tissues. 
Reviewed in 2014 by Bitto and Kaeberlein [6], two factors in particular have been highlighted 
by a number of recent experiments; growth and differentiation factor 11 (GDF11) levels in the 
blood decrease with age, and exposing old mice to GDF11 improved muscle function, 
neurogenesis, and a number of other physiological measures [3]; conversely levels of C-C 
motif chemokine 11 (CCL11) in blood increase with age, and exposing young mice to CCL11 
impairs neurogenesis, muscle function, and tissue regeneration [4]. Although human 
evidence is currently limited, studies such as those performed in this thesis hope to shed 
light on circulating mechanisms and biomarkers associated with ageing phenotypes. 
 
1.4.2 Models of longevity 
In ageing research analysis of many different species have highlighted conserved 
evolutionary pathways related to longevity between species [103], and not only this, that 
these mechanisms can be altered to influence the longevity of a species [104]. This suggests 
that these interventions are either altering the amount of “damage” done to the organism that 
causes ageing, or the “repair” of the damage is improved. However, the translation to human 
population genetics is very limited [68]. 
The most effective intervention that increases lifespan in model organisms (from fruit flies to 
mice) is “simply” restricting the caloric intake of the organisms [105]. This appears to affect a 
number of pathways, including mTOR and insulin signalling. Recently completed parallel 
experiments in Rhesus Macaques (a type of Old World monkey) at two institutes found 
conflicting results, possibly due to differences in control monkeys; the study that found a 
significant survival advantage in calorie-restricted monkeys fed the control animals ad 
libitum, whereas the study with no effect limited the food intake of the controls [106]–[108]. 
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Human evidence is inconclusive, but there are suggestions of cardiovascular benefits in 
observational studies [109]. 
Senescence in cells - permanent cell-cycle arrest – is hypothesised to contribute to 
senescence at the organismal level (ageing) as cells begin to express a Senescence-
Associated Secretory Phenotype (SASP) which is pro-inflammatory and potentially 
oncogenic [59], [110]. Senescence in cells can be caused by multiple factors including DNA 
damage, telomere shortening, and oxidative stress, and is hypothesised to have evolved as 
an anti-tumour-progression system that removes cells from the cell-cycle if sufficiently 
stressed [111]. In 2011 a seminal study was published in which the authors used a mouse-
model of accelerated-ageing and a transgene which allowed inducible elimination of 
senescent cells (those which express high amounts of p16INK4a) to show that removal of 
senescent cells from tissues in vivo delays ageing-associated phenotypes [112]. Whilst the 
study has limitations (the ageing-accelerated mice are not a natural population) and as yet 
no practical use (due to the nature of the genetically modified mice) the implication is quite 
clear; that removing senescent cells may present a viable treatment option for some age-
related diseases or traits, after a lot more research. It is worth noting that although the mice 
were protected from some age-related pathologies (sarcopenia, cataracts, and loss of 
subcutaneous fat [112]) the mice did not actually live longer; this may be a manifestation of 
the age-accelerated nature of the mouse model, or it could be that reducing senescent cell 
build-up in peripheral tissues may increase healthspan (improved muscle function and 
eyesight, for instance) specifically, rather than lifespan [110]. 
Mouse models of particular phenotypes are used extensively in biomedical research to 
understand mechanisms; for instance in Chapter 3 (examining muscle strength) the findings 
parallel a mouse model which has a particular pathway reduced in macrophages that causes 
a muscle-loss-like phenotype [113]. Similarly in Chapter 5 (examining cognitive function) the 
literature contained information on mice with accelerated AD-like symptoms that were 
concordant with the results [114]. The utility of model organisms in research has clear value, 
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taken with the results of observational evidence in humans and an awareness of the 
limitations of both types of research. 
 
1.5 Summary 
The variability in the ageing process, affected by many factors including genetics, exposures, 
and lifestyle choices, make it inherently hard to predict; common indicators of ageing include 
loss of muscle strength, declines in cognitive ability, and sustained chronic inflammatory 
load. The specific molecular pathways and mechanisms remain to be elucidated in humans, 
although promising targets have been identified in mouse models, and epidemiological 
studies are necessary to understand what occurs in natural human populations during 
ageing.  
Studies of gene expression in whole blood could identify biomarkers useful for determining 
“biologically old” individuals at highest risk of frailty, and highlight plausible biological 
mechanisms when accompanied by evidence from laboratory models and cell-culture 
experiments. Expression of genes is at the intersection between the physiological measures, 
genetic factors, and environmental exposures, and could prove crucial to many age-related 
traits and diseases. Of particular importance is the identification of biomarkers with 
prognostic value, and identifying mechanistic pathways driving or responding to age-related 
changes. 
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1.6 Aim and objectives 
The aim of this thesis is to contribute to the existing knowledge base with exploratory 
analyses into whole blood transcriptome alterations in age-related traits, in vivo in human 
populations, aiming to elucidate mechanisms and discover biomarkers. I have analysed three 
common well-established ageing phenotypes that are easily measured, not disease-specific, 
and for which predictive markers would be of great value: muscle strength, cognitive function, 
and inflammation. The studies are hypothesis generating, therefore in each paper the 
majority of time is spent attempting to interpret the associations observed; hypothesising why 
the associations are observed. Many similar publications in the literature are sorely lacking in 
the interpretation of their results and simply report associations; this work aims to go further.  
This was achieved by the completion of a number of epidemiological analyses in the 
InCHIANTI study, a human population study of ageing, and where possible with replication in 
other studies. This hypothesis-free approach accompanied by extensive reading of the 
literature has led to valuable contributions to the knowledge-base. The objectives of the 
individual studies were as follows, and correspond to the data chapters of this thesis; 
3. To identify the transcripts in human whole blood samples most closely associated 
with muscle strength, a known marker of frailty, 
4. To lead a meta-analysis within the CHARGE consortium investigating the 
transcriptome associations with muscle strength, and their relation to ageing, 
5. To identify the transcripts most closely associated with cognitive ability, known to 
decline with age, 
6. To identify the transcripts most closely associated with inflammation, specifically the 
age-related increase in chronic inflammatory load, 
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Chapter 2 – Methods 
 
Each data chapter 3-6 is an individual body of work in the form of a published paper, and 
therefore have methodology sections relevant to that work. However, due to journal 
requirements the methods are described in brief; here I will discuss them in more detail, but 
may in part seem repetitive in order to be clear. 
 
2.1 The InCHIANTI study (Invecchiare Nel Chianti) 
The InCHIANTI study of ageing included 1453 members of the Italian population at two sites 
(Greve in Chianti, and Bagno a Ripoli) in the Tuscany region of Italy between 1998 and 1999 
for their baseline visit [115]. The participants were invited back every three years, and in 
2014 the participants returned for their fourth follow-up visit. From the onset this was a study 
designed to investigate the reduced mobility of elderly people, and as such at baseline “650 
persons aged 65 years or more was drawn from the population registry […] then, random 
samples of 50 men and 50 women were drawn from the age strata 20-29, 30-39, 40-49, 50-
59, 60-64 years” (Figure 2.1a) [116]. The analyses presented here utilise data from the third 
follow-up visit (2007/08), where the mean age of the participants is 73 years (range 30-104, 
Figure 2.1b). Once available, the 2014 data will used for prospective analyses. 
A high response rate to surveys imply more accurate data, as using the results of analyses to 
generalize about the population requires a representative sample (that is, the responders do 
not differ from the non-responders). The response rate for the InCHIANTI study was very 
good, particularly in the elderly; of 1270 persons aged ≥65 who were chosen randomly from 
the population register, 1154 were eligible (i.e. had not died or moved away) and chose to 
participate (91.6%). The response rate was lower for people aged ≥85 (78%), possibly due to 
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mobility problems or illness, and was also lower for people aged <65 (69.4%), possibly due 
to other commitments (participants were required to spend several days with the 
investigators). 
 
Figure 2.1 | The age distribution of males and females in the InCHIANTI study 
 
The plot shows back-to-back histograms portraying the distribution of ages for males and 
females separately in the InCHIANTI study. The top panel (A) shows the baseline 
distributions (1998/1999), the bottom panel (B) shows the participants in 2007/2008 during 
their third follow-up visit after baseline. SD=standard deviation. 
Number of individuals 
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InCHIANTI is an ideal resource for the analyses presented in this thesis; the cohort covers a 
wide age range, and is rich in older individuals and phenotypes relevant to age-related 
research. These include cognitive assessments (to determine those with cognitive 
impairment/ dementia), “frailty”-related phenotypes (muscle strength, walk-speed, etc), and a 
battery of blood markers including interleukin-6 (IL-6) and broad cell counts (including 
neutrophils, lymphocytes and monocytes). The primary measures used in this thesis are 
presented with summary statistics in table 2.1, for the individuals who participated in the 
follow-up 3 examination, and have gene expression and cell-count data (n=695; see section 
2.2 for inclusion information). 
 
Table 2.1 | InCHIANTI cohort summary statistics 
    All participants Aged <65 Aged 65:84 Aged ≥85 p-value 
 
    
    N n (%) 695 (100) 161 (23.2) 429 (61.7) 105 (15.1) 
 Sex (females) n (%) 382 (55) 82 (51) 228 (53) 72 (69) 9.8E-03 
Age min : max 30 : 104 30 : 64 65 : 84 85 : 104 
 
 
mean (SD) 72.2 (15.3) 47.6 (10) 77.5 (4.2) 88.4 (3.9) 
 Smoking Never, n (%) 381 (54.8) 77 (47.8) 234 (54.5) 70 (66.7) 3.2E-03 
status Former, n (%) 240 (34.5) 41 (25.5) 171 (39.9) 28 (26.7) 4.1E-01 
  Current, n (%) 74 (10.7) 43 (26.7) 24 (5.6) 7 (6.7) 1.1E-09 
Stature Height (cm) 161 (9.8) 167 (8.9) 160 (9) 155 (9.3) 6.3E-24 
mean (SD) Weight (Kg) 70 (13.8) 74 (15.8) 71 (12.5) 62 (12.7) 1.3E-10 
 
Waist (cm) 95 (12.1) 91 (13.7) 97 (10.9) 93 (12.2) 2.1E-02 
Cell counts Neutrophils (%) 57.5 (9.1) 55.1 (8.4) 58.2 (9.1) 58.3 (9.6) 1.3E-03 
mean (SD) Lymphocytes (%) 30.9 (8.7) 34 (7.7) 30.1 (8.7) 28.9 (8.7) 2.9E-07 
  Monocytes (%) 8 (2.1) 7.5 (1.8) 8.1 (2.2) 8.3 (2.1) 1.7E-03 
  Eosinophils (%) 3.2 (2.1) 2.9 (1.8) 3.1 (1.9) 4 (3.1) 2.2E-04 
Hand grip Males: mean (SD) 37.6 (11.6) 51 (9.5) 34.4 (7.8) 25.4 (7.4) 4.2E-46 
strength (Kg) Females: mean (SD) 21.6 (6.9) 30.1 (5.3) 20.4 (4.9) 15.5 (5.1) 1.1E-49 
MMSE * mean (SD) 25.6 (5.6) 29.2 (1.6) 25.5 (4.6) 20.3 (8.6) 1.4E-39 
  MMSE <24, n (%) 144 (20.9) 3 (1.9) 87 (20.4) 54 (54) 5.5E-23 
  MMSE ≥24, n (%) 544 (79.1) 158 (98.1) 340 (79.6) 46 (46) 2.3E-26 
Interleukin-6 min : max 0.38 : 13 0.38 : 13 0.58 : 13 1.2 : 13 
 (pg/mL) ^ mean (SD) 3.8 (3) 1.98 (1.6) 3.99 (2.9) 5.86 (3.6) 3.5E-28 
              
* for MMSE 688 of 695 participants have this data; ^ for interleukin-6, the maximum value was capped at 13 pg/mL 
p-value from ANOVA 
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2.2 Gene Expression Quantification 
Upon collection of the whole blood samples from the participants, 2.5ml of whole blood was 
stored in PAXgene Blood RNA tubes to preserve the levels of mRNA transcripts, which 
would otherwise degrade [117]. PAXgene tubes contain reagents that protect RNA 
molecules from degradation by RNases and prevent further gene expression [118]. RNA was 
then extracted using the PAXgene Blood mRNA kit (Qiagen, Crawley, UK), which includes 
the following steps; centrifugation to remove cellular debris, addition of buffers and 
proteinase K to digest proteins and stabilise pH, addition of ethanol to improve binding 
conditions, and finally brief centrifugation in a RNA spin column which selectively binds the 
RNA, allowing contaminants to wash through. DNase enzymes digest any residual DNA to 
reduce contamination, and the resulting RNA was stored for later analysis [118]. All of the 
PAXgene processing was performing in Italy within days of collection (RNA is stable for at 
least 3 days after collection [117]). Although variation was minimised as much as possible, 
stabilisation of RNA has many possible sources of error; plastic and glassware was 
eliminated of any residual RNases, all work was performed in an RNase-free environment, 
and contamination by bacteria or fungi is possible so aseptic technique was followed [118].  
The development of array-based technologies has revolutionised the types of analysis that 
can be conducted using data from a single experiment. Although second-generation 
sequencing (or next-generation, as it was known) is now quicker, more accurate, and more 
affordable than ever before [119], the use of microarrays is still the prominent method for 
large human cohorts [69], due to their comparative cost and laboratory time. Gene 
expression arrays are used to determine the relative amounts of many different cDNA 
(complementary DNA, derived from RNA) molecules in a sample, and I have made extensive 
use of these during the studies described in this thesis.  
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2.2.1 Illumina HumanHT-12 v3 Expression BeadChip Kit 
In 2008, during the third follow-up visit (“year 9”) of the InCHIANTI study participants, the 
current Illumina gene expression array (the Illumina HumanHT-12 v3 Expression BeadChip) 
was used for relative abundance estimation of the RNA in the peripheral blood of the 
participants. Professor Andrew Singleton’s group at the National Institute of Aging (NIA) in 
the USA carried out the wet lab work for the arrays. I will here describe the chip using 
information from the data sheets provided by Illumina [120]. 
Conceptually the arrays work as follows; there are a number of ‘probes’ bound to the array 
(each made of 50bp sequences of DNA) that hybridise (bind) to complementary strands of 
nucleotides, such as cDNA (PCR-amplified RNA) from a sample. Once hybridisation has 
completed the array is put onto a scanner that excites fluorescent markers only on those 
probes with bound cDNA; therefore the degree of fluorescence reflects the relative 
abundance of the cDNA in the sample (and therefore the relative amounts of RNA in the 
original blood sample). This is shown in figure 2.2. 
 
Figure 2.2 | Showing a sequence of cDNA binding to a probe on an array. 
The cDNA molecule 
(blue) matches the probe 
sequence, binds to it and 
fluoresces in the Illumina 
scanner. Additional 
“address” sequences are included for technical reasons (systematically identifying probes). 
“Beads”, such as on the left, make up the “surface” of the array to which the probes are 
bound; many beads are used in a single array. Figure from Illumina Inc. [121] 
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Described next are the various processes and pipelines used to ensure data quality 
(compiled from [79], [122]), which were carried out by members of Professor Tim Frayling’s 
group in Exeter; Illumina’s BeadStudio software was used to ‘normalise’ the arrays to remove 
as much technical variability between the experiments (arrays) as possible. Each probe is 
given a corresponding ‘detection p-value’ which indicates whether the probe was determined 
to have fluoresced to a significant degree above the ‘background’ level (noise). P-values < 
0.01 were taken as significant expression – values above this were not deemed to be 
significantly different from the background. We also excluded ‘outlier’ arrays (subjects) that 
appeared to have unusually high or low expression (fluorescence) intensities; arrays were 
excluded from analyses if the mean intensity for the whole array was greater or less than 3 
standard deviations from the cohort median. Probes were excluded from further analysis if 
they were significantly expressed in <5% of the participants. Of the 710 subjects that had 
array profiling on their peripheral blood RNA, 698 passed this quality control procedure, with 
16571 of the 48803 probes also going forward into future analyses. The array data is publicly 
available via the Gene Expression Omnibus (unique ID: GSE48152) [123]. 
The data that are then passed to analysts comes in matrix format, with ‘Probe IDs’ on one 
axis, and participant identifiers on the other. The probes are then used like any other variable 
in an epidemiological analysis. 
 
2.2.2 Affymetrix microarray comparison 
In chapters 4 and 6 of this thesis we collaborated with the Framingham Heart Study (FHS), 
which used a different microarray platform, the Affymetrix GeneChip Human Exon 1.0 ST. 
This differs from the Illumina HumanHT-12 array which has 48803 probe sequences; the 
Affymetrix Exon array has over 5 million, with multiple probes mapping to each exon in 
recognised genes that combine into probesets (www.affymetrix.com). This allows more 
robust estimates as the reliance on individual probe data is reduced, and allows gene-
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averages to be computed for comparison to the Illumina data. 17,876 gene-level probesets 
are available from this platform. 
 
2.2.3 Quantitative Real-Time PCR 
It is widely considered that technical replication of microarrays using quantitative real-time 
polymerase chain reaction (qRTPCR) techniques is essential, as the microarrays, although 
very useful, are inherently less accurate than qRTPCR (<80% agreement) [124]. qRTPCR 
concurrently amplifies (replicates) cDNA molecules in a sample and quantifies the 
abundance of specific transcripts using pre-designed sequences (probes). The Applied 
Biosystem's TaqMan Low Density Array (TLDA) qRTPCT system was utilised throughout the 
studies comprising this thesis, as it has up to 384 wells, so that many genes can be 
measured in multiple samples using qRTPCR, and it uses minimal resource (the isolated and 
archived RNA from previous participant visits) [125]. Chapters 3, 5 and 6 all used TLDA 
qRTPCR to validate results; Chapter 4 was a meta-analysis with multiple cohorts and 
microarray platforms, so PCR validation was not sought. 
TLDA quantifies RNA by first reverse-transcribing it into complimentary DNA (cDNA) then 
amplifying (replicating) the cDNA using polymerase enzymes and detecting the fluorescence 
of specifically designed probes that only fluoresce if a specific sequence is present and being 
processed by the polymerase (schematically represented in figure 2.3). This process is 
repeated (cycled) 40-50 times, and the stage at which fluorescence is detected (the “cross-
over”, or Ct) is proportional to the amount of RNA in the sample. The comparative Ct 
approach was used to determine the relative expression of target genes compared to stable 
control genes, and finally normalisation allows multiple samples to be compared [126].  
 PhD Thesis | Luke Pilling 
42 Chapter 2 – Methods 
Figure 2.3 | Schematic representation of quantitative real-time polymerase chain reaction 
 
This simplified schematic represents the process by which the relative abundance of a 
specific RNA transcript is estimated in a sample by TLDA qRTPCR. Fluorescence occurs in 
step 3 when the fluorescent probe is digested by the Taq polymerase during the elongation 
phase (when the polymerase is replicating the sequence). This PCR amplification step is 
repeated (cycled) through 40-50 times; RNA that is more abundant in the original sample will 
fluoresce at an earlier cycle than a less abundant RNA molecule. Information compiled from 
multiple sources [127], [128]. 
 
2.3 Statistical analysis 
To gain insight into relationships in the large and complex data sets inherent to genomic 
epidemiology we need to apply statistical techniques. In this thesis I have focussed on cross-
sectional (one time point), gene-expression array data (16,571 probes/variables) in a cohort 
of human study participants (n=698, age range 30-104). 
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2.3.1 Regression Analysis 
For the primary analysis each gene (probe on the array) is assessed for its association with 
an outcome using linear or logistic regression, as appropriate (for continuous or binary 
outcome variables). It is often necessary to log-transform the expression probe and other 
biological traits (such as IL-6) to introduce a Gaussian distribution (many biochemical traits 
are right/positively skewed). Regression models then test for linear associations, which 
highlight correlations between specific gene expression probes and “gross” phenotypes of 
the individuals, such as muscle strength and circulating IL-6 levels. Findings highlighted by 
this approach are then re-analysed in more detail, such as returning to the raw data and 
performing various sensitivity analyses, for example stratification and checking for outlier 
individuals. 
Regression analysis allows rigorous adjustment for potential confounding factors in the 
analysis, so it can be determined whether an observed association is simply due to 
correlation with another trait. For instance, in the analysis of gene expression and cognitive 
function we included age and sex as confounders (as well as technical covariates) so that 
the findings were independent of age and sex. In a number of analyses it has been 
necessary and interesting to investigate the linearity of the association; in a linear regression 
model it is assumed that the association between x and y is linear, but this may not truly be 
the case. A spline model can be fitted to the data which plots a series of linear lines 
(connected by points known as knots) through the values which is then “smoothed” to show a 
curve, if one exists. Confounding factors can also be taken into account (see figures 2.4 and 
5.3 for examples). 
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Figure 2.4 | A cublic spline plot showing the association between IL-6 and age in InCHIANTI.  
 
The graph shows the association between age and IL-6 (logged) by cubic spline regression, 
adjusted for sex, waist circumference, smoking status (pack-years) and highest education 
level attained (p=4.9x10-35). IL-6 is here expressed as “relative difference from the mean”, as 
it has been adjusted for the confounders. N knots=4. 
 
 
Choosing appropriate confounding factors to adjust for is important in an epidemiological 
analysis, which can be categorised into “biological” and “technical”. Firstly there are 
biological differences between men and women with regards to ageing (e.g. muscle 
strength), so “sex” was taken into account. Due to the wide age-range included, “age” was 
also included as a continuous cofactor to determine the transcripts associated with the 
phenotype independent of age (except in models where mediation with age was tested). 
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Depending on the analysis, “stature” may also be taken into account (e.g. height and weight, 
or waist circumference). Smoking-status is known to significantly affect whole blood gene 
expression, so this is also taken into account [129]. 
Technical covariates include “study site” (the urban and rural sites for InCHIANTI), and 
batches; the blood RNA processing was performed in multiple batches, and there are 
significant differences in (for example) mean expression between some of the batches, so 
these are included as factor variables. Lastly I also adjust for “relative cell counts”; the 
rationale is that the RNA profile of a whole blood sample is dependent on both the 
expression in specific cell types and the relative abundance of the different cell types to one 
another. This is actually a strength of the study, as the expression changes we identify may 
be proxies for changing cell types with certain phenotypes; our future work aims to address 
this. There are also measures of absolute numbers of the cells, however because the gene 
expression values are calculated on the microarray as fluorescence relative to the baseline 
(control genes) expression on each specific array we reasoned that the proportions of the 
cell types to one another is more relevant than absolute values. 
 
2.3.2 Multiple testing 
When performing many parallel analyses in order to reduce the likelihood of false-positive 
associations we must adjust the threshold required for an association to be termed 
“significant”. Traditionally “statistical significance” is when the likelihood of observing a result 
as extreme or more so than the one observed is less than 5% [130], but this is only true for a 
single hypothesis. When testing 16571 associations if we used the 5% threshold we would 
expect 1 in 20 false-positive associations purely by chance (i.e. 829 of 16571 would be 
p<0.05).  
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Several methods for controlling the false-discovery rate (FDR) have been proposed, and two 
have been used in these analyses; firstly the Bonferroni correction provides a new adjusted 
threshold for significance (0.05 / N tests performed) which is highly conservative (that is, 
susceptible to false-negative findings; this is because it assumes all the tests are completely 
independent, when in fact expression profiles may be correlated [131]). Secondly the 
Benjamini-Hochberg (BH) method (or similar) is used in most of the analyses due to the 
improved trade-off between false-positive and –negative findings [132]; BH provides FDR-
corrected p-values that are based on the p-value provided by the model, the rank of the p-
value (when ordered by significance), and the number of tests overall. Therefore rather than 
just defining a new threshold (as per Bonferroni), the BH method is actually based on the p-
values themselves, the distribution (ranking), and the number of tests.  
 
2.3.3 Mediation Analysis 
In analysis 4 (Chapter 6) the methods differ from the outline above; I determined the gene 
expression profiles associated with age-related inflammation by performing mediation 
analyses. There is a strong positive association between age and IL-6 which is associated 
with a number of age-related morbidities and mortality [38]; by assessing the proportion of 
the age~IL-6 association mediated by each gene transcript I aimed to determine the specific 
genes statistically related to this process. This is a novel analysis method in this context. 
Methodologically it is straightforward to determine the proportion of an association that is 
mediated by another factor when using regression-based techniques. By performing two 
models and examining the change in the coefficient between the exposure and outcome after 
adjustment for the proposed mediator; if it is reduced, then a proportion of the association 
has been statistically accounted for by the additional independent variable. However this 
same procedure is also used to determine a significant confounder, so it is essential to have 
a biologically-informed conceptual model prior to the analysis. 
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For an individual proposed mediator this method is sufficient. However in our analysis we 
assessed the proportion of the age~IL-6 association mediator by each gene transcript 
individually, and thus desired a method that not only provided the “proportion mediated” but 
also an estimate of the statistical significance of the mediation, in order to adjust for multiple 
testing. Two methods were available for this; the Sobel test derives a p-value from the 
variance in coefficients and standard errors between the models [133]; the second available 
method uses re-sampling of the data (bootstrapping) to derive confidence intervals [134]. I 
used the bootstrapping method in Chapter 6 of this thesis to determine confidence intervals 
because this empirically tests the robustness of the association in subsets of the whole 
sample, rather than making assumptions distributional assumptions, as in the Sobel test 
[135], [136]. In order to control for multiple testing we adjusted these confidence intervals 
according to the Bonferroni method, because it minimises the likelihood of a false-positive 
finding due to the highly conservative threshold, and because implementation of the BH 
method to confidence-limits is not, to our knowledge, possible. Bonferroni adjustment to the 
confidence intervals was applied using the following formula (after personal correspondence 
with the authors of the ‘mediation’ R package);  
(1 – 0.05 / 16571) * 100 = 99.9997% 
Any gene expression mediator with these adjusted confidence intervals not crossing zero 
was considered significant and tested for replication. 
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2.4 Statistical packages: R and STATA 
For statistical analysis of data I have used both R and STATA, as different situations have 
required. Both have their advantages and disadvantages; briefly, STATA is most useful when 
exploring cohort phenotype data given the easier command structure and graphical interface; 
R though has many advantages over STATA, not least its object-oriented nature that allows 
multiple datasets to be loaded, manipulated, and analysed in parallel. R therefore lends itself 
to use on servers (for “big data”, “-omics” scale analyses), and is highly flexible due to its 
open-source nature; many programs and functions have been written by others to perform 
complex analyses, each of which can be dissected by the user as desired. Additionally, its 
most natural environment is a Unix system, another highly flexible and practical working 
environment. 
 
2.5 Linux and Perl 
Unix is an operating system environment with commands and file structures which provide 
the user with a simple and efficient platform for processing files and running programs. Linux 
(one of the ‘flavours’ of Unix) is free, completely open source, and is widely used in 
academia. For instance the systems biology high-performance computer cluster on the 
University of Exeter Streatham campus (“Zeus”, which I was fortunate enough to have 
access to during the course of my research) runs a version of Linux known as “Scientific 
Linux v6.3” (maintained by research labs including CERN) [137]. Perl is a scripting language 
that is, in essence, a more intuitive and compact way of using Unix to parse data [138]. 
The combination of Linux running both Perl and R meant that all analyses, no matter the 
scale, were easily carried out using high-performance servers, and due to the script-based 
nature of the workflows these are 100% reproducible. Throughout my research career I have 
made particular effort to back up the scripts and data used for analyses, and to extensively 
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comment on my codes. A selection of scripts and workflows utilised and developed during 
these projects are available on the accompanying CD-ROM. 
 
2.6 Text-mining the literature for genes 
For the muscle strength meta-analysis (Chapter 4) I developed a program in Perl that 
systematically searches the literature for genes and specific search terms. This functions in 
two parts; firstly GeneCards (www.genecards.org [139]) hosts a list of all publications relating 
to every gene, including those with older or out-dated gene symbols (this can be very 
problematic as names are updated, so this resource is very valuable), then the script 
downloads this list of publications and uses NCBI PubMed (www.ncbi.nlm.nih.gov/pubmed) 
to save the title and abstract into a database. Once the database of all publications for each 
gene is created, the 2nd part of the pipeline can be used to mine this database for specific 
search terms using regular expressions (programmatically searching a piece of text for a 
specific string or pattern). For instance, in Chapter 4 I created a database for each of the 
significant genes associated with muscle strength and searched for terms “muscle” and 
“inflam” to see, for each gene, how many publications also mention those terms in the title or 
abstract. The program can also search for pairs of terms, such as “muscle AND inflam”, to 
see how many publications for each gene contain both of those terms in the title or abstract. 
For each positive finding the abstract is extracted and a web-page created so that, for each 
gene, I can view the abstracts containing the search terms (e.g. “muscle”) and quickly build a 
summary of how they relate. 
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2.7 The CHARGE consortium 
Large meta-analyses are now becoming possible as many population study cohorts take 
advantage of the relative ease and affordability offered by microarray technologies to 
measure many thousands of transcripts in hundreds or thousands of samples. The CHARGE 
consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology [140]) was 
formally initiated in 2008 for GWAS meta-analyses with the approval of a set of principles 
and procedures to improve the reliability of GWAS findings. A number of working groups 
were initiated to study different outcomes, which now number over 40, with phenotypes 
including; adiposity, age of menopause, blood pressure, cardiovascular disease, depression, 
and many more. In 2011 a gene expression working group was formed with the aim of 
determining in detail the peripheral gene expression associations with age. 
The analysis of gene expression and age involved over 14 cohorts (>15,000 samples, 
including 698 from InCHIANTI), across multiple countries and continents, and utilising 
different array technologies [76]. This should give the most robust results from the meta-
analysis, as the “true” gene expression associations with age (irrespective of sample or 
technological bias) should be identified. Almost 1,500 genes were found to be associated 
with age, substantially more than the 295 found in the InCHIANTI analysis alone [79]. 
The CHARGE gene-expression and age analysis was seminal in the field and created 
guidelines for following analyses. A large number of phenotypes are now under investigation, 
including; C-reactive protein (CRP), tobacco exposure, blood pressure and lipid levels, not to 
mention the analysis of muscle strength included as part of this thesis (see Chapter 4). 
These cohorts are now extending their phenotyping to include DNA methylation arrays, 
which will lead on to the next generation of analyses and understanding of complex traits and 
diseases. 
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3.1 Overview 
In this analysis of peripheral gene expression associations with muscle strength we report a 
single positive association between the gene CEBPB and hand grip strength. Grip-strength 
was chosen as it is commonly used in the gerontological field as a broad measure of muscle 
strength – a trait strongly linked with frailty. The aim of the analysis was to discover any 
genes expressed in peripheral immune cells that were associated with “general” muscle 
strength. 
For this analysis I undertook the bioinformatic analyses (transcriptome-wide screen, 
validation of phenotype, investigation of cell-type effects), performed the literature review, 
and worked with the co-authors to interpret the results and write the manuscript. 
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3.2 Summary 
Introduction: Declining muscle strength is a core feature of aging. Several mechanisms 
have been postulated, including CCAAT/enhancer-binding protein-beta (C/EBP-β) triggered 
macrophage-mediated muscle fibre regeneration after micro-injury, evidenced in a mouse 
model. We aimed to identify in-vivo circulating leukocyte gene expression changes 
associated with muscle strength in the human adult population.   
Methods: We undertook a genome wide expression microarray screen, using peripheral 
blood RNA samples from InCHIANTI study participants (ages 30-104 yrs). Logged 
expression intensities were regressed with muscle strength using models adjusted for 
multiple confounders. Key results were validated by real-time PCR. The Short Physical 
Performance Battery score (SPPB) tested walk speed, chair stand and balance performance. 
Results: CEBPB expression levels were associated with muscle strength (beta coefficient = 
0.20560, p=1.03*10-6, false discovery rate q=0.014). The estimated handgrip strength in 70 
year old men in the lowest CEBPB expression tertile was 35.2 kg compared to 41.2 in the top 
tertile. CEBPB expression was also associated with hip, knee, ankle and shoulder strength 
and the SPPB performance score (p=0.018). Near study-wide associations were also noted 
for TGFB3 (p=3.4*10-5, q=0.12) and CEBPD expression (p=9.67E-5, q=0.18) but not for 
CEBPA expression.  
Conclusions: We report here a novel finding that raised CEBPB expression in circulating 
leukocyte derived RNA samples in-vivo is associated with greater muscle strength and better 
physical performance in humans. This association may be consistent with mouse model 
evidence of CEBPB triggered muscle repair: if this mechanism is confirmed it may provide a 
target for intervention to protect and enhance aging muscle.  
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3.3 Introduction  
Aging is associated with a gradual loss of muscle mass and strength [141] accompanied by 
increasing susceptibility to injury and decreased capacity to repair and regenerate muscle 
[142]. Severe muscle loss (or ‘sarcopenia’) can eventually result in impairments and 
limitations to physical functioning. In 1995 Falkner et al [143] argued that ‘everyday’ 
contraction-induced injury contributed to muscle aging. Other suggested causes for 
sarcopenia include loss of motor unit and local motor neurone changes, but also pathways 
with systemic elements such as hormone / growth factor signalling, and inflammation [141].  
Muscle repair after injury or change of use starts with an initial acute inflammatory response 
(typically from 0 to 48 hours) followed by a repair and regeneration phase, typically lasting 
from 48 hrs to 10 days [144]. Following injury, local muscle tissue secretes pro-inflammatory 
(Th1) cytokines (in particular TNF-α and IFN-γ, but also IL-1β, IL-6 and others) (see Fig. 3.1a 
for simplified representation of the pathways from the published literature) that instigates an 
innate immune response. Neutrophil invasion enhances inflammation at the injury site [144], 
[145], and is followed by local migration of macrophages, monocytes [146] and T-helper type 
1 (Th1) lymphocytes. Monocytes are then available to differentiate into specific macrophage 
sub-types [147], which are essential for effective muscle regeneration [148]. 
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Figure 3.1 | Macrophage polarization during muscle injury/repair 
 
Macrophages have a repertoire of phenotypes ranging from classical activation, to several 
alternative activation states. These are generally termed pro-inflammatory / M1 (a) and anti-
inflammatory / M2 (b) respectively. They are functionally distinct, and the correct 
differentiation at the right time is critical to an effective regeneration process. Drawn from the 
literature, this diagram represents that main factors involved in the classical (a) and 
alternative activation states (b) of macrophages as the time from wounding progresses. The 
review by Tidball et al, 2010, was particularly informative. 
Key: LDL = low-density lipid, Th1 = T-helper type 1 / pro-inflammatory response, Th2 = T-
helper type 2 / anti-inflammatory response. 
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At the late stage of the pro-inflammatory phase there is increased production of IL-4, IL-13 
and Transforming Growth Factor-beta (TGF-β) from T-helper type 2 (Th2) lymphocytes; 
phagocytosis of necrotic tissue also influences this change in phenotype. These cytokines 
inhibit the production of Th1 cytokines and initiate the accumulation of alternatively activated 
(anti-inflammatory / M2) macrophages, which include wound-healing and regulatory 
phenotypes [149], thereby promoting tissue repair [150] (Fig. 3.1b). As inflammation is 
attenuated, myoblast differentiation is induced and new muscle fibers are formed.  
CCAAT-enhancer-binding protein-beta (C/EBP-β) has a pivotal role in these processes. In 
2009, Ruffell et al showed in a mouse model that deletion of two CREB binding sites from the 
CEBPB promoter prevented C/EBP-β induction and prevented the transition from M1 to M2 
macrophage-specific gene expression during muscle repair [113]. In their model, the pro-
inflammatory response was unaffected but muscle fiber regeneration was severely 
compromised, with the injured area showing a fibrotic appearance, with fewer, smaller and 
calcified myofibers. Although CEBPB is expressed at basal levels in M1 macrophages, 
significant (typically 10 fold) up-regulation of CEBPB above constitutive levels is required for 
M2 activation, and therefore muscle repair [151].  
Another pathway suggested as pivotal in muscle regeneration is Wnt signalling; age-related 
loss of muscle strength due to increased fibrosis was associated with increased systemic 
Wnt signalling in aged mice [152]. Conversely, others have found that Wnt signalling induced 
the myogenic specification of resident myeloid stem cells during muscle regeneration [153], 
therefore it is likely that an optimal trade-off may be reached, but that it changes over the 
lifespan of an organism. 
While muscle repair has been studied in depth ‘in-vitro’ and in animal models, “in-vivo” 
human studies are intrinsically more difficult. In theory, gene expression patterns could be 
studied in serial muscle biopsies but this would be too invasive and would interfere with 
repair processes. In this study, we instead examined expression in blood (leukocyte) 
samples collected with immediate stabilization of RNA, so that results reflect in-vivo mRNA 
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expression. Blood derived white cell transcriptome studies have already proved valuable in 
identifying signatures of major diseases and drug responses [154]. Studying systemic factors 
in muscle strength may be particularly informative, as experimental transplantation of old 
muscle to a young rat host results in regeneration as marked as that seen in young muscle, 
suggesting that circulating factors may be critical [46].  
In this study, we aimed to test the relevance of CEBPB and other transcripts to muscle 
strength in-vivo. The InCHIANTI population study (www.inchiantistudy.net) is particularly 
useful for this as it includes a wide age-range and muscle strength measures at multiple 
sites.  
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3.4 Methods 
3.4.1 Samples 
InCHIANTI [115] is a population-based, prospective study in the Chianti area (Tuscany) of 
Italy. The participants were enrolled in 1998-2000, and were interviewed and examined every 
three years.  Ethical approval was granted by the Instituto Nazionale Riposo e Cura Anziani 
institutional review board in Italy. Participants gave informed consent to participate.  
 
3.4.2 RNA collection, extraction and the whole transcriptome scan 
Peripheral blood specimens preserving in-vivo RNA expression were collected in 2008/9 
from 733 participants. RNA was extracted from peripheral blood samples using the PAXgene 
Blood mRNA kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. This 
ensures the transcript expression is as near to its in-vivo levels as possible. Whole genome 
expression profiling of the samples was conducted using the Illumina Human HT-12 
microarray (Illumina, San Diego, USA) as previously described [155]. Data processing was 
done using the Illumina and Beadstudio software (Illumina, San Diego, USA) as previously 
described. All microarray experiments and analyses complied with MIAME guidelines. Data 
from 698 individuals and 16571 probes passed our quality control process; 12 subjects were 
excluded on the basis that their mean signal intensities across all probes with p = <0.01 were 
>3 standard deviations from the cohort mean; probes with <5% of subjects giving intensities 
with p >= 0.01 different from background were also excluded. 
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3.4.3 Hand-grip strength 
Maximum hand-grip strength was measured using a grip dynamometer, recording the 
maximum force generated (kg) during two attempts with each hand. In our analysis we used 
the participant’s highest measured grip strength for either hand. 
 
3.4.4 Statistical analysis  
Expression data were available for 707 individuals. Seven individuals were excluded 
following subject level QC steps, where all intensity data were missing or +/- 3 standard 
deviations from the mean (leaving 698 individuals). The relationship between gene 
expression and hand-grip and other muscle strength was tested mainly using linear 
regression models with natural log-transformed gene expression level as the dependent 
variable. Separate regression models were fitted for each of the 16,571 expressed probes. 
We used the false discovery rate (FDR) to account for multiple testing. R (statistical 
computing language) v2.8.1 was used for large-scale analyses and STATA v10.1 for 
confirmation and additional exploration. 
Regression models were adjusted for potential confounding factors on gene expression: age; 
gender; lifetime pack-years smoked (in five categories: none, less than 20 years, 20 to 39 
years, 40 plus years, and missing); waist circumference (as a continuous trait); highest level 
of education attained (in five categories: none, elementary, secondary, high school, and 
university / professional); study site (individuals were drawn from a rural village [Greve] and 
an urban population [Bagno a Ripoli]); and the proportion of leukocyte cell types (neutrophil 
%, lymphocyte %, monocyte %, eosinophil %). We also controlled for potential hybridization 
and/or amplification batch effects in all our analyses. 
The Short Physical Performance Battery score is a summary of performance on walk speed, 
time to stand up from the sitting position several times (chair stands) and graded balance 
 PhD Thesis | Luke Pilling 
60 Chapter 3 – Analysis 1 – Muscle Strength 
tests [156], and SPPB scores are predictive of disability progression and mortality. Physical 
activity was classified based on the MET (Metabolic Equivalent) [157] approach into: Hardly 
any activity; Mostly sitting/some walking; Light exercise 2-4 hrs/week; Moderate 1-2 hrs or 
light >4 hrs/wk;  Moderate exercise >3hrs/wk; Intense exercise many times/wk; Walks 5+ 
km/day, 5+days/wk. 
 
3.4.5 TaqMan Low Density Array (TLDA) validation of microarray results 
We selected a subsample of 100 male subjects with middle tertile lymphocyte percentages 
for validation of the CEBPB expression data.  Total RNA (30 to 170 ng) was reversed 
transcribed in 20μl reactions using the Superscript III VILO kit (Invitrogen, Paisley, UK), 
according to the manufacturer’s instructions. CEBPB expression levels for each target 
transcript were then measured using the Taqman Low Density Array (TLDA) platform 
(Applied Biosystems, Foster City, USA), using commercially available assay CEBPB-
Hs00942496_s1.  Reaction mixes contained 50l 2x TaqMan universal master mix (no 
AMPerase) (Applied Biosystems, Foster City, USA), 30l dH2O and 20l cDNA template. 
Cycling conditions were 50C for 2 minutes, 94.5C for 10 minutes followed by 50 cycles of 
97C for 30 seconds and 57.9C for 1 minute. CEBPB expression was measured in triplicate 
for each sample. Relative gene expression levels were calculated using the comparative Ct 
technique  using the StatMiner relative quantification software developed for analysis of 
TLDA plates (Integromics, UK). Gene expression levels were calculated relative to the 
geometric mean of the 3 genes – COQ2, NFKB1 and TNF - whose transcript expression was 
most stable across all samples, as identified by the GeNorm function of the StatMiner 
software (Integromics, UK). 
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3.4.6 Gene Set Enrichment Analysis 
GSEA is an alternative method of analysing RNA-expression data, in which gene-sets are 
specified by the user (can be custom, or downloaded from the GSEA site) and the 
association across the whole set of genes (usually related functionally) is tested against a 
phenotype. We downloaded the 16 Gene Ontology [158], [159] pathways in which CEBPB is 
involved, which included ‘inflammatory response’, ‘defense response’, ‘response to stress’ 
and ‘RNA metabolic process’. See [79] for detailed methods. 
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3.5 Results 
Six hundred ninety eight people were included in the analysis, ranging in age from 30 to 104 
yrs (Table 3.1). Nearly 45% of the sample was male, and 54% had been non-smokers. In 
linear models adjusted for multiple potential confounders (see methods 3.4), CEBPB 
transcript expression emerged as the most strongly associated with handgrip muscle 
strength: beta-coefficient = 0.20560, p=1.03*10-6 (table 3.2) (for table of top 250 regression 
results see Supplementary Table 1; for QQ-plot see Supplementary Figure 3.1). CEBPB 
was also the only transcript to reach study wide significance accounting for multiple statistical 
testing of array data (false discovery rate FDR q-value=0.014). Associations with muscle 
strength for 6 other transcripts were likely to be robust (i.e. with a FDR q-value<0.2, 
indicating that >80% of these are valid associations).  Notable in these was TGFB3 
(p=3.4*10-5, q=0.12) and CEBPD expression (p=9.67E-05, q=0.18). Relatively little is known 
about the four other transcripts (TAAR8, EXOC1, CBWD5 and CA433556-CD40L). There 
were no associations with other measured CEBP- transcripts, namely CEBPA, CEBPZ, 
CEBPG and CEBPE (for all p>0.18). 
 
 
3.5.1 CEBPB expression and grip strength: effect sizes 
We focussed on CEBPB expression, being the only gene to reach study wide significance 
with muscle strength. First, we explored the associations between CEBPB expression and 
white blood cell counts. In regression models adjusted for the same terms as previously but 
testing each white cell sub-type separately, we found a strong negative association between 
CEBPB expression and increasing lymphocyte percentage (standardised beta=-0.50, 
p<0.001) and a marginally less strong positive association with increasing neutrophil 
percentage (standardised beta=0.47, p<0.001). There was no association with circulating 
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monocyte percentage. We tested the model for interactions between CEBPB expression and 
lymphocyte percentage for handgrip muscle strength: the interaction term was not significant 
(p=0.250).  
 
Table 3.1 | Characteristics of the study sample 
Study sample characteristics   
 n % 
Age (years)   
30yrs – 65yrs 163 23.35 
66yrs – 85yrs 444 63.61 
86yrs - 104yrs 91 13.04 
   
Gender   
Men 313 44.84 
Women 385 55.16 
   
Site   
Greve 342 49 
Bagno a Ripoli 356 51 
   
Education   
None / elementary 416 59.61 
Secondary 93 13.32 
High school 87 12.46 
University / Professional 102 14.61 
   
Pack years smoked (lifetime)   
None 379 54.30 
<20 153 21.92 
20-39 101 14.47 
40+ 55 7.88 
missing 10 1.43 
   
Waist Circumference (cm)   
Mean (sd) 698 95.3 (12.1) 
   
Leukocyte fraction (%) Mean SD 
Neutrophils 57.5 9.14 
Lymphocytes 30.8 8.66 
Monocytes 7.97 2.13 
Eosinophils 3.17 2.11 
Basophils 0.55 0.21 
   
Leukocyte fraction (n K/µL) Mean SD 
Neutrophils 3.68 1.30 
Lymphocytes 1.94 0.76 
Monocytes 0.50 0.16 
Eosinophils 0.20 0.15 
Basophils 0.01 0.03 
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Table 3.2 | Probes most closely associated with hand grip-strength (natural log kg), with a 
false discovery rate q value <20% 
Rank Probe Gene 
Strength 
Coefficient 
95% CI p-value q-value 
1 ilmn_1693014 CEBPB 0.20560 0.14 to 0.27 1.03E-06 0.014416 
2 ilmn_1772523 TAAR8 1.06986 0.66 to 1.48 2.46E-05 0.123658 
3 ilmn_1687652 TGFB3 1.25827 0.76 to 1.75 3.40E-05 0.13609 
4 ilmn_1745583 EXOC1 1.30954 0.78 to 1.84 5.01E-05 0.148728 
5 ilmn_1652417 CBWD5 -1.22926 -1.73 to -0.73 5.38E-05 0.150724 
6 ilmn_1890206 CD40L 1.24223 0.73 to 1.76 7.74E-05 0.171274 
7 ilmn_1782050 CEBPD 0.18314 0.11 to 0.26 9.67E-05 0.182561 
Note: models adjusted for age, gender; lifetime pack-years smoked; waist circumference; education; 
study site; proportions of leukocyte cell types plus RNA hybridization and amplification batch. 
 
 
To provide estimates of the unadjusted effect sizes, we show the distribution of handgrip 
muscle strength by tertile of CEBPB expression in men and women separately (figure 3.2) 
for those in the middle tertile of both neutrophil and lymphocyte percentages (n=160). Using 
our fully adjusted models, we estimated grip strength for 70 year old men or women (table 
3.3). This showed similar results to the unadjusted data, with mean handgrip strength in men 
in the highest CEBPB expression tertile being 41.2 kg compared to 35.2 kg in the bottom 
tertile. In women, there was a similar spread of predicted mean grip strength (from 26.0 to 
20.0 kg respectively).    
Advancing age is associated with lower hand-grip strength (beta=-0.5, p<1e-10) and 
separately with lower CEBPB expression (beta=-0.15, p<1e-4): however age (beta=-0.04, 
p>0.05) ceases to be significantly associated with grip-strength when CEBPB expression is 
included as an explanatory covariate. 
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Table 3.3 | Regression model based estimated hand grip strength for men and women aged 
70 and with lymphocyte percentage at mean value (30.8%)  
 Men   Women  
C\EBP-β 
expression 
tertile 
Estimated 
mean strength 
(kg) 
95% Prediction 
interval (kg) 
 Estimated 
mean strength 
(kg) 
95% Prediction 
interval (kg) 
      
1 35.2 24.1 to 46.3  20.0 9.1 to 31.0 
2 38.2 37.1 to 39.4  23.1 22.1 to 24.0 
3 41.2 29.4 to 53.0  26.0 14.0 to 37.9 
 
Note: models adjusted for age, gender; lifetime pack-years smoked; waist circumference; education; 
study site; proportions of leukocyte cell types plus RNA hybridization and amplification batch. 
 
 
Figure 3.2 | Demonstrating increased CEBPB expression with higher grip strength 
 
Using a box-plot and tertiles of CEBPB expression, the association with grip strength is 
clearly visible. CEBPB is split by gender because of the natural disparity in muscle strength. 
Note: participants with ‘normal’ (mid-tertile) leukocyte percentages. Adjacency lines are 
1.5*the interquartile range above/below the 75th and 25th percentiles. Key: CEBPB = 
CCAAT/enhancer-binding protein beta. 
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To confirm the microarray result we re-measured CEBPB expression in 100 male InCHIANTI 
subjects. Very similar results were found plotting tertile of CEBPB expression against grip 
strength (Supplementary Figure 3.2): those in the top expression tertile had higher mean 
strength compared to those in the bottom tertile (CEBPB expression correlation with 
handgrip strength p=0.048, excluding 5 outlier values).  
 
3.5.2 Associations with strength in other muscle systems and physical performance 
We next examined associations between CEBPB expression and muscle strength measured 
at other sites, in models adjusted as previously. There were significant positive associations 
with measures at the knee, hip, ankle and shoulder (Supplementary table 3.2).  
A critical question is whether the changes in muscle strength seen are of functional 
significance. Those in the highest tertile of CEBPB expression were far less likely to have 
impaired performance on the Short Physical Performance Battery (SPPB) score 
(Supplementary table 3.3): the highest expression tertile group had an Odds Ratio=0.42 
(95%CI 0.20 to 0.86, p=0.018) for having impaired performance (SPPB score<10, 22.35% of 
the sample). There were trends for the three subscales, with a significant association for walk 
speed impairment (OR=0.33, 95%CI 0.14 to 0.80, p=0.014).  
 
3.5.3 Muscle strength and physical activity 
In post-hoc sensitivity analyses, we explored whether the association of CEBPB expression 
with muscle strength was explained by higher levels of physical activity. Adjusting for seven 
levels of physical activity over the previous one or three years had limited impact on the 
association between CEBPB expression and hand grip, which remained strongly significant 
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(beta=0.13, 95%CI: 0.06 to 0.19, p=0.001 and beta=0.16, 95%CI: 0.09 to 0.23, p<0.001 
respectively). 
 
3.5.4 A potential mechanism underlying the CEBPB association with muscle strength  
To identify, as far as possible, the likely general mechanisms mediating the CEBPB 
association with muscle strength, we searched the Gene Ontology database [160] for 
pathways in which CEBPB is involved: this yielded 16 results, most of which are 
inflammatory/immune related, including acute and chronic stages of inflammation, response 
to stress and wound-healing. Gene ontology does not include a specific pathway explicitly 
including both CEBPB and muscle, or macrophage activation states. A Gene-Set Enrichment 
Analysis (see methods), which determines whether sets of biologically related genes are 
more strongly associated with grip strength than might occur by chance, showed no 
significant associations (p-values>0.05). A leading alternative pathway involved in muscle 
repair is WNT signaling, but we found no evidence that β-catenin (downstream effector of 
Wnt) expression was associated with grip strength in our leukocyte samples (p>0.05). 
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3.6 Discussion 
Loss of muscle strength is a core feature of aging, and a range of potential local and 
systemic mechanisms have been proposed to explain it [141]. Amongst the more promising 
is the theory that contraction-induced damage to muscle is more common and associated 
with impaired repair in old age [143]. Almost every activity of daily living involves lengthening 
contractions, the majority of which do not induce injury: with age, however, the increasing 
numbers of highly stretch-susceptible fibers place the muscles of older animals and humans 
at greater risk [161]. A recently published mouse model with reduced CEBPB expression 
after muscle injury prevented the transition from the pro-inflammatory M1 to the M2 
macrophage mediated repair and regeneration phases, and resulted in sarcopenia like loss 
of muscle fibers and fibrosis of muscle tissue [113]. Until now, the relevance of this 
experimental demonstration to muscle strength in people in-vivo was unknown.  
We set out to test blood leukocyte derived gene expression associations with muscle 
strength in an adult human population. We found, for the first time, that increased CEBPB 
expression was strongly associated with greater muscle strength in a human population. 
C/EBP-β is a transcription factor playing a role in 16 pathways classified within the Gene 
Ontology system [160]: however, we did not find evidence of deregulation of these general 
(mostly inflammatory) pathways. We also found no evidence that β-catenin (downstream 
effector of Wnt), an alternative potential explanatory pathway influencing proliferation and 
differentiation of muscle-residing monocytes [153], is differentially expressed. The most likely 
remaining explanation for our finding appears to be that higher CEBPB expression occurs 
with more effective M2 macrophage mediated regeneration in muscle tissue; C/EBP-β is 
involved in both M1 and M2 expression profiles. However additional activation above basal 
expression, via CREB, only occurs in M2; IL-10, produced by regulatory macrophages, is 
dependent upon C/EBP-β-mediated transcription [162], as is Arg-1 (produced by wound-
healing macrophages) [163], and others. 
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Clearly, further work is needed to confirm that the M2 mediated regeneration process is 
indeed the source of the higher CEBPB expression in our blood derived RNA samples. The 
regeneration phase after injury is relatively lengthy (8 days typically) compared to the initial 
pro-inflammatory phase (2 days), and therefore regeneration related signaling can be 
expected to predominate in population level studies of participants unselected with respect to 
the timing of everyday muscle fiber injury. 
C/EBP-β is a transcription factor and as such its specificity of action is tightly regulated by 
phosphorylation and competing cofactors. The precise nature of the promoters that C/EBP-β 
binds to and activates (i.e. M1 or M2) is dependent on upstream effectors of CEBPB 
expression, such as TGF-β, and on whether C/EBP-β is partnered with pro-inflammatory 
cofactors such as NF-κB or with anti-inflammatory cofactors such as STAT6 (fig. 3.1a and 
3.1b). We found both TGFB3 and 1 of 3 isoforms of TGFBr2 were significantly associated 
with measures of strength (p=3.4*10-5 and p=0.037 respectively). As TGF-B (produced by 
macrophages after phagocytosis of apoptotic cells (fig. 3.1b)) attenuates pro-inflammatory 
signals [164], it’s up-regulation alongside CEBPB is a further indication that an enhanced 
anti-inflammatory (M2) phenotype is advantageous for maintaining muscle strength.  
There is high homology between the C/EBP members; they can form heterodimers [165], 
and substitute for one-another to rescue functionality [166]. However, each is separated 
functionally by their response to stimuli, their location within the nucleus and their tissue 
specificity (i.e. macrophage or muscle cell). C/EBP-δ (which was also associated with muscle 
strength in our study) has previously been shown to reverse the inactivation of PPAR-γ [167]; 
this results in the stimulation of fatty acid oxidation, glycolysis, mTOR activation and anti-
inflammatory actions in macrophages in order to increase hepatic lipogenesis in the liver and 
adipose tissue [168]. This is due to differing ratios of saturated to unsaturated fatty acids in 
the blood, which promote either M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes 
respectively [169]–[171]. It is therefore interesting that we found a correlation between 
CEBPD expression and muscle strength in our cohort. This may possibly be due to an effect 
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of CEBPD on circulating saturated fatty acid levels in leaner people, producing a more M2-
like response and better muscle repair. Again, this will require further work to elucidate the 
exact mechanism. 
Large scale gene-expression studies are confounded by the high variability between healthy 
individuals. Results can be affected by a range of factors from ethnicity to employment, 
including details of blood-sample storage [154], and therefore we have used a collection 
procedure designed to stabilize RNA at the point of collection from the participants’ veins. 
We found the proportion of different white cell sub-types to be a significant factor when 
analysing CEBPB expression. Due to the nature of the investigation (observing increased 
CEBPB expression hypothesized to be due to, or involved with the causation of, increased 
anti-inflammatory macrophages) it is not surprising that varying proportions of neutrophils 
(and lymphocytes) between people influences CEBPB expression: however, we found no 
evidence of interactions between CEBPB expression, leukocyte subtype proportions and 
muscle strength. In addition, the CEBPB expression association with strength was still 
present in those with ‘normal range’ mid-tertile lymphocyte and neutrophil counts. 
Neutrophils are upstream of macrophages; they are involved in the initial recruitment to sites 
of muscle injury, and amplify the chain of events leading to successful resolution of damage 
[47], [144].  
Along with C/EBP-β, C/EBP-δ and TGF-β, 4 other probes were associated (genome-wide) 
with grip-strength. These were Trace Amine Associated Receptor 8 (TAAR8), EXOcyst 
Complex component 1 (EXOC1), COBW domain-containing protein 5 (CBWD5) and Cell-
surface receptor 40 ligand (CD40L). CD40L is associated with neutrophil count and has 
previously been described to be involved in inflammation [172]. TAAR8 is a receptor for trace 
amines, which are important in neuronal function [173]. EXOC1 and CBWD5 are proteins 
necessary for exocytic vesicle targeting [174] and neurotransmission respectively. CD40L 
may therefore play a role in M1 macrophage activation, whilst the remaining genes may 
reflect improved motor neuron function in people with better muscle strength. 
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A simple association between CEBPB expression and muscle strength would be of limited 
interest without evidence that the effect size is big enough to influence everyday functioning, 
impairment and disability. Lower handgrip muscle strength in 45-68 year old men in the 
Honolulu Heart Program was predictive of disability 25 years later [39]. The short physical 
performance battery (SPPB) score is a well validated and widely used objective measure of 
functional impairment, and is predictive of subsequent disability and mortality [36]. Our 
finding of an association between higher CEBPB expression and a markedly lower risk of 
impairment on the SPPB suggests that our findings may be of clinical and practical 
significance.  
Given the mouse model demonstrating that increased CEBPB expression is necessary for 
muscle regeneration, it is plausible that the CEBPB expression associations reported here 
with muscle strength reflect a causal relationship, although the statistical association may 
theoretically reflect an effect rather than a cause. As noted, future work is needed to confirm 
that higher CEBPB expression in peripheral blood derived samples does indeed reflect 
greater M2 macrophage mediated muscle repair. Studies of responses to experimentally 
induced muscle stresses could chart the temporal response from early reaction to injury 
through to the later repair phases in people of different ages and strengths. It may be 
possible to explore the effects of polymorphisms (SNPs) in the implicated genes on 
expression and strength. Eventually, experimental approaches to enhance CEBPB pathway 
expression and related repair may provide a means of protecting and enhancing aging 
muscle.   
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3.7 Conclusions 
We have presented the first report of the association between raised CEBPB expression in-
vivo and greater muscle strength in humans. This may be consistent with mouse model 
findings that C/EBP-β signalling is critical for regeneration of muscle fibres after injury.  TGF-
β, a key initiator and cofactor is also up-regulated. These changes are big enough to affect 
functioning. Independent replication and mechanistic studies linking CEBPB expression in 
leukocytes to muscle are needed. 
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3.9 Supplementary Information 
Supplementary Table 3.1: Top 250 microarray probes (genes) associated with hand-grip 
strength (kg) 
Probe-ID P B Q Gene Description 
ilmn_1693014 1.0E-06 0.206 0.0144 CEBPB CCAAT/enhancer binding protein (C/EBP) / beta 
ilmn_1772523 2.5E-05 1.070 0.1237 TAAR8 trace amine associated receptor 8 
ilmn_1687652 3.4E-05 1.258 0.1361 TGFB3 transforming growth factor / beta 3 
ilmn_1745583 5.0E-05 1.310 0.1487 EXOC1 exocyst complex component 1 
ilmn_1652417 5.4E-05 -1.229 0.1507 CBWD5 COBW domain containing 5 
ilmn_1890206 7.7E-05 1.242 0.1713 CA433556 
 ilmn_1782050 9.7E-05 0.183 0.1826 CEBPD CCAAT/enhancer binding protein (C/EBP) / delta 
ilmn_1805973 1.3E-04 1.442 0.1949 GPR19 G protein-coupled receptor 19 
ilmn_1699091 1.6E-04 1.365 0.2031 C14orf118 chromosome 14 open reading frame 118 
ilmn_1717579 1.6E-04 1.114 0.2037 C17orf64 chromosome 17 open reading frame 64 
ilmn_1811955 1.6E-04 1.108 0.2040 PRMT5 protein arginine methyltransferase 5 
ilmn_1737847 2.1E-04 1.458 0.2274 RMND5B 
required for meiotic nuclear division 5 homolog B (S. 
cerevisiae) 
ilmn_1773228 2.4E-04 1.326 0.2390 DLST dihydrolipoamide S-succinyltransferase 
ilmn_2401987 2.8E-04 1.284 0.2547 DLEC1 deleted in lung and esophageal cancer 1 
ilmn_1810805 2.9E-04 1.153 0.2560 HEATR5B HEAT repeat containing 5B 
ilmn_2179018 3.0E-04 -0.296 0.2599 NDUFAB1 NADH dehydrogenase (ubiquinone) 1 / alpha/beta subcomplex 
ilmn_1724145 3.9E-04 0.819 0.2798 CBX4 chromobox homolog 4 
ilmn_1718136 4.4E-04 -0.159 0.2889 hCG_25371 
ilmn_1750088 4.4E-04 -0.797 0.2893 VRK2 vaccinia related kinase 2 
ilmn_1676895 4.6E-04 0.790 0.2911 BTNL8 butyrophilin-like 8 
ilmn_2305407 4.9E-04 0.752 0.2962 ZBTB16 zinc finger and BTB domain containing 16 
ilmn_1720604 5.0E-04 1.056 0.2971 ARSG arylsulfatase G 
ilmn_1787541 5.2E-04 0.716 0.2991 SPSB2 splA/ryanodine receptor domain and SOCS box containing 2 
ilmn_1734290 5.5E-04 1.235 0.3027 MAPRE3 microtubule-associated protein / RP/EB family / member 3 
ilmn_1730054 5.8E-04 0.449 0.3063 GSTT1 glutathione S-transferase theta 1 
ilmn_2396002 6.7E-04 -0.957 0.3141 MRPL10 mitochondrial ribosomal protein L10 
ilmn_1663090 6.9E-04 1.134 0.3156 SON SON DNA binding protein 
ilmn_2081682 7.2E-04 0.152 0.3181 SMAP2 small ArfGAP2 
ilmn_2376403 7.4E-04 0.106 0.3190 TSC22D3 TSC22 domain family / member 3 
 
Note: Linear regression models adjusted for age, sex, waist circumference, smoking-status, 
highest education level, study site, hybridization-batch, amplification-batch and leukocyte 
proportions 
### Only top 30 shown in print. Full table available on the Aging Cell website: 
http://dx.doi.org/10.1111/j.1474-9726.2011.00782.x  
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Supplementary Table 3.2: Regression based estimated of CEBPB expression associations 
with measures of strength 
Measure N Mean SD  
Regression 
Coefficient 
Lower 
95% CI 
Upper 
95% CI  
p-value 
Knee         
Flexion (kg) 626 17.77 5.62  1.533 0.404 2.662 0.008 
Extension (kg) 626 18.99 5.83  1.713 0.527 2.899 0.005 
Hip         
Flexion (kg) 629 21.17 6.82  2.522 1.111 3.933 0.000 
Extension (kg) 616 19.90 5.46  0.889 -0.330 2.109 0.153 
Abduction (kg) 655 21.02 6.26  1.856 0.688 3.024 0.002 
Adduction (kg) 655 19.03 5.91  1.637 0.566 2.709 0.003 
Ankle         
Flexion (kg) 626 17.99 5.43  1.254 0.005 2.504 0.049 
Extension (kg) 626 28.06 7.76  2.663 1.016 4.310 0.002 
Shoulder         
Abduction (kg) 658 18.78 5.87  1.587 0.511 2.663 0.004 
 
Note: models adjusted for age, gender; lifetime pack-years smoked; waist circumference; 
education; study site; proportions of leukocyte cell types plus RNA hybridization and 
amplification batch. 
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Supplementary Table 3.3: Odds ratio for having impaired performance on 
performance scores, comparing those with top tertile CEBPB expression to lowest 
tertile expression  
Measure N 
% impaired 
performance 
 
Odds Ratio 
(top vs lowest 
tertile expression) 
95% 
Confidence 
interval  
p-
value 
       
Walking 680 15.04  0.33 0.14 to 0.80 0.014 
Chair stands  690 18.19  0.63 0.29 to 1.40 0.253 
Balance 690 16.62  0.46 0.19 to 1.11 0.084 
       
Short Physical 
Performance 
Battery Score 
(SPPB) 
690 22.35  0.42 0.20 to 0.86 0.018 
 
Note: models adjusted for age, gender; lifetime pack-years smoked; waist circumference; 
education; study site; proportions of leukocyte cell types plus RNA hybridization and 
amplification batch. 
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Supplementary Figure 3.1: QQ plot for muscle strength and gene expression associations 
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Supplementary Figure 3.2: Microarray Validation 
 
Hand Grip strength by tertiles of C\EBP-ß expression measured by TLDA, for 95 men (5 
excluded as outliers) with middle tertile lymphocyte and neutrophil percentages (p=0.048). 
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Chapter 4 – Analysis 2 – Muscle Strength Meta-analysis 
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4.1 Overview 
This meta-analysis of four independent cohorts assesses the association between whole-
blood gene expression and muscle strength. The aim was to extend the original analysis in 
InCHIANTI (presented in Chapter 3) and identify novel associations that may provide insight 
into mechanism or biomarkers. 222 genes were associated with muscle strength, and more 
than 50% had not been linked to muscle in the literature previously. CEBPB, the gene 
identified in Chapter 3, did not replicate in the other cohorts. 
In this analysis I performed the transcriptome-wide analysis in InCHIANTI, coordinated the 
collaborators to perform the analysis in their cohorts, performed the meta-analysis, 
developed novel methods to assess gene/phenotype associations in the literature, and 
worked with the co-authors to interpret the results and write the manuscript. All data 
acquisition was performed by the co-authors on this manuscript. Detailed author 
contributions are included in Supplementary Table 6.0. 
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4.2 Summary 
Introduction: Muscle strength in midlife is predictive of disability and mortality in later life; 
loss of muscle strength is a key feature of aging. Blood factors, such as GDF11, influence 
muscle function and repair in mice, and inflammation is linked to muscle decline in humans. 
We identified circulating gene expression associations with muscle strength in adults. 
Methods: Meta-analysis of whole blood gene expression and hand-grip strength in four 
independent cohorts (n=7,781, ages: 20-104 years, weighted mean 56 years), adjusted for 
confounders including age, sex, height, weight, and leukocyte subtypes. Three cohorts used 
Illumina HumanHT-12 microarrays, one used Affymetrix Exon-array data (gene level). 
Separate analyses were also performed in subsets (old/young, male/female).  
Results: In the meta-analyses, expression of 222 unique genes were significantly associated 
with muscle strength (FDR<0.05). Significant genes include ALAS2 (rate limiting enzyme in 
heme synthesis), PRF1 (perforin, a cytotoxic protein previously associated with age-related 
chronic inflammation), and IGF1R and IGF2BP2 (growth factor-related), but not GDF11. 
Gene Ontology pathway analysis found enrichment for “hemoglobin biosynthesis” and 
“innate immune activation”. 115 (of 222) genes have not previously been linked to muscle in 
the literature. Analyzing the Affymetrix and Illumina cohorts separately, 90 genes (40% of 
222) showed independent replication (p<0.05). 
Conclusions: Blood transcripts associated with muscle strength in adults include genes 
involved in innate immune pathways and hemoglobin synthesis, but also include novel 
markers needing characterization. The link between muscle strength and circulating growth 
factors may differ between humans and mice. Further work is needed on subgroup specific 
expression (especially in the frail elderly) and on long-term prediction of frailty and disease. 
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4.3 Introduction 
Muscle strength correlates with health and physical function, and poor muscle strength in 
midlife is a strong, independent predictor of health status decline and mortality over 25 years 
[175]. Sufficient muscle strength in the hands, arms and legs is needed for everyday 
functioning; persons with poor strength are at high risk of disability, injury from falls, and 
other age-related morbidities [36], [141]. Mechanisms that lead to decline of muscle mass 
and strength with aging are unknown. Current theories emphasize the role of denervation not 
compensated by adequate re-innervation, mitochondrial dysfunction, cellular senescence, 
inflammation and changes in microenvironment [176], [177]. However, empirical evidence for 
these theories in humans is lacking. With the growing availability of genomic data it is now 
possible to determine if muscle strength is associated with the expression of certain genes, 
which might suggest pathways driving or secondary to the determinants of muscle strength in 
mid and later life. 
Studies in mice using a technique known as heterochronic parabiosis – where an old and a 
young mouse are surgically attached so as to share a circulatory system – have shown that 
the lower muscle regenerative capacity in older compared to younger animals is due to 
circulating factors [46], [102], and that restoration of circulating GDF11 (growth and 
differentiation factor 11) improves muscle function in older mice [3]. Thus, insights into the 
relationship between circulating factors and muscle strength in adults could help identify 
biomarkers and develop interventions aimed at improving strength. 
Previous studies of transcriptome associations with muscle strength in humans were 
conducted predominantly in muscle tissue, and are mostly based on a group of biologically 
plausible candidate genes and on relatively small sample sizes due to the challenges of 
obtaining human muscle tissue. For example one study investigated associations between 
circulating cytokines and expression of 44 candidate genes in muscle in 88 aged men [178], 
while another assessed >26,000 genes in only 51 men [179], raising severe challenges of 
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false positive statistical associations due to multiple testing. Pathways such as Wnt signaling 
[180], Kelch proteins [181], and insulin-like growth factors (IGF’s) [182] are known to play 
crucial roles in muscle homeostasis in muscle tissue. The immune system also plays a 
critical role in muscle maintenance and repair after damage [47].  
A transcriptome-wide study of whole blood transcript associations with grip strength 
conducted by the InCHIANTI Aging Study (n=679, mean age 72 years, 71% ≥72 years old) 
found only one gene, CEBPB (CCAAT/enhancer-binding protein beta, required for 
macrophage-mediated muscle repair in a murine model [113]), to be robustly associated with 
muscle strength in older humans after adjustment for confounders and multiple testing [183]; 
however this study had a limited sample size (n=679). A follow-up study in humans found 
that CEBPB expression increased following exercise-induced muscle damage [184]. 
In the present study we sought to test associations between transcripts expressed in whole 
blood and hand grip strength in multiple human cohorts. Our underlying aim was to identify 
the transcripts in blood driving or responding to muscle strength in adults, with subgroup 
analysis by age-group and gender. Using a robust meta-analysis framework within the 
CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium 
[140] we have analyzed data from four independent cohorts (n=7,781 participants) to identify 
the genes whose level of expression assessed by blood transcripts was associated with 
muscle strength. 
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4.4 Methods 
4.4.1 Study Sample 
Four cohorts were included in the discovery analysis; the Framingham Heart Study [185] 
(FHS, n=5,582, ages=24-90), the InCHIANTI study [115] (n=679, ages=30-104), the 
Rotterdam study [186] (RS, n=591, ages=46-89) and the Study of Health in Pomerania [187] 
(SHIP, n=986, ages=20-81) (total n=7781). The FHS study included two related generations 
of participants (accounted for in the statistical methodology); the FHS Generation 2 (n=2,427, 
ages=40-90) and Generation 3 (n=3,155, ages=24-78) cohorts were included. The 
Netherlands Study of Depression and Anxiety [188] (NESDA, n=1,989, ages=18-65) is also 
reported, but was not included in the meta-analysis due to unavailable data on white cell 
proportions necessary for the meta-analysis protocol. Detailed study design information can 
be found in the online methods and references. 
 
4.4.2 Phenotype 
The primary phenotype was hand-grip strength in kg (a normally distributed phenotype). In 
the FHS, hand grip strength was measured with a Jamar dynamometer with three trials 
performed in each hand, and the maximum of the six trials for each participant was used in 
the analysis. In InCHIANTI each participant recorded their maximum grip strength three 
times in each hand, and the maximum recorded value of the six trials was used. In the 
Rotterdam Study grip strength of the non-dominant hand was measured three times for each 
participant, and the maximum recorded value was used. In the SHIP cohort participants were 
asked to press the hand dynamometer firmly for several seconds, once per hand (left and 
right), and the maximum value was used. 
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Table 4.1 | Characteristics of the study cohorts 
 
Meta-analysis cohorts 
 
 
Variables FHS Gen2 * FHS Gen3 * InCHIANTI ~ RS3 ~ SHIP ~ 
 
NESDA 
        
N 2427 3155 679 591 982 
 
1989 
N >= 60 years (%) 1319 (54%) 48 (1%) 547 (81%) 264 (45%) 268 (27%) 
 
158 (8%) 
Sex (male), n (%) 1095 (45%) 1470 (47%) 311 (46%) 272 (46%) 435 (44%) 
 
1328 (67%) 
Age, mean±SD 66 ± 8.9 46 ± 8.8 72 ± 15 60 ± 7.9 50 ± 14 
 
42 ± 13 
Age, min:max 40 : 90 24 : 78 30 : 104 46 : 89 20 : 81 
 
18: 65 
WBC-counts yes ɫ yes yes yes yes 
 
no 
        
Grip strength 
       
Mean ± SD (Kg) 31 ± 12 38 ± 12 29 ± 12 25 ± 9.4 38 ± 12 
 
38 ± 12 
Min : max (Kg) 1 : 76 5 : 84 3 : 76 2 : 55 11 : 73 
 
10 : 90 
        
Microarray 
platform 
Affymetrix 
GeneChip 
Human Exon 
1.0 ST 
Affymetrix 
GeneChip 
Human Exon 
1.0 ST 
Illumina 
HumanHT-
12 v3 
BeadChip 
Illumina 
HumanHT-
12 v4 
BeadChip 
Illumina 
HumanHT-
12 v3 
BeadChip 
 
Affymetrix 
Human 
Genome 
U219  
                
FHS=Framingham Heart Study; Gen=generation; RS3=Rotterdam Study 3; SHIP=Study of Health in Pomerania; 
NESDA=Netherlands Study of Depression and Anxiety; SD=standard deviation; WBC=white blood cell 
* FHS cohorts analysed together prior to overall meta-analysis 
~ Illumina-based cohorts analysed together prior to overall meta-analysis 
∞ cohort not included in meta-analysis due to data missing from analysis protocol 
ɫ cell counts imputed in this dataset; see methods 
 
 
4.4.3 Peripheral Gene Expression Data 
Blood samples were drawn from participants and RNA was isolated, reverse-transcribed to 
cDNA, which was then amplified and hybridized to a microarray individually for each cohort; 
methods described in detail online. Briefly, the FHS used Affymetrix Human Exon 1.0 ST 
GeneChips, characterizing the expression of 16798 unique genes (after exclusion of 
probesets with relative log expression mean values <3).  
The InCHIANTI and SHIP studies used the Illumina HumanHT-12 v3 Expression BeadChip 
Kit, and the RS used the Illumina HumanHT-12 v4 Expression BeadChip Kit, with 37,348 
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probes measured on both Illumina platforms (22,911 unique genes; after exclusions of 
probes expressed above background in <5% of participants this becomes 15,639 unique 
genes). Quantile normalization and log2 transformation was performed separately in each 
cohort according to published methods, and both probes and samples were z-transformed; 
details available in the online methods.  
Systematic mapping of probe sequences to RefSeq transcripts found 26,746 pairs of probes 
(one Affymetrix Exon ST and one Illumina HumanHT-12 that mapped to the same RefSeq 
transcript) corresponding to 17,534 unique RefSeq gene symbols (see Online Methods for 
details of annotation sequence mapping and additional information on array normalization). 
Finally the NESDA cohort utilized the Affymetrix Human Genome U219 Array, with 
expression information available on 18,212 unique gene identifiers. 
The Human Genome Nomenclature Committee [189] list 19,060 protein-coding genes (Sept 
15th 2014), less than the total “unique identifiers” mapped by the two arrays used in the 
overall meta-analysis; this discrepancy is due to probes on the array mapping to non-protein-
coding transcripts, which we have included under the term “unique genes” or “transcripts” in 
this manuscript. 
 
4.4.4 Statistical Analysis 
Using the R statistical software [190] and package “lme4” [191] each cohort performed a 
linear mixed effects model for each probe in their microarray data, using the probe as the 
outcome, muscle strength as an independent variable, and with the following confounders 
included as fixed effects; age, sex, height (cm), weight (kg), cell count estimates (neutrophils, 
monocytes, basophils and eosinophils), and fasting state (where applicable). The following 
covariates were included as random effects; batch (e.g. amplification and/or hybridization), 
study site (InCHIANTI), family structure (in FHS), and RNA integrity number (RIN), a 
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measure of RNA quality (where available). Empirical cell counts were only available in half of 
the FHS cohort; the rest of the cohort was imputed using partial least square regression 
methods (see online methods for more details). 
 
4.4.5 Meta-analysis 
A sample-size weighted meta-analysis method was used, where an overall p-value and Z-
score for each probe are calculated which together describe the significance of the effect, 
and the direction and magnitude, respectively; this method was chosen over the effect 
size/standard error method because of the multiple array technologies and technical 
considerations that differed between the cohorts. The analysis was done using the Meta-
Analysis Tool for Genome Wide-Association Scans (METAL) [192] which took the effect size, 
sample size, and p-values from the individual cohort results as input (we set the “minor 
allele”, “major allele”, “minor allele frequency”, and “strand” to the same for all cohorts and 
probes, as this method was developed for GWAS and these options are not relevant for gene 
expression data). 
Five pre-specified analyses were performed; all study participants, those ≥60 years, <60 
years, males only, and females only. For each analysis, the Illumina-based cohorts 
(InCHIANTI, RS, SHIP) were meta-analyzed together first, as these technologies are very 
similar, then a secondary meta-analysis was performed which used the FHS results and the 
Illumina results as the input; these are the final meta-analysis results reported. This reduced 
the heterogeneity in the meta-analysis due to array differences between the cohorts. 
Before interpretation of the results, probes were excluded if they were expressed in <5% of 
the sample or if the heterogeneity p-value calculated by METAL was <0.05. The Benjamini-
Hochberg (BH) [132] false-discovery rate (FDR) correction was applied to each analysis to 
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determine the statistically significant probes for each analysis. Validation was described as a 
gene with p<0.05 in the NESDA cohort. 
 
4.4.6 Ontology enrichment analysis 
The WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) online resource is a method for 
determining pathway enrichment [193]. We conducted a “Gene Ontology” analysis (database 
version: 11th Nov 2012) and a “Human Phenotype Ontology” analysis (database version: 20th 
May 2014), which uses a systematic approach to phenotype abnormalities to link them into 
ontologies [194]. Default analysis options were selected, including BH multiple testing 
adjustment, and the list of 17,534 genes included in the meta-analysis we used as the 
“background”. 
 
4.4.7 A priori genes associated with muscle function 
We selected sets of genes known to influence muscle function for a priori analysis to 
highlight whether the pathways in muscle tissue are also associated with strength in whole 
blood. Kelch proteins, including KLHL19, KLHL31, KLHL39m, and KLHDC1, are involved in 
skeletal muscle function and development [181]; canonical and non-canonical Wnt signaling 
play crucial roles in maintenance and development of skeletal muscle [180]; insulin-like 
growth factors (IGF’s) are also known to play roles in muscle growth and homeostasis [182], 
and finally supplementation of GDF11 in mice ameliorates sarcopenia [3]. In their 2007 
study, Melov et al identified 586 unique genes expressed in muscle that were associated with 
endurance exercise training and differed between older and younger men [179], which we 
also checked for associations with muscle strength in this analysis. 
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4.4.8 Systematic literature search for genes 
For each significant gene in the analysis a systematic search of literature was performing by 
accessing the “publications” list from GeneCards (www.genecards.org) [139], which has the 
advantage of including publications where the gene ID may have changed over time. From 
this list the title and abstract were downloaded from NCBI PubMed 
(www.ncbi.nlm.nih.gov/pubmed). Searches were then made within each publication for the 
text string “muscle”, and results counted. 
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4.5 Results 
4.5.1 Cohort characteristics 
Characteristics of the cohorts are presented in Table 4.1. Complete data for the planned 
meta-analysis were available for 7,781 participants from the four cohorts, namely the FHS, 
InCHIANTI, RS and SHIP. Sample sizes for the subgroup analyses were 1) older participants 
≥60 years (n=2,402), 2) younger participants <60 years (n=5,379), 3) male participants 
(n=3,557), 4) female participants (n=4,224). Overall the cohorts were quite similar with 
respect to sex-distribution and sampling methods, differing only by age distribution and 
unexpectedly lower mean hand-grip strength in the RS. To cope with incomplete overlap 
between the two microarray platforms used (Affymetrix in the FHS cohorts, and Illumina in 
InCHIANTI, RS, and SHIP) we first analyzed the FHS generations 2 and 3 together, then the 
Illumina-based cohorts, and finally an overall meta-analysis combining the two platform-
specific meta-analyses was performed on the genes that had coverage in both platforms. 
 
4.5.2 Meta-analysis: genes associated with muscle strength 
Overall, 26,746 probe-pairs (corresponding probes on the Affymetrix and Illumina platforms), 
mapping to 17,534 unique gene identifiers, were available for the meta-analysis. Across all 
five analyses (“all individuals”, “older”, “younger”, “males”, “females”) 264 probe-pairs (222 
unique genes) were significantly associated with muscle strength (FDR<0.05; Figure 4.1; 
see Supplementary Tables 4.1-4.5 for significant results in each analysis) after correction 
for multiple confounders, and excluding results with significant heterogeneity (het p<0.05). In 
the individual analysis including all participants (n=7,781) 246 probe-pairs (208 unique 
genes) were significant; after restricting to the older (≥60 years, n=2,402) participants no 
probe-pairs were significant; within the younger (<60 years, n=5,379) participants 39 probe-
pairs (31 unique genes) were significant; within the male participants (n=3,557) 26 probe-
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pairs (24 unique genes) were significant; and finally limiting to the female participants 
(n=4,224) 1 probe-pair (1 unique gene) was significantly associated with muscle strength. 
Of the 222 unique genes associated with muscle strength in the meta-analysis all were 
significant (nominal p<0.05) in FHS alone, and 90 (40%) were also independently associated 
with muscle strength (nominally significant; p<0.05) in the Illumina meta-analysis. The 
proportion “independently replicated” was greater (21, of 30, 70%) in the top 30 most 
significant genes identified in the meta-analysis. 
The overlap between the five analyses was moderate (Figure 4.2, Supplementary Tables 
4.6-4.7). Of the 222 genes associated with muscle strength in any analysis, 176 (79%) were 
only associated in the “all individuals” meta-analysis at transcriptome-wide significance. In 
the “older” participants no genes were significantly associated (transcriptome-wide) with 
muscle strength, and in the “females” analysis only one gene was associated, DEFA4, which 
was only statistically significant in that subset. The other two analyses - “younger” and 
“males” - had 31 and 24 genes associated with strength respectively, most of which were 
also identified in the overall meta-analysis (see Figure 4.2 for details). Supplementary table 
4.8 contains additional summarized information about the genes in table 4.2 and those that 
overlap between subset analyses. 
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Figure 4.1 | Gene expression probe-pairs associated with muscle strength in all participants 
A) compares the individual meta-analyses performed in the Illumina-cohorts and the FHS 
separately. The red points represent gene transcripts significantly associated with muscle 
strength (FDR<0.05). The light grey points were excluded due to significant heterogeneity 
(Cochran's Q-test p < 0.05 [192]). The darker grey points were not significant in this analysis. 
The grey line shows the trend across all the genes. The red line shows the trend across 
genes significantly associated with muscle strength (FDR<0.05). 
B) Shows the meta-analysis results by Manhattan plot. The blue line indicates those probes 
significantly associated after Benjamini-Hochberg correction, the red line shows those 
significant after Bonferroni correction, for comparison. 
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Table 4.2 | Top 20 unique genes associated with muscle strength in the meta-analysis of all 
participants in all four discovery cohorts 
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Figure 4.2 | Venn diagram showing the overlap between the five meta-analyses 
 
This plot shows a Venn diagram of genes with significant associations between whole-blood 
expression and muscle strength in the meta-analysis of 7,781 participants. Although five 
meta-analyses were performed, there were no significant associations in the “older” subset 
so it is excluded from this plot. 222 unique genes in total were associated with muscle 
strength in at least one analysis. Additional information is available in Supplementary 
Tables 4.6/4.7. 
 
 
4.5.3 Significant genes only available on one array 
Due to differences between the array technologies and relative abundance of transcripts not 
all the genes were eligible for the meta-analysis. In the analysis on all individuals, 1,123 
probes (898 unique identifiers) were present on the Affymetrix Exon array that did not have a 
corresponding probe on the Illumina array; 21 of these probes (14 unique genes) were 
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significantly associated with hand-grip strength after BH adjustment for multiple testing (see 
Table 4.3 for top 20 probes in the “all individuals” analysis and Supplementary Tables 4.9-
4.13 for list of significant probes in each of the five analyses in FHS only).  In the Illumina 
array, 7,768 probes (6,119 unique gene identifiers) were available that did not map to a 
gene/transcript in the Affymetrix Exon array (after excluding lowly expressed probes). None 
of the probes were significantly associated with muscle strength after BH multiple testing 
correction. 
 
4.5.4 Ontology enrichment of strength-associated genes 
Using the 208 genes associated with muscle strength in the meta-analysis of all participants, 
two analyses were performed using the WebGestalt web resource; 
1. Gene Ontology analysis found that 10 biological processes (Table 4.4; including 
“hemoglobin metabolic process” and “innate immune response”) were significantly enriched 
(FDR<0.05), 10 molecular functions were enriched (including “protein binding genes”), and 
10 cellular component pathways were enriched (including “intracellular membrane-bound 
organelle”) (See Supplementary Table 4.14 and Supplementary Figure 4.1).  
2. Human Phenotype Ontology analysis found 10 phenotypes significantly enriched in the 
genes, including “Anemia due to reduced life span of red cells”, “Hemolytic Anemia”, and 
“Abnormality of erythrocytes” (See Supplementary Table 4.15 and Supplementary Figure 
4.2). 
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Table 4.3 | Top 20 probes in the FHS analysis that did not map to a corresponding Illumina 
probe, ordered by p-value 
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4.5.5 A priori genes associated with muscle function 
Of 20 IGF-genes tested in this meta-analysis (from IGF1 to IGFL4) two were significantly 
associated with muscle strength: IGF1R (positively associated) and IGF2BP2 (negatively 
associated) (meta-analysis FDR=3.2x10-2 and FDR=1.2x10-3, respectively). GDF11 
expression was not associated with muscle strength (FDR>0.05). 40 unique Kelch genes 
were tested in the meta-analysis; none were associated with muscle strength in whole blood 
(FDR>0.05). 18 unique Wnt genes (from WNT1 to WNT9B) were tested in the meta-analysis; 
none were associated with muscle strength in whole blood (FDR>0.05). All 10 Frizzled genes 
(FZD1-10, receptors for the Wnt pathway) were also available to test; none were associated 
with muscle strength. Similarly all three Dishevelled genes were available to test (DVL1-3, 
acts directly downstream of the Frizzled receptors) and none were associated with muscle 
strength. Of 586 genes identified by Melov et al that were differentially expressed in muscle 
tissue between old and young men following endurance training [179] four were associated 
with muscle strength in this analysis: ANP32B, CIRBP, MCM7 and MGST1. 
 
4.5.6 Most associated genes are not previously linked to muscle in the literature 
By systematically searching the literature for each of the 222 genes significantly associated 
with muscle strength we determined that 115 have not been mentioned in the same title or 
abstract as the search term “muscle” (as of 12th Nov 2014; Supplementary Table 4.16). 
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Table 4.4 | Ten biological processes were enriched in the genes associated with muscle 
strength in the overall analysis 
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4.5.7 Few genes replicate in the NESDA cohort 
NESDA was not included in the meta-analysis due to data limitations, notably the lack of 
empirically determined or reliably imputed white cell count data, the use of a different 
microarray technology (a predecessor to the Exon array used by FHS, much more dissimilar 
than the v3/v4 Illumina arrays are to one another), and a younger population than the other 
cohorts included in the meta-analysis (max age=65, see Table 4.1). 
As noted above, in total 222 unique genes were associated with muscle strength across all 
the meta-analyses performed. Of 208 genes significantly associated with muscle strength in 
analysis 1 (all participants) it was possible to test 144 in the NESDA cohort; 7 genes were 
also associated with muscle strength (p<0.05) in the NESDA cohort with the same direction 
of effect (ACSL6, ALDH5A1, CARHSP1, FGL1, NRG1, PIGB, SIGLEC7). No genes were 
significantly associated with muscle strength in the older subset. Of 31 unique genes 
associated in the younger subset, 23 were available to test in NESDA; none replicated. Of 24 
genes significant in the males only analysis 12 were available to test in NESDA, one of which 
was significant (ALAS2, B=-0.009, p=0.01). Finally in the analysis on females only 1 gene 
was significant in the meta-analysis but was not associated with strength in the NESDA 
cohort. 
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4.6 Discussion 
In this discovery study we set out to determine whether specific transcript levels in blood are 
associated with muscle strength in multiple human cohorts including mostly middle-aged 
volunteers. Previous cross-sectional (and longitudinal) studies have shown that the degree 
and rate of loss of strength (and muscle mass) is greater in older (male) participants [195]. 
We therefore performed stratified analyses by gender and age to determine whether 
transcripts or pathways associated with muscle strength in whole blood differ between these 
groups. 222 unique genes were associated with muscle strength in at least one analysis, 115 
of which were not previously linked to the term “muscle” in the published literature cataloged 
on GeneCards and PubMed (as of 12th Nov 2014). 
Expression of GDF11, a protein that can reverse age-related muscle dysfunction in mice [3], 
was not associated with muscle strength in this analysis. Instead, we observe significant 
associations between muscle strength and expression of IGF1R and IGF2BP2 (positive and 
negative directions of association with muscle, respectively), growth factors involved in 
skeletal muscle growth [182]; it may be that the circulating growth factor pathways required in 
humans are different to those in mice. No genes from the Wnt or Kelch pathways (both 
known to be important for muscle function [180], [181]) were associated with muscle strength 
in whole blood in this analysis, potentially due to the specificity of these particular pathways 
to muscle tissue. We also examined 586 genes identified by Melov et al that differ in 
expression in muscle between old and young men after endurance training [179], four of 
which were associated with grip strength in this study: MGST1 (negative direction), an 
immune mediator [139] which may also protect against oxidative stress [196]; MCM7 
(positive direction), regulates DNA replication during proliferation [197] and is up-regulated in 
peripheral leukocytes following IGF-1 administration [198]; CIRBP (positive direction), with 
promotes inflammation in response to shock and sepsis [199]; and ANP32B (negative 
direction), a cell-cycle progression and anti-apoptosis factor [139]: however lack of strength 
measures in the original study make direct comparison challenging. 
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The gene ALAS2, which is known to be a rate-limiting step in heme biosynthesis [200] and is 
found in erythrocytes in blood [201], was most strongly associated with muscle strength in 
the meta-analysis (negative direction) and was also associated in the NESDA cohort. Other 
genes of note include CCR6 and PRF1 (both positively associated with muscle strength and 
age [79]); CCR6 is implicated in B-cell maturation and recruitment of other immune cells 
during immune responses [202]; perforin (PRF1), a protein secreted by cytotoxic T-cells 
creates pores in membranes to permit apoptosis-inducing granzyme into the target cell [203], 
was also significantly associated with strength. In a separate study PRF1 expression 
mediated age-related inflammation [204]. NANOG expression is positively associated with 
strength in this analysis (Table 4.2), can reverse ageing of some stem cells [205] and, in 
combination with three other genes (OCT4, SOX2, and LIN28, not significant in this 
analysis), can induce pluripotency of somatic cells [206]. This may suggest that 
differentiation (of whole blood cells) is inversely correlated with muscle strength, but the 
mechanisms are unclear. 
 
4.6.1 Enrichment analysis 
In ontology enrichment analyses using the online tool WebGestalt we identified statistically 
significant enrichment for genes in the biological process “Hemoglobin Metabolic Process” (5 
of 14 genes in the biological process were associated with strength) and the phenotypic 
abnormality “Hemolytic Anemia” (8 of 54 genes), amongst others. Hemoglobin levels are 
positively associated with muscle strength and density [207]. Circulating reticulocytes 
(erythrocyte precursors with some residual RNA present) were not adjusted for in this 
analysis and are likely the source of the associations with genes such as ALAS2, which 
appears to be exclusively expressed by erythrocytes in blood [201].  
“Innate Immune Response” (18 of 539 genes) is also enriched in the Gene Ontology 
annotation results from WebGestalt; this includes cells such as macrophages which are 
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essential for maintenance of muscle strength due to their anti-inflammatory, wound-healing 
response [47]. CEBPB, the gene implicated in the macrophage wound-healing response 
[113] and significantly associated with muscle strength in the 2012 study by InCHIANTI [183], 
did not replicate in the other cohorts. This could be due to methodological differences 
between the previous study and this meta-analysis, as well as differences in age distribution 
(81% of the InCHIANTI cohort is aged >=60 years, compared to only 31% of the meta-
analysis participants, which includes the InCHIANTI cohort; Table 4.1). Whether the original 
finding was a false-positive is unclear given the mouse model evidence of plausible biological 
mechanism [113] and evidence from a study in humans showing that exercise-induced 
muscle damage is associated with change in CEBPB expression in peripheral blood cells 
[184]. Further work on this marker will be required in older and frail groups. It is important to 
note that although the haematology pathways were more statistically significant, the immune 
pathway actually contained more genes associated with muscle because the significance is 
related to the proportion of the total genes in the pathway that are present. Examination of 
Supplementary Table 4.14 is necessary for a full appreciation of this and the biologic 
implications. 
 
4.6.2 Heterogeneity in subset analyses 
Five analyses were performed; one in all participants, and four in subsets. The majority of 
genes (79%) were only associated in the analysis including all study participants. Overlap 
between the subsets of analyses was variable (see Figure 4.2 and Supplementary Tables 
4.6/4.7 for details) and no genes were identified at transcriptome-wide significance when just 
analyzing individuals over 60 years of age. Although the sample size was still reasonably 
high (2,402 participants) variability in the strength phenotype as individuals age, and 
development of different co-morbidities and chronic inflammation (for instance multiple co-
morbidities reduce the association between anemia and disability [208]) may reduce the 
power to detect associations. However in the younger group (n=5,379) we find 31 unique 
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genes associated in the meta-analysis; this analysis could have more power firstly due to the 
sample size, but also the participants have a greater range of strength values, with lower 
levels of chronic inflammation and disease. Defensin, Alpha 4, Corticostatin (DEFA4, 
negative strength association in the analysis of females only) is a cytotoxic peptide that has 
antimicrobial activity against Gram-negative bacteria (predominantly) [202], and there 
appears no obvious explanation for this finding in females. These results confirm previous 
work indicating that the immune response is strongly associated with muscle strength [176], 
[177]. 
 
4.6.3 Limitations 
There are several potential limitations of this study including its cross-sectional design.  As 
such it is not possible to determine if changes in muscle strength lead to differential gene 
expression or whether gene expression affects muscle strength.  Future longitudinal studies 
should address this by testing gene expression associations with subsequent changes in grip 
strength.  A second potential limitation is the “whole blood” nature of the tissue studied, 
which makes it impossible to determine the specific cellular origins of gene expression 
associations.  Third, the microarray technology used across the participating cohorts was not 
the same; although 21 (70%) of the top 30 meta-analysis results were independently 
replicated between the platforms, replication of the less strong results was limited. However, 
this does suggest that our top results are very robust to cohort and array differences. 
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4.6.4 Conclusions 
We have identified robust associations between the expression of 222 genes muscle 
strength in human whole blood. For 115 genes this is the first published evidence in the 
literature linking them to muscle. Genes identified include key growth factor-related genes, 
although not GDF11, the innate immune response, and hemoglobin metabolism. Further 
work is needed to characterize expression patterns in the older groups and to investigate the 
cellular origins of gene expression signals. Future research should also include independent 
replication and longitudinal data to assess long-term prediction of frailty and disease. 
Perhaps most importantly, this analysis suggests that there are heterogeneous processes 
involved in muscle strength in mid- versus later-life, and separate analyses are needed of 
muscle strength at advanced ages. 
  
 PhD Thesis | Luke Pilling 
104 Chapter 4 – Analysis 2 – Muscle Strength Meta-analysis 
4.7 Funding and Acknowledgements 
All authors declare no competing financial interests.  
FHS gene expression profiling was funded through the Division of Intramural Research 
(Principal Investigator, Daniel Levy), National Heart, Lung, and Blood Institute, National 
Institutes of Health, Bethesda, MD. Dr. Murabito is supported by NIH grant R01AG029451.  
Dr. Kiel is supported by NIH R01 AR41398. The Framingham Heart Study is supported by 
National Heart, Lung, and Blood Institute contract N01-HC-25195. 
The InCHIANTI study was supported in part by the Intramural Research Program, National 
Institute on Aging. D.M. and L.W.H. were generously supported by a Wellcome Trust 
Institutional Strategic Support Award (WT097835MF). W.E.H. was funded by the National 
Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health 
Research and Care (CLAHRC) for the South West Peninsula. The views expressed in this 
publication are those of the authors and not necessarily those of the NHS, the NIHR or the 
Department of Health in England. 
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, 
Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), 
the Netherlands Organisation of Scientific Research NWO Investments (nr. 
175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-
015; RIDE2), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare 
and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The 
authors are grateful to the study participants, the staff from the Rotterdam Study and the 
participating general practitioners and pharmacists. The generation and management of 
RNA-expression array data for the Rotterdam Study was executed and funded by the Human 
Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, 
Erasmus MC, the Netherlands. We thank Marjolein Peters, MSc, Ms. Mila Jhamai, Ms. 
 PhD Thesis | Luke Pilling 
105 Chapter 4 – Analysis 2 – Muscle Strength Meta-analysis 
Jeannette M. Vergeer-Drop, Ms. Bernadette van Ast-Copier, Mr. Marijn Verkerk and Jeroen 
van Rooij, BSc for their help in creating the RNA array expression database. 
SHIP is part of the Community Medicine Research net of the University of Greifswald, 
Germany, which is funded by the Federal Ministry of Education and Research (grants no. 
01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social 
Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald 
Approach to Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of 
Education and Research (grant 03IS2061A). The University of Greifswald is a member of the 
'Center of Knowledge Interchange' program of the Siemens AG and the Caché Campus 
program of the InterSystems GmbH. 
 
 
  
 PhD Thesis | Luke Pilling 
106 Chapter 4 – Analysis 2 – Muscle Strength Meta-analysis 
4.8 Supplementary Information 
Due to their number and size, supplementary figures and tables are not included in the 
printed version of this thesis. Please see the accompanying CD-ROM. 
 
Supplementary Table 4.0 | Authors list 
 
 
Order Position Initials Name Titles Cohort 
Starred first authors / analysts (ordered by inclusion in meta-analysis, then sample size) 
 
1 First-first L.C.P. Luke C. Pilling MSc InCHIANTI 
 
2 First R.J. Roby Joehanes PhD FHS 
 
3 First T.K. Tim Kacprowski MSc SHIP 
 
4 First M.J.P. Marjolein J. Peters MSc RS 
 
5 First R.J.2 Rick Jansen PhD NESDA 
Middle, active co-authors ranked alphabetically by cohort, then surname 
 
6 Middle D.K. David Karasik PhD FHS 
 
7 Middle D.P.K. Douglas P. Kiel PhD FHS 
 
8 Middle L.W.H. Lorna W. Harries PhD InCHIANTI 
 
9 Middle A.T. Alexander Teumer PhD SHIP 
Middle co-authors are ranked alphabetically by cohort, then by surname 
 
10 Middle D.L. Daniel Levy PhD FHS 
 
11 Middle H.L. Honghuang Lin PhD FHS 
 
12 Middle K.L. Kathryn Lunetta PhD FHS 
 
13 Middle P.J.M. Peter J. Munson PhD FHS 
 
14 Middle S.B. Stefania Bandinelli MD InCHIANTI 
 
15 Middle W.E.H William Henley PhD InCHIANTI 
 
16 Middle D.G.H Dena G. Hernandez MSc InCHIANTI 
 
17 Middle A.B.S. Andrew B. Singleton PhD InCHIANTI 
 
18 Middle T.T. Toshiko Tanaka PhD InCHIANTI 
 
19 Middle G.G. Gerard van Grootheest Msc NESDA 
 
20 Middle A.H. Albert Hofman PhD RS 
 
21 Middle A.G.U. André G. Uitterlinden PhD RS 
 
22 Middle R.B. Reiner Biffar MD SHIP 
 
23 Middle S.G. Sven Gläser MD SHIP 
 
24 Middle G.H. Georg Homuth PhD SHIP 
 
25 Middle C.M. Carolin Malsch MSc SHIP 
 
26 Middle U.V. Uwe Völker PhD SHIP 
Starred last authors / group leaders 
 
27 Last B.W.J.H.P. Brenda W.J.H. Penninx PhD NESDA 
 
28 Last J.B.J.M. Joyce B.J. van Meurs PhD RS 
 
29 Last L.F. Luigi Ferrucci MD, PhD InCHIANTI 
 
30 Last T.K.2 Thomas Kocher MD SHIP 
 
31 Last J.M.M. Joanne M. Murabito MD, ScM FHS 
 
32 Last-last D.M. David Melzer MBBCh, PhD, FFPH InCHIANTI 
 PhD Thesis | Luke Pilling 
107 Chapter 5 – Analysis 3 – Cognitive Function 
Chapter 5 – Analysis 3 – Cognitive Function 
 
 
Leukocyte CCR2 Expression Is Associated with Mini-Mental State 
Examination Score in Older Adults 
Rejuvenation Research (2012); 15:4. 395-404. 
 
Harries, Lorna W * 
Bradley-Smith, Rachel M * 
Llewellyn, David J 
Pilling, Luke C 
Fellows, Alexander 
Henley, William 
Hernandez, Dena 
Guralnik, Jack M 
Bandinelli, Stefania 
Singleton, Andrew 
Ferrucci, Luigi 
Melzer, David 
 
* These authors contributed equally  
 PhD Thesis | Luke Pilling 
108 Chapter 5 – Analysis 3 – Cognitive Function 
5.1 Overview 
In this study we analysed the expression of genes in InCHIANTI for their association with 
cognitive function – the Mini-Mental State Examination (MMSE) score. It is a general feature 
of ageing that general cognitive ability decreases, so we chose to undertake this analysis 
and found a single marker (gene CCR2) to be negatively associated with MMSE score 
(therefore to have higher expression in those individuals with some form of cognitive 
impairment). We also assessed gene expression associations with change in MMSE score 
over 9 years, hoping to discover a marker for cognitive decline, but found only the CCR2 
gene again. 
I undertook the bioinformatic analysis (transcriptome-wide screen, validation of phenotype, 
gene-set enrichment analysis, investigation of confounders, interrogation of online 
databases), and worked with the other authors in reviewing the literature, discussing and 
interpreting the results, and writing the manuscript. This project was initiated as a lab-based 
investigation led by Rachel, however the emphasis of the study changed dramatically after 
the bioinformatic analysis revealed the CCR2 finding. 
  
 PhD Thesis | Luke Pilling 
109 Chapter 5 – Analysis 3 – Cognitive Function 
5.2 Summary 
Introduction: Circulating inflammatory markers may play an important role in cognitive 
impairment at older ages.  Mice deficient for the chemokine (C-C motif) receptor 2 (CCR2) 
develop an accelerated Alzheimer’s-like pathology, and CCR2 is also important in 
neurogenesis. To identify human gene transcripts most closely associated with Mini Mental 
State Examination (MMSE) scores we undertook a genome-wide and inflammation specific 
transcriptome screen in circulating leukocytes from a population-based sample.  
Methods: We measured in-vivo transcript levels by microarray analysis in 691 subjects 
(mean age 72.6 yrs) in the InCHIANTI study. We assessed expression associations with 
MMSE performance at RNA collection and prior 9 year change in MMSE score in linear 
regression models.  
Results: In genome-wide analysis, raised CCR2 expression was cross-sectionally the most 
strongly associated transcript with lower MMSE score (beta=-0.16, p=5.1x10-6, False 
discovery rate ‘FDR’ q=0.077). Amongst inflammatory transcripts, only CCR2 expression was 
associated with both MMSE score and accelerated decline in score over the preceding 9 
years (beta=-0.16, p=5.1x10-6, q=0.003; and beta=-0.13, p=5.5x10-5, q=0.03; respectively). 
CCR2 expression was also positively associated with ApoE e4 Alzheimer’s disease risk 
haplotype.  
Conclusions: We show for the first time that CCR2 expression is associated with lower 
MMSE scores in an older human population. Laboratory models of Ccr2-mediated -amyloid 
removal and regulation of neurogenesis affecting cognitive function may be applicable in 
humans. CCR2-mediated pathways may provide a possible focus for intervention to 
potentiate protective reactions to Alzheimer’s pathology in older people, including for people 
with adverse ApoE haplotype.   
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5.3 Introduction 
Cognitive impairment and dementia at older ages commonly results from accumulating 
vascular and neurodegenerative pathology in the brain [209] and is experienced by over half 
of adults aged 85 or over [50]. Major risk factors for cognitive impairments in later life include 
APOE e4 haplotype [210], but the underlying biological mechanisms are still unclear. Gene 
expression arrays offer a new approach to identifying the most important molecular 
mechanisms causing or responding to the pathologies underlying cognitive decline. The most 
accessible tissue for gene expression array analyses in large numbers of older people is 
circulating blood leucocytes, which are likely to be most sensitive to inflammatory and related 
mechanisms.  
Chronic low-level inflammation has been proposed as a key mechanism underlying cognitive 
decline and dementia, and has been implicated in the neuropathological cascade leading to 
late onset Alzheimer’s disease (LOAD) [211]. Inflammatory factors have been further 
implicated in cognitive impairment and dementia using mouse models [212]. These include 
transgenic animals in which chemo-attractant proteins or receptors such as Ccl2 or Ccr2 
have been abolished [212].  These genes, associated with the migration of phagocytic and 
inflammatory macrophages, have been associated with Alzheimer’s pathology and peripheral 
atherosclerosis [212]–[214]. Ccr2-deficient mice show early accumulation of β-amyloid, with 
premature mortality [214]. Blood-borne systemic factors including CCR2 and CCL11 were 
also recently implicated in the negative regulation of neurogenesis and cognitive function in 
rodent studies [4].  
The importance of CCR2 and related signaling in human age-related cognitive impairment is 
unclear. Maes et al (2007) identified leukocyte expression differences between 14 
Alzheimer’s Disease and control individuals in a microarray experiment [215], while Grunblatt 
et al identified five peripheral blood leucocyte genes whose mRNA correlated significantly 
with MMSE (Mini Mental State Examination) score in a smaller series of Alzheimer’s and 
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control individuals [216].  These studies present initial evidence that brain changes in 
pathologically-specific dementia patients may be detectable using peripheral leukocyte gene 
expression, but it is currently not known if this also applies to age-associated cognitive 
decline. 
In the current study, we used a genome-wide and inflammation-focused approach to identify 
the most strongly associated in-vivo transcript levels in circulating leukocytes associated with 
MMSE score or rate of change in MMSE score in a general population sample of 
predominantly older people. The MMSE is a widely used measure of cognitive function in 
prospective epidemiological studies of elderly populations, and is sensitive to moderate or 
severe cognitive declines, often due to dementia [217], [218]. To ensure population 
relevance, no exclusions for co-morbidity were made in the main analysis. 
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5.4 Methods 
5.4.1 Study cohort 
We used InCHIANTI, a population-based study of aging [115], which has followed older 
persons over a 9 year period to assess ‘normal’ aging using both interviews (conducted at 
the participants home by experienced interviewers) and blood samples (in the study clinic, all 
patients fasted for 8 hours prior to collection). Peripheral blood samples for RNA extraction 
were collected from participants at the 9 year follow-up (2008/9). Cohort demographics are 
given in table 1. Ethical approval was granted by the Instituto Nazionale Riposo e Cura 
Anziani institutional review board in Italy. Participants gave written informed consent to 
participate and for sample collection after having received an extensive description of the 
procedures, purposes and potential risks of the study. RNA was extracted from each sample 
using the PAXgene Blood mRNA kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. To ensure population relevance, no exclusions for co-morbidity were made in 
the main analysis. 
 
5.4.2 Whole transcriptome scan 
Whole genome expression profiling of the samples was conducted using the Illumina Human 
HT-12 microarray (Illumina, San Diego, USA), data processing was carried out using the 
Illumina and Beadstudio software (Illumina, San Diego, USA) as previously described [155]. 
Baseline intensities were calculated as mean and SD computed over all beads for a 
particular probe. QC steps included correction for local background effects, removal of outlier 
beads, computation of average bead signal and SD for each probe and gene, calculation of 
detection p-values using negative controls present on the array, quantile normalization 
across arrays, check of outlier samples using a clustering algorithm, and checks of positive 
controls. Subject level QC steps included removing individuals where the expression 
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intensity was +/- 3 standard deviations from the mean. All microarray experiments and 
analyses complied with MIAME guidelines [219]. Following microarray data QC steps, 16,571 
transcripts gave reliable signals above background (p<0.01) in >5% of the sample population 
and were therefore eligible for analysis. 
 
5.4.3 Assessment of cognitive function 
Participant interviews and clinical assessment, including the Mini-Mental State Examination 
of global cognitive function (MMSE), were undertaken at baseline, and at years 3, 6 and 9 of 
follow-up.  The MMSE is an assessment of global cognitive function widely used in both 
hospital and community settings as a dementia screening tool [220], [221]. 
 
5.4.4 Included sample and statistical analysis 
From 733 blood samples collected, RNA quality and microarray QC steps resulted in loss of 
35 participants from the analysis. From the remaining 698 participants, 7 were excluded due 
to absence of MMSE data, yielding 691 individuals. Three further individuals were dropped 
from the regression models due to incomplete leukocyte data. (See table 5.1 for summary 
statistics of the cohort included in the analyses). All the remaining 688 individuals were 
included in the analyses, irrespective of other pathologies. 
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Table 5.1 | This table summarises the population statistics for the 691 participants eligible for 
our study. 
 
Summary statistics 
Age (years) n 
 
30-49 86 (12.5%) 
 
50-69 98 (14.2%) 
 
70-89 479 (69.3%) 
 
90-104 28 (4%) 
Mean age at RNA-collection 72.6 (SD: 15.3) 
   
Gender % 
Men 44.8 
Women 55.2 
   
MMSE score 
 Mean score at RNA-collection 25.58 (SD: 5.66) 
Mean change in MMSE (9 years) -1.31 (SD: 4.71) 
Frequency of scores at RNA collection % 
 0-18 8.14 
 19-23 12.79 
 24-27 30.52 
 28-30 48.55 
   
Education % 
None 13.31 
Elementary 46.02 
Secondary 13.46 
High school 12.59 
University / Professional 14.62 
   
Pack years smoked (lifetime) % 
None 55.72 
0.1-20 22.87 
20-39 14.33 
40+ 7.09 
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Associations between gene expression and MMSE score at RNA collection were analysed 
using multiple regression models adjusted for the following potential confounding factors: age 
in years (as a continuous variable), gender, highest level of education received (in five 
categories: none, elementary, secondary, high school, and university/professional), lifetime 
pack-years smoked (in four categories: none, 0.1 to 20 years, 20 to 39 years, and 40 plus 
years), blood leukocyte type (neutrophil, lymphocyte, monocyte, eosinophil percentages) 
each as continuous variables, hybridisation and amplification batch (in 10 and 14 categories 
respectively), and study site; participants lived in either a rural village (Greve) or an urban 
site (Bagno a Ripoli). 
Separate linear regression models were fitted for each of the full set of 16,571 probes which 
passed QC in the discovery dataset. We have expressed the effect sizes of the associations 
in standardized betas to aid in the interpretation (expression intensities vary from probe to 
probe, and the normalization procedures further affect the interpretability of coefficients). We 
controlled for the effect of multiple testing by measuring the statistical significance of each 
association using both the p-value and the q-value. The q-value quantifies significance in 
terms of the false discovery rate (FDR) rather than the false positive rate [222], and forms a 
measure of how likely a particular p-value is to represent a genuine association.  Expression 
levels were taken to have a significant association with MMSE score at RNA collection, or 
cognitive decline from baseline 9 years previously, if the association achieved a nominal p-
value ≤0.05 and a q-value <0.1. Our study was powered to detect expression differences of 
<0.25 SD for the 16,571 transcripts studied, allowing us to detect moderate expression 
differences between groups.  
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5.4.5 Inflammatory gene scan 
The large number of transcripts tested in the whole genome scan yields a very stringent 
requirement for statistical significance, resulting in a substantial risk of type II (false negative) 
error. Since leukocytes are an inflammation-related tissue, we carried out a sub-analysis 
focusing on a smaller subset of genes involved in inflammatory response only. The genes of 
interest were identified using the Molecular Signatures Database (MSigDb) [159], with search 
terms for inflammatory/immune-related gene pathways as defined by the Gene Ontology 
(GO) project (www.geneontology.org). 44 inflammation-related gene-sets were returned, 
comprising 635 unique probe IDs, which equate to 425 unique genes with available data in 
our cohort (Supplementary table 4.1). Linear regression models were carried out as 
described above. This study is powered to detect expression differences of <0.22 SD for the 
inflammation transcript set. 
 
5.4.6 Real-time PCR validation 
The expression of the CCR2 gene in a subcohort of 100 individuals selected at the extremes 
of the MMSE spectrum was validated by the use of a custom real-time PCR assay (probe 
and primer sequences available on request). Reaction mixes included 5l 2x TaqMan 
universal master mix (no AMPerase) (Applied Biosystems, Foster City, USA), 30l dH2O and 
2l cDNA template. PCR amplifications were performed on the ABI 7900HT platform 
(Applied Biosystems, Foster City, USA). Cycling conditions were 50C for 2 minutes, 94.5C 
for 10 minutes followed by 40 cycles of 97C for 30 seconds and 57.9C for 1 minute. The 
expression of each gene was measured in triplicate for each sample. Gene expression 
relative changes were quantified using the 2-DDCt method [223] relative to the geometric mean 
of the GUSB, B2M and PPIA endogenous controls. The correlation between quantifications 
achieved using microarray and by real-time PCR was then assessed using linear regression. 
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5.4.7 Gene Set Enrichment Analysis (GSEA)  
We also performed GSEA to identify gene sets/pathways associated with cognitive function, 
according to the method of Subramanian et al [159]. Molecular or biological function 
pathways were identified using Gene Ontology gene sets from the molecular signature 
database (MSigDB) (http://www.broadinstitute.org/gsea/msigdb/index.jsp). Gene set size 
filtering excluded gene sets containing less than 15 or more than 500 genes. Genes were 
ranked according to the magnitude of their association with cognitive function, and 
representation of each gene set within this ranked list was analysed. Gene sets significantly 
overrepresented at the top or bottom of the ranked list were taken to be significantly 
associated with cognitive function. A signal-to-noise metric was used to rank genes, and 
gene set enrichment scores were calculated using a weighted enrichment statistic. One 
thousand random permutations of the phenotype label were used to calculate the empirical 
p-values of each pathway compared to the p-values that would be ascertained by chance. 
Gene sets with a nominal p-value<0.01 and q-value<0.1 were considered associated with 
cognitive impairment or cognitive decline.  
 
5.4.8 Penalized cubic regression spline 
Using R package ‘mgcv’ [224] we fitted an adjusted generalized additive model (GAM) using 
a smoothed penalized cubic regression spline; the smoothing parameter was chosen 
automatically by cross-validation.  The same data and covariates that made up the original 
generalized linear regression (GLM) screen were used. GAM is applied here because it 
allows non-parametric fits, and thus if an aberrant relationship between expression and age 
had existed it could be highlighted. 
 
 
 PhD Thesis | Luke Pilling 
118 Chapter 5 – Analysis 3 – Cognitive Function 
5.5 Results 
5.5.1 Cohort Details 
Participant characteristics are given in table 5.1; the study sample had a mean age of 72.6 
years (SD: 15.3, range 30 to 104) and 55.2% were female. At RNA collection the mean 
MMSE score was 25.58 (SD 5.66), 21% of the sample had MMSE scores of 23 or less (8.1% 
with MMSE of 18 or less), and the mean change in MMSE scores over 9 years was -1.31 
(SD = 4.71). The correlation between MMSE change and MMSE at baseline is 0.14, and the 
correlation between MMSE change and MMSE at year 9 is 0.89. 
 
5.5.2 Genome wide analysis 
In genome wide analysis, only one transcript (CCR2, measured via probe ilmn_1774761) 
showed a very near significant genome wide association with MMSE score at RNA collection 
(beta=-0.16, p=5.1x10-6; q=0.076; table 5.2). No probes were significantly associated (q < 
0.1) with change in MMSE score over the preceding 9 years (table 5.2), although CCR2 was 
the most strongly associated transcript (beta=-0.13, p=5.5x10-5, q=0.70). Quantile-Quantile 
(QQ) plots comparing the observed p-values (-log10) with those that would be expected by 
chance alone (figure 5.1a) confirmed that large scale disruption to gene expression levels in 
blood was not a feature of MMSE score at RNA collection or change in score over the 
previous nine years, although some small deviations from the expected pattern were noted.  
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Table 5.2 | The ten probes most closely associated with MMSE score at wave 9 and change 
in MMSE score (baseline to year 9), ordered by false discovery rate q-value (n observations 
= 688). 
 Probe ID p-value Coefficient Beta 95% CIs q-value Gene   
MMSE score at year 9        
 ilmn_1774761 5.1E-06 -0.0042 -0.1616 -0.0056 -0.0027 0.076 CCR2  
 ilmn_2374362 2.7E-05 -0.0015 -0.1709 -0.0021 -0.0009 0.204 FAM108B1  
 ilmn_1791912 1.1E-04 0.0052 0.1475 0.0030 0.0074 0.356 SIDT2  
 ilmn_1758457 1.2E-04 0.0008 0.1473 0.0005 0.0011 0.361 TBC1D16  
 ilmn_1796094 1.5E-04 -0.0044 -0.1486 -0.0063 -0.0025 0.381 CD36  
 ilmn_1693949 1.7E-04 0.0011 0.1153 0.0006 0.0015 0.390 UNQ1944  
 ilmn_1724266 2.8E-04 0.0017 0.1382 0.0009 0.0025 0.418 LYPD2  
 ilmn_1772821 3.7E-04 -0.0015 -0.1561 -0.0022 -0.0008 0.430 KIAA1671  
 ilmn_2313434 3.9E-04 0.0013 0.1476 0.0007 0.0019 0.433 TCP1  
 ilmn_2393573 4.1E-04 -0.0019 -0.1073 -0.0027 -0.0010 0.434 RASSF1  
Change in MMSE score (9 years)       
 ilmn_1774761 5.5E-05 -0.0040 -0.1305 -0.0056 -0.0024 0.700 CCR2  
 ilmn_2374362 1.5E-04 -0.0015 -0.1345 -0.0022 -0.0009 0.700 FAM108B1  
 ilmn_1796094 2.2E-04 -0.0047 -0.1146 -0.0067 -0.0026 0.700 CD36  
 ilmn_1761941 2.6E-04 -0.0017 -0.1135 -0.0024 -0.0009 0.700 C4orf18  
 ilmn_2313434 2.7E-04 0.0015 0.1273 0.0008 0.0022 0.700 TCP1  
 ilmn_1712684 3.1E-04 -0.0011 -0.1245 -0.0015 -0.0006 0.700 FAM20C  
 ilmn_1866887 3.4E-04 -0.0011 -0.1290 -0.0016 -0.0006 0.700 BX537605  
 ilmn_1772821 5.6E-04 -0.0016 -0.1277 -0.0023 -0.0008 0.700 KIAA1671  
 ilmn_1703314 5.7E-04 0.0013 0.1167 0.0007 0.0020 0.700 KLHL36  
  ilmn_1789751 6.1E-04 -0.0039 -0.0985 -0.0058 -0.0020 0.700 MFSD1   
Models adjusted for: age, gender, highest education level, smoking-status, site, hybridization-batch, 
amplification-batch, leukocyte proportions (and MMSE-baseline score, in 'change' models). 
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Figure 5.1 | Quantile-Quantile plots for gene expression analysis of MMSE score at RNA 
collection 
 
A. The Quantile-Quantile plot for the genome wide analysis of MMSE at RNA collection is 
shown. The actual P-values (-log10) obtained are given on the y-axis, plotted against 
expected P-values (-log10) given on the X-axis. This graph shows potential deviations to the 
p-value distribution that might be expected by chance. B. The Quantile-Quantile plot for the 
focused analysis of inflammatory genes is shown. The actual P-values (-log10) obtained are 
given on the y-axis, plotted against expected P-values (-log10) given on the X-axis. This 
graph shows potential deviations to the p-value distribution that might be expected by 
chance. The positive association with CCR2 transcript is the outlier. 
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5.5.3 Specific analysis of inflammation related transcripts 
In a targeted analysis on inflammation-related transcripts only, the CCR2 transcript was 
associated with MMSE score at RNA collection (beta=-0.16, p=5.1x10-6, q=0.003; table 5.3) 
and also with cognitive decline score over the previous nine years, using a false-discovery 
rate (FDR) of q<0.1 (beta=-0.13, p=5.5x10-5, q=0.03; table 5.3; figure 5.2). As in the genome 
wide analysis, other large-scale alterations in the expression of inflammatory genes were not 
present (after accounting for multiple testing) for either cognitive function or decline, although 
one large effect (CCR2) was evident on the QQ plot (figure 5.1b). 
 
5.5.4 Modeling of relationship between CCR2 transcript expression and MMSE/delta 
MMSE using spline analysis 
To understand any non-linearity in the relationship between CCR2 expression and MMSE 
(and change in MMSE over 9 years, delta-MMSE) we fitted a penalized cubic spline 
regression model for; A. CCR2 expression and MMSE at RNA collection, and B. CCR2 
expression and delta-MMSE over the preceding nine years (see figure 5.3 for spline plots). 
We found the relationships to be approximately linear throughout the MMSE or delta-MMSE 
ranges.   
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Table 5.3 | The ten inflammation-related probes most closely associated with MMSE score at 
wave 9 and change in MMSE score (baseline to year 9), ordered by false discovery rate q-
value (n observations = 688). 
 
  Probe ID p-value Coefficient Beta 95% CIs q-value Gene   
MMSE score at year 9        
 ilmn_1774761 5.1E-06 -0.0042 -0.1616 -0.0056 -0.0027 0.003 CCR2  
 ilmn_2366212 1.5E-03 0.0083 0.1267 0.0040 0.0125 0.232 CD79B  
 ilmn_1677440 2.6E-03 -0.0055 -0.1194 -0.0084 -0.0025 0.262 ATP6AP2  
 ilmn_2276996 2.8E-03 -0.0009 -0.1071 -0.0014 -0.0004 0.266 CCR2  
 ilmn_1785439 3.9E-03 0.0042 0.1239 0.0018 0.0066 0.279 CD79B  
 ilmn_1710017 3.9E-03 0.0045 0.1302 0.0019 0.0070 0.279 CD79B  
 ilmn_1764396 5.3E-03 -0.0011 -0.0725 -0.0017 -0.0004 0.288 HDAC4  
 ilmn_1763875 6.1E-03 0.0022 0.0842 0.0009 0.0035 0.291 ABCF1  
 ilmn_1738767 6.5E-03 -0.0012 -0.0780 -0.0019 -0.0005 0.293 PLP2  
 ilmn_1747227 7.1E-03 0.0008 0.1412 0.0003 0.0013 0.295 ADORA1  
Change in MMSE score (9 years)       
 ilmn_1774761 5.5E-05 -0.0040 -0.1305 -0.0056 -0.0024 0.033 CCR2  
 ilmn_2366212 2.1E-03 0.0087 0.1047 0.0041 0.0134 0.305 CD79B  
 ilmn_1710017 2.2E-03 0.0052 0.1013 0.0024 0.0079 0.310 CD79B  
 ilmn_1677440 2.9E-03 -0.0059 -0.0946 -0.0091 -0.0027 0.325 ATP6AP2  
 ilmn_1747227 3.2E-03 0.0009 0.1169 0.0004 0.0015 0.332 ADORA1  
 ilmn_1737398 3.3E-03 -0.0012 -0.0938 -0.0018 -0.0005 0.332 PTPLAD1  
 ilmn_1785439 4.1E-03 0.0046 0.1024 0.0020 0.0072 0.349 CD79B  
 ilmn_1682312 6.5E-03 -0.0025 -0.0726 -0.0040 -0.0010 0.377 CYBB  
 ilmn_1811049 6.8E-03 0.0012 0.0999 0.0005 0.0019 0.379 POU2AF1  
  ilmn_1771333 6.9E-03 -0.0035 -0.0877 -0.0057 -0.0014 0.380 CD47   
Models adjusted for: age, gender, highest education level, smoking-status, site, hybridization-batch, 
amplification-batch, leukocyte proportions (and MMSE-baseline score, in 'change' models). 
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Figure 5.2 | Boxplot of CCR2 expression by MMSE score at RNA collection 
 
The boxplot shows CCR2 transcript expression levels (relative units) as plotted on the Y-axis 
by MMSE score RNA collection on the X-axis. 
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Figure 5.3 | Cubic Spline plots for linearity of association between CCR2 expression and 
MMSE  
 
A. CCR2 expression and MMSE at RNA collection, and B. CCR2 expression and delta-
MMSE over the preceding nine years. These penalized cubic regression splines visualize the 
fitted (adjusted) relationship between CCR2 gene expression and MMSE score, and 
separately with change in MMSE over 9 years. The relationships are approximately linear 
after normalization (log-transformed expression data) and adjustment for multiple 
confounders. 
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5.5.5 Quantitative real-time PCR validation of CCR2 levels. 
To validate our microarray results, we also quantified CCR2 expression in a subset of our 
cohort using quantitative real-time PCR (QRT-PCR). We found that the expression level of 
CCR2 transcripts as measured by QRT-PCR correlated well with the expression levels 
measured by microarray analysis (r2 = 0.5, p=2 X 10-4). PCR-measured logged CCR2 
expression is significantly associated with MMSE is a one-sided test (B = -0.018, p = 0.096), 
however in this subset of participants the Illumina microarray probe is only modestly 
significant (B = -0.005, p = 0.013), suggesting power in 100 participants is a limiting factor. 
 
5.5.6 Gene set enrichment analysis 
No gene sets showed evidence of deregulation in association with MMSE score at RNA 
collection or change in score using GSEA (Gene Set Enrichment Analysis), at a FDR q-value 
of <0.1 (table 5.4).   
 
Table 5.4 | Biological and molecular functional pathway enrichments for negative correlation 
with MMSE are presented 
Pathway  Size     ES p-value q-value 
Aromatic compound metabolic process 17 -1.82 0 0.85 
Regulation of DNA metabolic process 29 -1.74 0.008 0.95 
T cell activation 27 -1.56 0.031 1 
Transferase activity transferring glycosyl groups 68 -1.42 0.034 1 
Cellular defense response 38 -1.52 0.035 1 
Anatomical structure formation 27 -1.55 0.036 1 
Positive regulation of lymphocyte activation 15 -1.58 0.039 1 
Coenzyme metabolic process 30 -1.44 0.045 1 
RNA export from nucleus 17 -1.52 0.045 1 
DNA recombination 32 -1.5 0.047 1 
ES refers to the non-specific enrichment score. 
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5.5.7 Post-hoc Sensitivity analyses 
To determine if the observed association is dependent on the inclusion of some younger 
people in the predominantly older sample, or dependent on the oldest old, we carried out a 
sensitivity analysis in subjects aged ≥70 and <90 years old at RNA-extraction; MMSE score 
and (logged) CCR2 expression were still strongly associated (beta=-0.15, p = 2e-4) within this 
age-range.  
ApoE genotype was available on n=480 (excluding e2e4 n=4) in our sample: CCR2 
expression was positively associated with ApoE risk haplotype (trend test across e2e2, e2e3, 
e3e3, e3e4, e4e4 groups: coef=0.02, CIs: 0.007 to 0.03, p=0.001). The association between 
CCR2 expression and MMSE at RNA collection was attenuated but remained significant after 
additional adjustment for ApoE status (beta = -0.1, p = 0.018). There was no statistical 
interaction between ApoE status and CCR2 expression, and ApoE status accounted for 1.6% 
of the variance in CCR2 expression. ApoE status is not significantly associated with MMSE 
(cross sectionally) or with change over 9 years in these 480 participants (p>0.05). 
Co-morbidity is very common with cognitive impairment in later life in the general older 
population, and therefore our approach has been to avoid disease specific exclusions: 
however, we did examine the effect of removing those diagnosed as having had a stroke 
(n=76 removed): CCR2 remained associated with MMSE score (beta = -0.14, p=0.001) in the 
stroke free group.  
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5.6 Discussion and Conclusions 
In this study, we have investigated associations between blood leukocyte-derived mRNA 
expression and MMSE scores in an ageing population. CCR2 expression reached 
inflammation-specific significance (and only narrowly missed genome wide significance after 
accounting for multiple testing), providing the first human population evidence of likely 
consistency with the Ccr2 mouse models. Our finding that ApoE haplotype status, the major 
inherited genetic risk factor associated with Alzheimer’s pathology, is associated with CCR2 
expression is also consistent with CCR2 signaling having a direct role in cognitive decline in 
later life in human populations.  
The MMSE score is a widely used measure of cognitive impairment in later life, although it 
has a ceiling effect that limits its ability to detect early subtle cognitive changes, particularly in 
younger highly educated participants [217], [225] and is not considered an appropriate 
measure to diagnose mild cognitive impairment or related prodromal diagnoses without 
supplementing it with other cognitive measures, although the population relevance of these 
clinically-derived constructs remains disputed [226]. Over several years follow-up the MMSE 
does however provide a useful measure of cognitive impairment and cognitive decline in 
participants with and without dementia [218], and is the most widely used measure to monitor 
cognitive function and decline in elderly adults in clinical settings. We therefore consider that 
it is an appropriate tool to assess age-related differences in cognitive function in our cross 
sectional population. 
Our functional, rather than pathological, classification of participants was important for 
several reasons. Cognitive decline leads to impairments in activities of daily living, and is a 
major public health threat. It is also rarely determined purely by one pathophysiological 
mechanism - mixed dementia is now considered to be the most common form of dementia 
[227] and functional decline has only a moderate association with the pathological changes 
of Alzheimer disease [228]. Finally, our use of a large, population-based cohort, rather than 
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from specialist clinics, gave us power to detect moderate biomarker effects that could be of 
clinical application in population testing and risk reduction: biomarkers of functional cognitive 
change may hold more clinical application in the population than markers of single 
pathological processes.  
We investigated blood leukocytes in order to identify clinically useful, minimally invasive 
markers of cognitive function since cortical tissue is inappropriate for the identification of 
cognitive decline risk or progression in the population. Furthermore, recent studies suggest 
that circulating systemic factors such as chemokines and their receptors have an important 
role in neurogenesis and cognitive function in animal models [4]. Peripheral inflammation has 
also been shown to impact negatively on human cognitive function [229] with chronic 
immune activation in the brain having an association with neurodegenerative disease and 
cognitive decline [230], [231].  
There are both similarities and differences between our data and previous studies [215], 
[216], [232], [233]. It has been suggested that genes involved in cytoskeletal maintenance, 
cellular trafficking, cellular stress response, redox homeostasis, transcription and DNA repair 
may be associated with Alzheimer’s Disease [226] and proteomics studies have suggested 
that circulating lymphocytes may be promising biomarkers for this disorder [234]. The 
differences could arise from different patient selection criteria; we used population data 
rather than data from clinical settings. Differences with prior proteomic findings in peripheral 
blood in cognitive decline [235], [236] may also be due to small study sizes or the possibility 
that circulating cytokines previously found associated with cognitive decline may be 
expressed by activated CNS inflammatory cells and released into the circulation, rather than 
being expressed by circulating leukocytes [237].  
The CCR2 receptor binds CCL2, a protein that is abundantly expressed in macrophage-rich 
areas of atherosclerotic plaques and in brain microglia [214] resulting in migration of 
macrophages and brain microglial cells to their site of action. In mouse models, vascular 
disruption of Ccr2  or Ccl2 leads to a reduction in atherosclerotic plaque formation in ApoE- 
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or LDL-R null mice, even when fed a high fat diet [213], [234]. This may be mediated by Ccr2 
depletion reducing macrophage infiltration. In mouse brain, Ccr2 knockout has been shown 
to result in accelerated disease progression, increased mortality and an increase in soluble 
antibody assemblies [114], [214]. Work on CCR2 gene knockout mice bred on a background 
of chimeric mouse/humanβ-amyloid precursor/presenilin over-expression  
(APPSwe/PS1/CCR2-/-) suggested that AD might be associated with a decreased expression 
of CCR2 [114]. Although our results at first appear to conflict with this, we suggest that the 
increased CCR2 levels we note in cognitively impaired individuals probably reflects a 
reactive increase in the need for chemoattractants in subjects with increased β-amyloid 
deposition. This is supported by the observation that the ligand for CCR2, CCL2, has 
previously been reported to be up-regulated in the brain of patients suffering from AD [238]. 
Recent studies have also suggested that CCR2 is with a key modulator of negative 
regulation of neurogenesis and cognitive function in mice [4]. Our data supports a role for 
CCR2 in the aetiology of age-related cognitive decline, and indicates that the CCR2 mouse 
models [114], [214] may have particular relevance to the human population. Although much 
more work is needed to confirm causality for this mechanism in human populations the 
mouse models alongside the statistical evidence provide good biological plausibility. 
Key limitations of our study include the possibility that that there are gene expression 
correlates of cognitive function in specific white cell subtypes which we have not measured 
separately. These are not however likely to be very marked or common, as we have found 
only limited overall expression changes. Similarly, as noted above the MMSE score, a widely 
used clinical measure of cognitive function in older people, suffers from a relative insensitivity 
to frontal-executive dysfunction and visuo-spatial deficits [239], and a ceiling effect inhibiting 
sensitive differentiation between medium and high cognitive performers [240]. Our cohort 
may also be subject to informative loss to follow up, and reflect a higher functioning group, 
since people with very impaired cognitive function may not have reported for blood sampling 
in year 9.  
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We note also that several probes to CCR2 transcripts were present on the chip, but only one 
showed associations with MMSE score. Differences in the relationship between phenotype 
and alternative specific probes for the same gene are not atypical in microarray studies. 
These discrepancies can arise from several factors including differences in binding dynamic 
of the individual probes, differences in the inter-individual intensities between probe signal 
which can add noise to the data and reduce power and the presence of alternatively-
processed isoforms which may bind probes differentially.  In the case of CCR2, three 
alternatively-expressed isoforms exist, with only a single probe, ilmn_1774761, capable of 
binding to all isoforms. If the effect we note is driven by a specific isoform, only those probes 
that identify the transcript in question will show a significant association. Since up to 90% of 
all genes are alternatively spliced, and the full transcriptomic output from any gene is not fully 
known at present, this can lead to apparent differences in the association of particular probes 
with disease phenotype in association studies. 
Future work should first seek to replicate our CCR2 finding, and explore associations with the 
full range of isoform specific probes for the main target genes. Work should also seek to 
gather more evidence on which of the near significant probes may in fact be associated with 
cognitive function. Future prospective studies will also provide valuable information as to the 
role of chemo-attractant proteins in age-related cognitive decline. Functional work in humans 
is also needed to clarify the mechanisms involved in the raised expression of CCR2 we 
observed in those with lower or declining MMSE scores. Studies of the role of CCR2 in 
specific forms of dementia (Alzheimer’s, vascular, Lewy Body etc, or mixed) would also help 
characterise the role of CCR2.  If raised expression of CCR2 is a helpful but insufficient 
response to the accumulation of β-amyloid, then attempts to increase this response further 
may potentially be effective. Studies of the role of CCR2 in vascular disease and pro-
inflammatory response would also be informative.  Our findings raise the possibility that 
CCR2 expression levels may also be associated with early, pre-symptomatic cognitive 
changes, although a more sensitive approach than change in MMSE score would be 
required to detect this. 
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To conclude, we have carried out the largest assessment of in-vivo leukocyte human gene 
expression alterations in conjunction with MMSE measured cognitive function in a 
predominantly older population, to date. We identified associations between MMSE score 
and CCR2 transcript levels, which may reflect the key role CCR2 plays in the removal of β-
amyloid and in regulation of neurogenesis. Work is now needed to confirm our findings, 
establish whether these reflect the proposed mechanisms and relate the circulating 
transcriptome changes to specific forms of brain pathology. 
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5.8 Supplementary Information 
 
Supplementary table 5.1 | This table shows the inflammatory gene set as defined by the 
Gene Ontology (GO) project (www.geneontology.org). N refers to the number of genes in the 
pathway 
GO - Pathway Name N[genes] N[genes in data] % 
Activation of immune response 17 12 70.6 
Acute inflammatory response 11 5 45.5 
Adaptive immune response 25 14 56.0 
Adaptive immune response go 0002460 24 13 54.2 
Antigen binding 28 15 53.6 
B cell activation 19 13 68.4 
Chemokine activity 42 15 35.7 
Cytokine activity 111 38 34.2 
Cytokine and chemokine mediated signaling 
pathway 
23 13 56.5 
Cytokine binding 46 33 71.7 
Cytokine biosynthetic process 40 24 60.0 
Cytokine metabolic process 41 25 61.0 
Cytokine production 72 46 63.9 
Cytokine secretion 18 10 55.6 
Cytokinesis 19 8 42.1 
Humoral immune response 31 17 54.8 
Immune effector process 38 22 57.9 
Immune response 232 149 64.2 
Immune system development 80 52 65.0 
Immune system process 326 218 66.9 
Immunological synapse 11 9 81.8 
Inflammatory response 124 81 65.3 
Innate immune response 23 8 34.8 
Interleukin 1 secretion 10 8 80.0 
Jak stat cascade 31 23 74.2 
Jnk cascade 47 32 68.1 
Leukocyte activation 67 42 62.7 
Lymphocyte activation 60 38 63.3 
Negative regulation of cytokine biosynthetic 
process 
11 5 45.5 
Negative regulation of immune system process 14 7 50.0 
Nuclear speck 11 7 63.6 
Positive regulation of cytokine biosynthetic process 24 16 66.7 
Positive regulation of cytokine production 15 11 73.3 
Positive regulation of cytokine secretion 10 6 60.0 
Positive regulation of immune response 29 16 55.2 
Positive regulation of immune system process 51 31 60.8 
Production of molecular mediator of immune 
response 
13 7 53.8 
Regulation of cytokine biosynthetic process 37 22 59.5 
Regulation of cytokine production 25 16 64.0 
Regulation of cytokine secretion 16 8 50.0 
Regulation of immune effector process 15 9 60.0 
Regulation of immune response 33 16 48.5 
Regulation of immune system process 67 41 61.2 
T cell activation 44 27 61.4 
 2031 1228 Mean = 59% 
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6.1 Overview 
Interleukin-6 (IL-6) is a circulating cytokine and is a marker of chronic inflammation, the 
levels of which increase with age. In this analysis of peripheral (leukocyte) gene expression 
the aim was to determine which genes statistically mediated (cross-sectionally) a proportion 
of the association between age and IL-6. The rationale for a “mediation” analysis is that 
genes that are statistically related to this association are likely to be markers of age-related 
inflammation, rather than inflammation independent of age per se. 
For this analysis I determined the methods to use, undertook the bioinformatics analysis 
(transcriptome-wide screen) in InCHIANTI (and worked with Roby Joehanes who undertook 
the analysis of the FHS data). I also organised and chaired the calls with the FHS, helped 
perform the literature review, interpreted the results, and co-wrote wrote the manuscript (with 
Professor David Melzer). The other co-authors generated the population-level and lab-based 
data for analysis, and contributed to discussions during the conference calls.  
 PhD Thesis | Luke Pilling 
135 Chapter 6 – Analysis 4 – Age-related Inflammation 
6.2 Summary 
Introduction: Chronically elevated circulating inflammatory markers are common in older 
persons but mechanisms are unclear. Many blood transcripts (>800 genes) are associated 
with interleukin-6 protein levels (IL-6) independent of age. We aimed to identify gene 
transcripts statistically mediating the age~IL-6 association, to define a signature specific to 
age-related inflammation. 
Methods: Blood derived in-vivo RNA from the Framingham Heart Study (FHS, n=2422, ages 
40-92 yrs) and InCHIANTI study (n=694, ages 30-104 yrs), with Affymetrix and Illumina 
expression arrays respectively (>17,000 genes tested), were tested for statistical mediation 
of the age~IL-6 association using resampling techniques, adjusted for confounders and 
multiple testing. 
Results: In FHS, IL6 expression was not associated with IL-6 protein levels in blood. 102 
genes (0.6% of 17,324 expressed) statistically mediated the age~IL-6 association of which 
25 replicated in InCHIANTI (including 5 of the 10 largest effect genes). The largest effect 
gene (SLC4A10, coding for NCBE, a sodium bicarbonate transporter) mediated 19% 
(adjusted CI 8.9 to 34.1%) and replicated by PCR in InCHIANTI (n=194, 35.6% mediated, 
p=0.01). Other replicated mediators included PRF1 (perforin, a cytolytic protein in cytotoxic T 
lymphocytes and NK cells) and IL1B (Interleukin 1 beta): few other cytokines were significant 
mediators.  
Conclusions: This transcriptome-wide study on human blood identified a small distinct set of 
genes that statistically mediate the age~IL-6 association. Findings are robust across two 
cohorts and different expression technologies. Raised IL-6 levels may not derive from 
circulating white cells in age related inflammation.  
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6.3 Introduction 
Chronically elevated levels of pro-inflammatory biomarkers are a core feature of aging, and a 
risk factor for many diseases and adverse phenotypes that are frequent in older persons [38]. 
Increased levels of pro-inflammatory markers in blood and other tissues with aging are 
paralleled by a progressive decline in overall immune responsiveness [60]. 
Elevated Interleukin-6 (IL-6) and C-reactive protein (CRP) have emerged as robust age-
related risk factors for multiple adverse outcomes including several diseases, disability, 
cognitive impairment and death [241].  IL-6 is a pleiotropic cytokine produced by several cell 
types, including immune cells, hepatocytes, vascular endothelial cells, adipocytes and 
skeletal muscle [241]. IL-6 levels are often undetectable in young individuals but increase 
with advancing age, even in the absence of detectable causes, including cardiovascular risk 
factors and disease [242]. High levels of IL-6 predict all major age-associated diseases, 
physical and cognitive disability and mortality [243]–[246]. The mechanisms that cause and 
sustain high levels of inflammatory markers in aging are largely unknown.  
The overproduction of pro-inflammatory markers may occur in many sites beyond circulating 
leukocytes; candidates include tissue resident macrophages, adipocytes, endothelial cells, 
cells within atherosclerotic plaques and muscle cells [247]. The accumulation of cells 
expressing a senescence-associated secretory phenotype [110], [248] in different tissues, 
possibly induced by age-related NF-kB dysregulation [249], may also be a possible cause. 
Data collected in animal models have provided inconsistent results and there is a scarcity of 
data in humans.  
In a recent study, the authors determined the whole blood gene expression transcripts 
associated with IL-6 levels in 2 human populations, independent of age [61]. That analysis 
identified 4139 genes that were significantly associated with interleukin-6 levels (FDR<0.05), 
independent of age, sex and blood cell components, of which 807 genes replicated in the 
smaller InCHIANTI cohort. Many of the top genes generally associated with blood IL-6 
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protein levels (independent of age) are in inflammation-related pathways or erythrocyte 
function, including the JAK/Stat signalling pathway and interleukin-10 signalling pathway.  
In the study presented here, we aimed to identify the subset of IL-6 associated gene 
transcripts that might be specific to the chronic inflammation of aging. To do this we utilized 
data from 2 independent community-based cohorts in a discovery (Framingham Heart Study, 
FHS) and replication (InCHIANTI) analysis. The cohorts utilize two different microarray 
platforms, allowing replication of findings robust to cohort and microarray differences. For 
each gene transcript measured on the microarray we tested whether the expression levels 
statistically mediate “age-related inflammation” (i.e. account for a significant portion of the 
statistical association between age and IL-6), as these may reflect the most relevant 
molecular pathways in aging, and additionally may help to identify the specific cell subtypes 
most closely involved.   
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6.4 Methods 
6.4.1 The participants 
Our study was performed in two independent and well-characterized human cohorts. The 
discovery cohort was the Framingham Heart Study (FHS) Offspring cohort, USA [185], with 
replication of the significant mediators in the InCHIANTI (Invecchiare in Chianti, aging in the 
Chianti area) study, a community-based study cohort study of aging in Florence, Italy [115]. 
FHS participants targeted in this analysis were from the Offspring Cohort enrolled in 1971 as 
the offspring (and offspring spouses) of the Original FHS cohort. Offspring participants who 
attended examination 8 (2005-2008) and had blood-derived RNA prepared were included in 
this analysis. This study was approved by the Institutional Review Boards at Boston 
University Medical Center, and all participants gave written informed consent [250]. 
InCHIANTI participants were originally enrolled in 1998-2000, and were interviewed and 
examined every 3 years. Ethical approval was granted by the Instituto Nazionale Riposo e 
Cura Anziani Institutional Review Board in Italy. Participants gave informed consent to 
participate. RNA was available at wave 4 (year 9) of the study, with IL-6 also measured at 
year 9. All the data required for the full analyses were available for 694 individuals (see 
Table 6.1 for further cohort details). 
 
6.4.2 RNA collection and extraction 
FHS: The methods for gene expression profiling were previously published [251]. Briefly, 
peripheral blood samples were extracted using the PAXgene Blood mRNA kit (PreAnalytiX, 
Hombrechtikon, Switzerland), and amplified by the WT-Ovation Pico RNA Amplification 
System (NuGEN, San Carlos, CA), according to manufacturer’s instructions. cDNA was then 
hybridized to the Human Exon 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA) for 
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quantification. The raw data were quantile-normalized and natural-log transformed, followed 
by summarization using Robust Multi-array Average [252]. The gene annotations were 
obtained from Affymetrix NetAffx Analysis Center (version 31). We excluded transcript 
clusters that were not mapped to RefSeq transcripts, resulting in 17,873 distinct transcripts 
(17,324 unique gene identifiers) for downstream analysis. 
 
 
 
Table 6.1 | Summary statistics of the Framingham and InCHIANTI cohort characteristics 
 
Framingham Heart Study Offspring   InCHIANTI 
Sex N %   Sex N % 
 
Men 1,093 45.1   
 
Men 313 45.1 
 
Women 1,329 54.9   
 
Women 381 54.9 
Age, years 
  
  Age, years 
  
 
40-54 199 8.2   
 
30-49 88 12.7 
 
55-69 1,359 56.1   
 
50-69 100 14.4 
 
70-84 817 33.7   
 
70-89 477 68.7 
 
85-92 47 1.9   
 
90-104 29 4.2 
 
Mean (SD) 2422 66.4 (9.0)   
 
Mean (SD) 694 72.2 (15.3) 
Tobacco Exposure 
  
  Tobacco Exposure 
  
 
None 775 32.0   
 
None 380 54.8 
 
Former Smoker 1444 59.6   
 
Former Smoker 240 34.6 
 
Current Smoker 203 8.4   
 
Current Smoker 74 10.7 
 
    
 
   
    
    
  
  
N Mean (SD)     N Mean (SD) 
BMI (kg/m2) 2422 28.5 (5.4)   BMI (kg/m2) 694 27.1 (4.3) 
Interleukin 6 (pg/mL) 2422 2.7 (3.0)   Interleukin 6 (pg/mL) 694 3.8 (2.9) 
Leukocyte Composition 
 
  Leukocyte Composition 
 
 
Neutrophils 2422 59.8 (7.9)   
 
Neutrophils 694 57.5 (9.1) 
 
Lymphocytes 2422 27.0 (7.5)   
 
Lymphocytes 694 30.8 (8.7) 
 
Monocytes 2422 9.2 (1.9)   
 
Monocytes 694 8.0 (2.1) 
 
Eosinophils 2422 3.3 (1.6)   
 
Eosinophils 694 3.2 (2.1) 
 
Basophils 2422 0.8 (0.2)   
 
Basophils 694 0.6 (0.2) 
 
 
 PhD Thesis | Luke Pilling 
140 Chapter 6 – Analysis 4 – Age-related Inflammation 
InCHIANTI: Peripheral blood samples were also extracted using the PAXgene Blood mRNA 
kit according to the manufacturer’s instructions [117], which preserves transcript expression 
levels as at the time of blood sampling. Samples were collected in 2008/9 (wave 4) from 733 
participants. Whole genome expression profiling of the samples was conducted using the 
Illumina Human HT-12 microarray (Illumina, San Diego, USA) as previously described [155]. 
Data processing was done using the Illumina and BeadStudio software (Illumina, San Diego, 
USA) as previously described. All microarray experiments and analyses complied with 
MIAME guidelines [219]. Participants were excluded if mean signal intensities across all 
probes with p≤0.01 were >3 standard deviations from the cohort mean; probes with <5% of 
participants giving intensities with p≤0.01 different from background also were excluded, 3 
further exclusions were made due to missing leukocyte data. More detailed methods have 
been previously published [79]. Data from 695 individuals and 16,571 probes (11,393 unique 
gene identifiers) passed our quality control process and went forward into our analyses. The 
expression data were first normalized using natural log transformation and standardized 
using z-scores. 
 
6.4.3 Serum Protein Measures 
FHS: The interleukin-6 concentration was assayed by the quantitative enzyme-linked 
immunosorbent assay according to the manufacturers’ protocols (R&D Systems, 
Minneapolis, MN, USA). The minimum detectable concentration was 0.039 pg/ml. Ten 
percent of measures were run in duplicate. Standard quality control was performed, and the 
mean intra-assay coefficient of variation was 4.0% and the inter-assay coefficient of variation 
was 3.7% [253] (http://www.framinghamheartstudy.org/researchers/description-
data/vascular-manuals/offspring_exam8_omni1_exam3_marker_manual.pdf). 
InCHIANTI: Serum IL-6 was quantified using a quantitative sandwich enzyme-linked assay 
(BioSource Cytoscreen UltraSensitive kits, BioSource International Inc., Camarillo, CA, 
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USA).  The lowest detectable concentration was 0.10 pg/ml and the interassay coefficient of 
variation (CV) was 7%. 
 
6.4.4 Blood Cell count Measurement 
FHS: We imputed the percentage of the immune cells comprising different cell types: 
neutrophil, lymphocyte, monocyte, eosinophil and basophil. The percentages of each cell 
type were then normalized, where the negative predicted values were set to 0 and the sum of 
the percentages for all cell types was set at 100% [personal communication, RJ]. 
InCHIANTI: Assessments of the number of red blood cells, white blood cells, platelets, the 
hemoglobin concentration were performed through an automated system at the Laboratory of 
Clinical Chemistry and Microbiological Assays, SS. Annunziata Hospital, Azienda Sanitaria 
10, Florence, Italy, using a Coulter LH 750 Hematology Autoanalyzer (Beckman Coulter Inc, 
Brea, CA, USA). 
 
6.4.5 Statistical analyses 
In all models using IL-6 as the outcome we used natural log of the serum levels to reduce the 
skewness inherent to the measure. 
Mediation analysis: Using the R statistical software application (v2.14.1) [190] and package 
‘mediation’ [254] (v4.2) we individually assessed whether each transcript statistically 
mediated the association between logged interleukin 6 serum levels (the ‘treatment’ as it is 
referred to in the package) and age (the ‘exposure’ that affects the treatment, and may be 
statistically mediated by the expression of genes in white cells – although no causality is 
inferred here). In each model (1 per gene) the mediating variable was the expression level of 
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that particular gene. The common approach to testing the effect of a potential mediator is to 
adjust for the proposed mediator in a linear/logistic model, and determine by how much the 
effect size is changed. Whilst this tells the analyst whether an association is affected by a 
mediator, it does not provide an estimate of statistical significance or confidence intervals for 
the mediation effect; hence we are using the package ‘mediation’ as this re-samples the data 
to determine confidence intervals for the mediation estimate. 
Using parametric linear regression models throughout, we modeled the mediating effects for 
each transcript on the association between IL-6 and age. Each model was adjusted for the 
following independent variables; sex, technical covariates (including microarray batches and 
study site – these are specific to each cohort) and, leukocyte sub-type proportions. The cell 
type proportions included lymphocytes, monocytes, eosinophils and basophils, but neutrophil 
percentage was not included (as it was closely negatively associated with lymphocyte 
proportion), to avoid these measures totaling 100% and leaving no degrees of freedom in the 
model. The package uses quasi-Bayesian resampling simulations to estimate the uncertainty 
of the effects derived from our parametric models. After exploration of the package it was 
decided that 10,000 simulations per model was sufficient to give relatively stable estimates 
whilst keeping computation time realistic.  
Although the package provides a p-value estimate, this was not of high enough resolution to 
control for multiple testing and was susceptible to sample distribution biases (following 
correspondence with package authors – who agreed with the following solution). We have 
therefore used adjusted confidence-intervals (CIs) to reflect the number of tests performed, 
akin to the Bonferroni adjustment [255]. In FHS the number of array probes (and thus 
models) available was 17,873, so the CI were set to 99.99972% (1-(0.05/17873)). Significant 
mediators are those with CIs that do not cross the null (0) value. When we refer to “genome-
wide significant mediators”, or “significant mediators in FHS”, these were determined by this 
CI-adjusted (Bonferroni) method. 
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6.4.6 Concordance with InCHIANTI 
Genes that mediate a proportion (≥5%) of the association between age and IL-6 after 
adjustment for multiple-testing in FHS were then assessed in the InCHIANTI study. Each test 
was conducted as described in the previous section for the FHS, except 95% confidence 
intervals that did not cross the null (0) were considered significant replication (rather than the 
multiple-testing adjusted confidence intervals applied to the discovery analysis in the FHS 
cohort). We are therefore using a discovery/replication procedure, where any findings 
significant in the discovery analysis after adjustment for multiple testing are considered 
independent tests for replication, and thus we accepted p<0.05 (i.e. 95% confidence 
intervals) as significant. 
 
6.4.7 InCHIANTI: PCR analysis of gene expression 
A number of genes including IL6 and SLC4A10 did not have gene expression information 
available in the InCHIANTI microarray data. We selected 2 random subsamples of 200 
InCHIANTI participants for additional analysis and validation using polymerase-chain-
reaction (PCR) techniques. Subsets of the participants were chosen because these are 
historic samples and the RNA is a finite resource. 
Firstly, PCR 383-well plates were used to assess the expression levels of SLC4A10, DAAM2 
and FLT3; total RNA (45–85 ng) was reverse transcribed in 13-uL reactions using the 
Superscript III VILO kit (Invitrogen, Paisley, UK), according to the manufacturer’s 
instructions. Expression levels for each target transcript  were then measured in triplicate 5ul 
reactions using 384-well plates on the ABI Prism 7900HT  platform (Life Technologies, 
Foster City, CA, USA), using commercially available assays (DAAM2 assay Id 
Hs00322497_m1, FLT3 assay Id Hs00174690_m1, SLC4A10 assay Id Hs00222849_m1). 
Gene expression levels were calculated relative to the mean crossing point of the 
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endogenous control genes IDH3B, GUSB and 18s, and normalized to the median DAAM2, 
FLT3 or SLC4A10 expression level across the sample. 
Secondly, TaqMan Low Density Arrays were used to measure IL6 and CDKN2A expression 
data. Total RNA (30–170 ng) was reverse transcribed in 20-lL reactions using the 
Superscript III VILO kit (Invitrogen, Paisley, UK), according to the manufacturer’s 
instructions. Expression levels for each target transcript  were then measured using the 
TaqMan Low Density Array  approach on the ABI Prism 7900HT  platform (Life 
Technologies, Foster City, CA, USA), using commercially available assays (IL-6 assay Id 
Hs00985639_m1, CDKN2A assay Id Hs00923894_m1). Gene expression levels were 
calculated relative to the mean crossing point of the endogenous control genes GUSB and 
18s, and normalized to the median IL6 or CDKN2A expression level across the 200 samples.  
 
6.4.8 Mediation Analysis in InCHIANTI PCR Subset 
To assess the statistical significance of the genes unavailable in the InCHIANTI microarray 
data but were selected for PCR analysis, we used the Sobel test, as it provides higher power 
in small samples sizes when compared to bootstrapping methods [135]. 
 
6.4.9 Analysis of significant mediators  
Clustering: Principal components analysis (R package: psych) was performed to determine 
the correlation structure of the significant mediators in FHS. Default options were used 
(including “Varimax” rotation). The number of components to extract was determined by 
Scree analysis. 
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Pathways: DAVID functional annotation tools [256] were used to test for enrichment of 
pathways or processes in the significant mediators identified by FHS. 
 
6.4.10 Sensitivity Analyses 
We ran the analysis using a binary phenotype of IL-6 using an empirically determined 
clinically relevant cut-point (>3.5pg/mL) [58]. To assess the effect of adjusting for whole white 
blood cell (WBC) count (number of cells in sample) in addition to the proportions of major 
white cell subtypes, we ran the analysis with and without WBC count. 
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6.5 Results 
6.5.1 Characteristics of the samples 
The cohorts differ in size and age-distributions, but are otherwise broadly similar (Table 6.1).  
Overall, 2422 participants from FHS (age-range: 40-92 years) were eligible for the discovery 
analysis. 694 participants (age-range: 30-104 years) from the InCHIANTI study had complete 
data for the replication analysis.  
 
6.5.2 Serum IL-6 protein levels associated with age but not with leukocyte IL-6 
transcript abundance   
Interleukin-6 serum (protein) levels (IL-6) were strongly positively associated with advancing 
age both in FHS (N=2422; unadjusted: beta=0.031, p=1x10-44) and InCHIANTI (N=694; 
unadjusted: beta=0.038, p=1 x10-61, adjusted: beta=0.036, p= 1.1 x10-36) (Figure 6.1 A and 
B). Circulating IL-6 receptor (a pro-inflammatory factor that enhances IL-6 activity) is 
associated with age independent of sex (coef = 0.0029, p = 2.2x10-5) but not when adjusted 
for IL-6 levels (coef = 0.0016, p = 0.054). Expression of IL-6 transcripts (from circulating 
blood leukocytes, see methods) was not associated with age in FHS and mildly negatively 
associated with age in InCHIANTI (Figure 1C & D) (FHS: N=2422, coefficient=0.013, p=0.12; 
InCHIANTI: N=186, coefficient=-4.7, p= 5.6 x10-4). Surprisingly, IL6 transcript levels also 
were not significantly correlated with IL-6 protein levels in serum in either study (FHS: 
coefficient=0.0064, p= 0.26; InCHIANTI: coefficient=0.021, p=0.76).  
 
6.5.3 Immune cell sub-type associations 
In InCHIANTI, directly measured lymphocyte, neutrophil, monocyte and eosinophil 
percentages were each associated with higher mean age (Beta= -0.1, 0.09, 0.02, 0.02; P= 
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9x10-9, 1x10-4, 2x10-4, 3x10-3, respectively); lymphocyte, neutrophil and basophil percentages 
were associated with serum IL-6 adjusting for age (Beta= -2.9, 2.8, -0.03; P= 4x10-14, 5x10-12, 
1x10-3, respectively); lymphocyte and neutrophil percentages mediated the association 
between age and IL-6 (proportion of effect mediated= 0.09, 0.06 respectively); the ratio 
between lymphocyte and neutrophil percentages also significantly mediated the age~IL-6 
association (proportion of effect mediated= 0.06). 
 
Figure 6.1 | The associations between interleukin-6 and age 
 
A) IL-6 protein serum levels and age in 694 InCHIANTI samples.  
B) IL-6 protein serum levels and age in 2422 FHS samples.  
C) IL-6 gene expression and age in leukocytes in 186 InCHIANTI samples.  
D) IL-6 gene expression and age in leukocytes in 2422 FHS samples. 
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6.5.4 A small set of transcripts partially mediate the serum IL-6 – age association 
Seven gene transcripts statistically mediate more than 5% of the association between age 
and IL-6 in both studies, although the approach is quite conservative and there may be other 
mediators we did not have the power or coverage to detect: 
Transcripts for 17,324 unique genes could be tested in FHS, of which 4693 (27.1%) were 
associated with age (FDR<0.05) and 4140 (23.9%) were associated with IL-6 [61]. However, 
expression of only 102 (0.6% of the 17,324) genes significantly mediated a proportion of the 
association between age and IL-6 (after adjustment for confounders – see methods - and 
multiple testing using 99.99972% confidence intervals, and after excluding 3 invalidly 
annotated transcripts, Supplementary Table 6.1). Twenty-nine genes mediated ≥5% of the 
association, with SLC4A10 (solute carrier family 4, sodium bicarbonate transporter) 
mediating 19% of the association (CI 8.9 to 34.1%) in FHS (Table 6.2).  
The InCHIANTI Illumina array provided data on n=11,393 genes, substantially fewer than the 
17,324 measured in FHS. Data on 9,971 unique genes were available in both cohorts with an 
additional 7,345 measured in FHS only and 1,422 in InCHIANTI only. Of the 102 genes 
partial mediators of the age~IL-6 association identified in FHS, 88 were available 
(Supplementary Table 6.1) in InCHIANTI and 17 of them significantly mediated the 
association of age with IL-6 after adjustment for confounders. Of the 29 genes mediating 
≥5% in FHS (Table 6.2), 22 were also in the InCHIANTI microarray data. Significant 
associations in the same direction were found for IL1B, VCAN, PRF1 and LTB. No genes 
mediating ≥5% had significant associations in both cohorts but different directions of effect. 
Four of those mediating <5% were significant and with opposite directions of effect 
(Supplementary Table 6.1).  
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Table 6.2 | Transcripts mediating ≥5% of the age~IL-6 association in FHS, with array based 
replication estimates from the InCHIANTI study 
    
 
  FHS InCHIANTI  
N Entrez Gene Description Prop 
ɫ
 99.9% CIs ˜ Prop 
ɫ
 95% CIs * 
1 57282 SLC4A10 
solute carrier family 4, sodium 
bicarbonate transporter 
0.191 0.089 0.341 
   
  
2 2322 FLT3 fms-related tyrosine kinase  -0.099 -0.211 -0.04 
   
  
3 9839 ZEB2 
Zinc Finger E-Box Binding 
Homeobox 2 
0.098 0.032 0.192 0 -0.008 0.008   
4 8460 TPST1 tyrosylprotein sulfotransferase 1 -0.09 -0.182 -0.036 -0.025 -0.07 0.012   
5 1432 MAPK14 
mitogen-activated protein kinase 
1 
0.086 0.03 0.172 0.001 -0.01 0.015   
6 3553 IL1B interleukin 1, beta -0.081 -0.171 -0.032 -0.052 -0.093 -0.023 * 
7 23500 DAAM2 
dishevelled associated activator 
of morphogenesis 2 
-0.079 -0.176 -0.027 
   
  
8 2153 F5 
coagulation factor V 
(proaccelerin, labile factor) 
0.075 0.026 0.148 0.014 -0.007 0.039   
9 1462 VCAN versican 0.073 0.024 0.15 0.043 0.018 0.076 * 
10 3820 KLRB1 
killer cell lectin-like receptor 
subfamily B, member 1 
0.068 0.019 0.135 0.016 -0.007 0.043   
11 5551 PRF1 perforin 1 (pore forming protein) -0.064 -0.14 -0.001 -0.057 -0.104 -0.021 * 
12 3267 AGFG1 ArfGAP with FG repeats 1 0.064 0.02 0.147 -0.003 -0.022 0.013   
13 51099 ABHD5 
abhydrolase domain containing 
5 
-0.062 -0.145 -0.017 0.002 -0.004 0.015   
14 400360 C15orf54 
chromosome 15 open reading 
frame 54 
0.062 0.017 0.123 
   
  
15 116369 SLC26A8 
solute carrier family 26, member 
8 
0.062 0.005 0.128 0.012 -0.008 0.037   
16 768211 RELL1 RELT-like 1 -0.06 -0.173 -0.011 
   
  
17 26253 CLEC4E 
C-type lectin domain family 4, 
member E 
-0.059 -0.135 -0.016 -0.012 -0.037 0.008   
18 2204 FCAR Fc fragment of IgA, receptor for 0.059 0.019 0.12 0.005 -0.004 0.021   
19 55350 VNN3 vanin 3 -0.056 -0.133 -0.01 -0.003 -0.019 0.008   
20 147947 ZNF542 zinc finger protein 542 0.054 0.016 0.115 
   
  
21 285533 RNF175 ring finger protein 175 0.053 0.012 0.125 0 -0.006 0.005   
22 330 BIRC3 
baculoviral IAP repeat-
containing 3 
-0.053 -0.119 -0.017 -0.01 -0.033 0.007   
23 4609 MYC 
v-myc myelocytomatosis viral 
oncogene homolog (avian) 
-0.052 -0.128 0 -0.048 -0.103 0   
24 1374 CPT1A 
carnitine palmitoyltransferase 
1A (liver) 
0.052 0.004 0.13 -0.001 -0.011 0.005   
25 22901 ARSG arylsulfatase G -0.052 -0.124 -0.012 0.001 -0.007 0.012   
26 317 APAF1 
apoptotic peptidase activating 
factor 1 
-0.051 -0.133 -0.013 0.013 -0 0.034   
27 84255 SLC37A3 
solute carrier family 37 (glycerol-
3-phosphate transporter), 3 
0.051 0.014 0.109 -0.004 -0.019 0.004   
28 55356 SLC22A15 
solute carrier family 22, member 
15 
-0.05 -0.153 -0.001 0.001 -0.004 0.013   
29 4050 LTB 
lymphotoxin beta (TNF 
superfamily, member 3) 
-0.05 -0.118 -0.006 -0.079 -0.138 -0.031 * 
ɫ Proportion of the IL-6~age association mediated; * significant at p<0.05 in InCHIANTI 
˜ Bonferroni-adjusted confidence intervals (ie. False-discovery-rate adjusted) 
 PhD Thesis | Luke Pilling 
150 Chapter 6 – Analysis 4 – Age-related Inflammation 
Three genes (SLC4A10, FLT3, DAAM2) with larger mediating effects (>7%) in the FHS 
analysis did not pass the background inclusion criteria in InCHIANTI microarray data. These 
were selected for confirmation by PCR in a random subset of the InCHIANTI sample. In 194 
samples (after exclusions / data cleaning) there was statistically significant partial mediation 
of the association between age and IL-6 for all 3 genes (SLC4A10 % mediated=35.6%, 
p=0.01; DAAM2 %=-7.92%, p=0.0001; FLT3 %=-1.03%, p=0.0002), although this small 
sample size of the replication makes comparisons of effect sizes difficult.  
As noted previously, both positive and negative mediators were identified. Figure 6.2 shows 
boxplots of expression (in FHS) for 4 genes that have been stratified by age (young 
≤65years, old >75) and IL-6 expression (tertiles); IL1B (negative mediator), SLC4A10 
(positive mediator), FLT3 (negative) and ZEB2 (positive). The plot illustrates that different 
mediators were positively or negatively associated with age and / or IL-6. Figure 6.2 also 
shows that SLC4A10 expression reduces with increasing IL-6 concentration, and also has 
markedly lower expression in the older group in general.  
 
6.5.5 Consistent negative findings  
Overall, very few interleukins or cytokines emerged as significant mediators (Figure 6.3) with 
all mediation effect sizes for these genes in FHS being <5%, with the sole exception of IL1B. 
Similarly there were few larger effect CD marker mediators (Cluster of Differentiation, used to 
identify and characterize leukocyte subtypes) other than notable exceptions with updated 
gene symbols, such as KLRB1 (CD161).  
CDKN2A (p16INK4a) expression is increased in-vivo with circulating lymphocyte cell 
senescence [257]. In InCHIANTI, CDKN2A array expression was not above background, so 
TaqMan Low Density Array real-time PCR measured expression in a subsample. Expression 
of CDKN2A was not a significant mediator of the IL-6~age association in either cohort. 
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Figure 6.2 | The relationships between expression of four genes, IL-6 protein, and age 
 
 
 
Boxplots of gene expression stratified by tertile of IL-6 serum protein concentrations, split by 
age group (white boxes are individuals <=65 years, grey boxes are individuals >75) in the 
FHS cohort. To be a statistically significant mediator of the age~IL-6 association, the genes 
are independently associated with both traits. 
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Figure 6.3 | Comparing the mediation effects of genes between FHS and InCHIANTI 
 
Scatter plots of the 
proportion of the 
age/serum-IL-6 
association mediated 
by each gene 
expression transcript 
in FHS and 
InCHIANTI for (A) all 
genes, (B) cytokines, 
interleukin-related and 
CD (cluster of 
differentiation) 
molecules. 
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6.5.6 Clustering and gene ontology enrichment of mediators 
To determine which genes “cluster” together (have similar expression profiles) we used 
principal components analysis. Eighteen clusters were identified by the Scree analysis of the 
102 significant mediators in FHS (Supplementary Figure 6.1). Of particular note, SLC4A10, 
the largest single mediator in FHS, only clusters strongly with KLRB1 (highlighted in yellow - 
also called CD161, which inhibits natural killer cell (NK) toxicity and is also expressed in 
some T cells). IL1B and ADM were also closely related. 
Gene ontology enrichment analyses of the 102 FHS expression probes were explored in the 
DAVID bioinformatics tool. Only 1 KEGG pathway was significant in the functional annotation 
analysis; the NOD-like receptor signalling pathway (p=4.9 x 10-5, Benjamin-Hochberg 
multiple testing adjusted p=3.2 x 10-3). In an analysis restricted to the 7 replicated genes 
only, no output was returned by DAVID. 
 
6.5.7 Sensitivity Analyses 
To test the consistency of the results of the associations of age and genes with linear IL-6 
concentrations, we also performed an analysis using a binary IL-6 trait as the outcome. The 
correlation between the proportions mediated by the genes was highly consistent, the R2 = 
0.81 (Supplementary Figure 6.2). 
Adjusting for WBC count slightly altered the ordering (by proportion mediated) in the list of 
significant mediators in FHS, however the final list of genes mediating >5% found to replicate 
in InCHIANTI did not change from the original list of 7. 
There were no significant interactions (p>0.05) between age, IL-6 and depression (measured 
by the CESD - Center for Epidemiological Studies Depression – scale).  
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6.6 Discussion 
Our study presents the first larger-scale transcriptome-wide analysis of age-related 
inflammation in human blood. Very strong associations were present in both study cohorts 
between age and serum IL-6 protein concentrations [61]. Examining statistical mediators of 
the age~IL-6 association, we identified and independently replicated 7 partial mediators with 
effect sizes ≥5%, including one larger effect transcript, namely SLC4A10. Our results include 
known immune markers and several novel genes not previously linked to aging. These 
results are very different from the many associations with general IL-6 levels independent of 
age (807 replicated genes) [61] and represent a mediator signature specific to age-related 
inflammation. 
Increased Interleukin 1 beta protein concentrations (IL1B), a cytokine involved in initiation of 
most inflammatory responses and a product of inflammasome activation, is a core feature of 
the pro-inflammatory state of aging [258]. IL1B expression emerged as the only replicated 
cytokine mediator in our analyses. The negative mediation value reflects IL1B expression 
increasing with IL-6, but decreasing with age (as shown in Figure 6.2). Perforin (PRF1) is 
one of the main proteins of cytolytic granules and is a key effector molecule for T-cell and 
natural killer-cell-mediated cytolysis. Perforin expression per cell falls with advanced age 
[259]. A high proportion of CB8+ T cells express Granzyme B but not PRF1 in response to an 
influenza challenge, and the absence of PRF1 results in Granzyme B degradation of the 
extracellular matrix and inflammation [260]. Alterations to T-cell populations (and other 
immune cell types) with aging leads to reduced antibody response and increased incidence 
of infectious disease, contributing to age-related inflammation [261]. Our finding of IL1B and 
perforin amongst the replicated mediators shows that our study was able to identify primary 
mechanisms involved in age-related inflammation.  
Our largest effect mediator SLC4A10 (19.1% in FHS, 35.6% in InCHIANTI) codes for NCBE 
(also called NBCn2) and is a sodium bicarbonate transporter, part of a gene family involved 
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in intracellular acid – base homeostasis. SLC4A10 expression is highest in the brain, and 
SLC4A10 has been linked to autism, epilepsy and mental retardation [262]. There are little 
published data on SLC4A10 in the immune system, but the BioGPS database [201] shows 
similar levels of expression in all studied leukocyte cell sub-types in humans, suggesting that 
SLC4A10 mechanisms may be widespread. Inflammation is associated with a local drop in 
pH resulting from infiltration of inflammatory cells, and extracellular acidosis in inflammation 
may be a ‘danger signal’ activating immune responses [263]. Farwell and Taylor [264] 
showed that a higher anion gap and lower bicarbonate level were associated with a higher 
leukocyte count and higher C-reactive protein level, in the NHANES study. Additionally, other 
members of the SLC superfamily are known to influence mTOR activity, which in turn affects 
inflammation [265]. Clearly, much more work is needed to clarify the mechanisms of 
involvement of SLC4A10 in age-related inflammation. 
FTL3 (also called CD135) emerged as the second largest effect gene in FHS (replicated in 
InCHIANTI), and plays a key role in lymphocyte (B and T cell) development but not for the 
development of other blood cells. The third larger effect gene, ZEB2, is mainly expressed in 
monocytes and is involved in epithelial-mesenchymal transition (ETM), which is 
characterized by the down-regulation of cellular adhesion complexes and is a key step in 
cancer development [266].  The ZEB2 mediation effect was not significant in the InCHIANTI 
array data, but further work using gold standard lab methods is needed to be sure that the 
InCHIANTI estimate is not a ‘false negative’ due to differences in array technology or sample 
size. 
An important finding of our study is that although we confirmed a strong positive relationship 
between serum interleukin-6 (IL-6) levels and age, we found strikingly few interleukins, 
cytokines or interferon gene transcripts mediating the age~IL-6 association in the studied 
blood white cells (Figure 6.3), with the exception of IL1B, based on an analysis checking 
synonyms for these genes. These findings suggest that the primary origin of age-related 
inflammation may not be circulating immune cells. This is further supported by the lack of 
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association between IL6 mRNA and IL-6 protein, although this could also be due to post-
transcriptional regulation or enhancement of expression at the level of translation, or 
regulation by moderation of the half-life of protein or RNAs. 
 
6.6.1 Limitations and Future Work 
Although moderate (50%) replication of the most significant mediators was observed, there 
were many small effect genes that were not significant in the InCHIANTI cohort. Our study 
includes two separate expression arrays (plus three PCR validations), with the arrays having 
different gene coverage and sensitivities, imposing some limitations. However the alternate 
technologies do provide evidence for the robustness of our positive findings across our two 
study cohorts. The Affymetrix Human Exon 1.0 ST array (used by FHS) uses 25-mer probes, 
typically grouped in sets of four per exon, to estimate exon-specific levels of expression, 
while the (InCHIANTI) Illumina Human HT12v3 array uses 50-mer probes biased towards the 
3′ end of mRNA transcripts to estimate whole-gene levels of expression [267]. The latter 
array appears less sensitive in our blood derived RNA samples as far fewer gene expression 
measures passed quality control in InCHIANTI than FHS, and thus some of the genes that 
appeared not to replicate may be found to be mediators in further studies. The analysis is 
cross-sectional, so more work will be needed to establish the direction of causation. The 
study subjects were of European origin, so further work will be needed to establish whether 
the results are applicable to other ethnic groups. The RNA samples were from whole blood 
containing a mixture of white cells with results reflecting overall expression patterns. Our 
results should be seen as starting points for establishing underlying mechanisms, including 
changes in cell subtype proportions not already adjusted for in our analyses.   
Future work should include studies to establish the cellular subtype origins of the novel 
mediators reported, and their mechanistic roles. This should account for associations with 
age-related diseases; a recent study found that white-blood cell counts, but not IL-6, is 
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associated with cardiovascular diseases in >70 year-olds [268]. As longitudinal follow-up 
becomes available, dynamic changes in expression and the predictive value of expression 
changes for age related health outcomes can be examined. Follow-up analyses, including 
analysis of C-reactive protein, are being initiated with collaborating cohorts. 
 
6.6.2 Conclusions 
To conclude, we have performed the first larger-scale transcriptome-wide analysis of age-
related inflammation in two human population cohorts. A small set of genes appear to have 
partially mediated the age~IL-6 association, several of which have not previously been linked 
to the pro-inflammatory state of aging. We have identified a novel larger effect partial 
mediator (SLC4A10, coding for NCBE), thought to be involved in pH homeostasis. We did 
not find increased expression of IL6 and cytokines with age in our blood derived data, 
suggesting that the raised IL-6 protein concentrations in blood may be predominantly 
generated from other body compartments. Further work is needed to distinguish mediators of 
age-related inflammation from the much larger numbers of age correlated expression 
changes in blood. 
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6.8 Supplementary Information 
 
Supplementary Table 6.1: 102 gene transcripts mediate the age IL-6 association in FHS 
 
      FHS InCHIANTI 
N Entrez Gene Prop 
ɫ
 99.9% CIs ˜ Prop 
ɫ
 95% CIs Significant? 
1 57282 SLC4A10 0.191 0.089 0.341 
   
  
2 2322 FLT3 -0.099 -0.211 -0.040 
   
  
3 9839 ZEB2 0.098 0.032 0.192 0.000 -0.008 0.008   
4 8460 TPST1 -0.090 -0.182 -0.036 -0.025 -0.070 0.012   
5 1432 MAPK14 0.086 0.030 0.172 0.001 -0.010 0.015   
6 3553 IL1B -0.081 -0.171 -0.032 -0.052 -0.093 -0.023 * 
7 23500 DAAM2 -0.079 -0.176 -0.027 
   
  
8 2153 F5 0.075 0.026 0.148 0.014 -0.007 0.039   
9 1462 VCAN 0.073 0.024 0.150 0.043 0.018 0.076 * 
10 3820 KLRB1 0.068 0.019 0.135 0.016 -0.007 0.043   
11 5551 PRF1 -0.064 -0.140 -0.001 -0.057 -0.104 -0.021 * 
12 3267 AGFG1 0.064 0.020 0.147 -0.003 -0.022 0.013   
13 51099 ABHD5 -0.062 -0.145 -0.017 0.002 -0.004 0.015   
14 400360 C15orf54 0.062 0.017 0.123 
   
  
15 116369 SLC26A8 0.062 0.005 0.128 0.012 -0.008 0.037   
16 768211 RELL1 -0.060 -0.173 -0.011 
   
  
17 26253 CLEC4E -0.059 -0.135 -0.016 -0.012 -0.037 0.008   
18 2204 FCAR 0.059 0.019 0.120 0.005 -0.004 0.021   
19 55350 VNN3 -0.056 -0.133 -0.010 -0.003 -0.019 0.008   
20 147947 ZNF542 0.054 0.016 0.115 
   
  
21 285533 RNF175 0.053 0.012 0.125 0.000 -0.006 0.005   
22 330 BIRC3 -0.053 -0.119 -0.017 -0.010 -0.033 0.007   
23 4609 MYC -0.052 -0.128 0.000 -0.048 -0.103 0.000   
24 1374 CPT1A 0.052 0.004 0.130 -0.001 -0.011 0.005   
25 22901 ARSG -0.052 -0.124 -0.012 0.001 -0.007 0.012   
26 317 APAF1 -0.051 -0.133 -0.013 0.013 0.000 0.034   
27 84255 SLC37A3 0.051 0.014 0.109 -0.004 -0.019 0.004   
28 55356 SLC22A15 -0.050 -0.153 -0.001 0.001 -0.004 0.013   
29 4050 LTB -0.050 -0.118 -0.006 -0.079 -0.138 -0.031 * 
30 23604 DAPK2 -0.049 -0.118 -0.003 -0.003 -0.017 0.005   
… Continued on digital version only     
* Abridged gene name from Entrez 
ɫ
 Proportion of the IL-6~age association mediated by this gene/probe 
˜ 99.9997% CIs were used in the discovery analysis in the FHS, to account for multiple testing 
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Supplementary Figure 6.1: Principal Components Analysis of 102 significant mediator gene 
transcripts in FHS. 
 
18 components of 
variance were 
identified for the 
102 significant 
mediators in FHS. 
In the heatplot the 
components are 
the x-axis, and 
each gene is on 
the y-axis. The 
colour represents 
the correlation 
between the gene 
and the 
components (red 
= positive, blue = 
negative). The 
genes have been 
hierarchically 
clustered with 
respect to 
correlation with 
the component. 
The highlighted 
genes load to the 
same component, 
and in fact are the 
only two genes to 
load to it, 
indicating they 
have a different 
expression profile 
to the other 
genes.  
 PhD Thesis | Luke Pilling 
161 Chapter 6 – Analysis 4 – Age-related Inflammation 
Supplementary Figure 6.2: Sensitivity analysis of transcripts mediating the age binary IL-6 
(‘high’ defined as >3.5pg/mL of IL-6) association  
 
 
 
This figure shows the proportion of the age~IL-6 association mediated by each gene when 
using first continuous IL-6 (y-axis) and using a binary IL-6 (‘high’ defined as >3.5pg/mL of IL-
6) variable (x-axis). Although there is slight variation in the absolute proportion mediated, the 
trend is very strong, particularly for the stronger effects.  
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Chapter 7 – Discussion and Conclusion 
 
7.1 Summary of Thesis 
Human ageing exhibits significant inter-individual variation; some individuals succumb to 
age-related disease much later than others. Efforts to understand the processes involved 
and determine predictive factors and mechanisms to “ageing well” are progressing, but much 
remains to be elucidated; few robust biomarkers exist in humans – IL-6 being one of the few 
– yet ageing traits can be reversed in experiments in mice, giving hope that interventions 
could be identified in humans. Biomarkers in blood could not only be used to identify 
individuals at the greatest risk, but may also have mechanistic implications leading to 
treatments to improve healthspan. 
I have performed analyses on whole blood gene expression profiles to gain insight to 
mechanisms of ageing and age-related disease. During the course of my PhD I have 
performed the first population-based studies of whole-blood gene expression and ageing 
phenotypes in the InCHIANTI ageing study, including;  
 In depth analysis of muscle strength, including identifying transcripts associated with 
muscle strength, investigating the robustness with other strength phenotypes, 
confounders and cell-type adjustment, and presenting plausible biological insight 
utilising published experimental models. 
 A follow-up analysis of gene expression and muscle strength involving meta-analysis 
of four independent cohorts, where I co-ordinated and performed a meta-analysis of 
gene expression and muscle strength, involving not only the transcriptome-wide scan, 
but also sensitivity and subset analyses, pathway analysis, investigation of the 
phenotype and confounders, and systematically screening the literature. 
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 An analysis of cognitive function involved not only the cross-sectional transcriptome-
wide screen, but also an analysis of cognitive decline over 9 years, subset and 
pathways analysis, in depth investigation of the robustness of the association with 
respect to linearity and confounders. 
 Finally I performed an analysis of age-related inflammation in collaboration with the 
Framingham Heart Study (FHS), in which we applied mediation analysis to genomic 
epidemiology in a novel way; I determined the genes whose expression statistically 
mediated a proportion of the association between age and IL-6, providing novel 
insight into the specific inflammatory pathways that are age-related. The analysis 
included investigation and validation of the phenotypes, extensive literature follow-up, 
clustering analysis in the FHS, and analysis of PCR data. 
In the following sections I will summarize the key findings and conclusions of each individual 
analysis, and draw the ideas together in a final discussion. 
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7.2 Summary of Data Chapters 
 
7.2.1 Chapter 3 – Muscle Strength 
To identify the gene transcripts most closely associated with muscle strength in the 
InCHIANTI ageing study I utilised microarray data available on 698 of the participants who 
also had hand-grip strength measured using a dynamometer. After adjustment for selected 
confounding factors and multiple testing a single gene – CCAAT/enhancer-binding-protein 
beta (CEBPB) - was statistically significant. This association was confirmed using qRTPCR, 
a gold-standard lab method for quantifying nucleic acid sequences. CEBPB was already 
known to be a transcription factor with multiple functions, with various binding partners 
providing specificity.  
Evidence of a conditional knock-out mouse model provided a biological link; by specifically 
inhibiting the activation of CEBPB by CREB the up-regulation of CEBPB required to initiate 
the ‘alternative’ macrophage function (which is characterised by anti-inflammatory secretions 
and promotion of wound-healing) could not occur, whilst allowing basal expression of CEBPB 
to be maintained. These mice had impaired repair of muscle following injury, as occurs 
during the normal use of muscle; repair is a normal part of muscle maintenance and 
development. It is very thought provoking that CEBPB was the only gene found to be 
robustly associated with muscle strength from peripheral blood samples taken from the 
InCHIANTI population. Of note is that the damage to muscle in the mice was artificially 
induced by cardiotoxin, which caused local necrosis and infiltration of pro-inflammatory 
macrophages; in the mice with altered CREB-domain in the CEBPB promoter there was no 
subsequent anti-inflammatory response and the muscle tissue appeared highly fibrotic [113]. 
This is in contrast to the “everyday” contraction-induced injury that causes damage in 
humans [269], however the response should be comparable (pro-inflammatory M1 phase 
followed by anti-inflammatory M2 phase). 
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The importance of this finding is the link between plausible biological mechanism and 
observational data in humans using a highly relevant phenotype, maximum hand grip 
strength, which is a well-established marker of poor prognosis and disability [270]. Although 
using additional strength measures (e.g. quadriceps) does not provide additional predictive 
value of ageing phenotypes beyond just using measures of “maximum grip strength” [271], 
other measures of strength (such as knee strength) were measured in the InCHIANTI 
participants and replicated the finding with CEBPB. Therefore the use of hand grip in this 
study is applicable to the wider ageing and sarcopenia research field. 
Reflecting on the limitations of this study; firstly, muscle strength (an age-related phenotype) 
was assessed for associations with gene expression using linear regression models adjusted 
for a number of potential confounding factors such as sex and adiposity, and also for age. 
Therefore the conclusion was that CEBPB is associated with muscle strength in an elderly 
population (InCHIANTI is an ageing study, and as such the majority of the participants 
(>70%) are over 72 years of age), not that CEBPB was associated with age-related muscle 
loss; this is a hypothesis drawn from the results and from the literature. In Chapter 6 I 
assessed which transcripts mediate the association between age and inflammation. 
Performing a similar analysis to assess which transcripts mediate a proportion of the 
association between age and muscle strength I found that only 18 genes were significant 
mediators. CEBPB mediated the largest proportion of the age~muscle strength association of 
any measured gene (5%). Secondly, we were not in a position to get independent replication 
in the same paper. Thirdly, the data is from whole blood, a heterogeneous mixture of cells 
that could affect the gene-expression associations; we could only investigate and control for 
the effects of “broad” cell counts (e.g. “lymphocytes”, but not the proportion of T- or B-cells), 
which was a crucial adjustment to identify the association between CEBPB expression and 
muscle strength, and future studies will investigate this further. 
Future work: the replicability of this study is discussed in Chapter 4, however more studies of 
older people are needed to dissect the interaction with age. Data on specific cell subtypes is 
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essential to determine the origins of the associations observed. Developments in microarray 
and sequencing technology will allow a much more detailed analysis of isoforms, genes, and 
non-coding transcripts not available to test in the data. 
 
 
7.2.2 Chapter 4 – Muscle Strength – CHARGE Meta-analysis 
In chapter four I coordinated and performed a CHARGE meta-analysis on four independent 
cohorts (including InCHIANTI), and found that expression of 222 unique genes were 
associated with muscle strength in 7781 participants, after adjustment for confounding 
factors and multiple testing. Subsequent bioinformatic analyses included gene ontology 
enrichment analysis, text mining the literature, and utilisation of databases such as BioGPS 
[201] which displays the relative expression of genes across human tissues. 
The genes found to be significantly associated with muscle strength covered a variety of 
biological functions, and although “haemoglobin metabolic process” and “innate immune 
response” pathways were significantly enriched, only 33% of genes associated with muscle 
were in an enriched biological process. Genes hypothesised to be associated with muscle 
strength a priori included GDF11 (mouse model showed that supplementation of GDF11 
protein restored muscle function [3]), which was not associated with muscle strength, 
possibly highlighting different growth factor pathways for muscle in the circulation between 
mice and humans. IGF1R and IGF2BP2 (insulin-like growth factor-related genes) were 
significantly associated with strength in opposite directions (positive and negative, 
respectively). Both are implicated in glucose homeostasis and diabetes [69], [272]. I found 
that of the 222 genes, 115 had not been associated with the term “muscle” before in 
publications; this analysis therefore identified many novel genes to follow-up.  
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CEBPB expression was not significantly associated with muscle strength in this meta-
analysis. Using a power calculate (R package “pwr”) and following parameters (r=0.04 – this 
is the correlation coefficient between CEBPB and strength in InCHIANTI – alpha=0.05 and 
desired power of 0.8) suggests that a sample size of 4,903 should be sufficient to replicate 
the association. The lack of replication could be due to the lower average age in the meta-
analysis (weighted mean = 56 years, compared to 72 years in InCHIANTI, with >70% of the 
sample aged over 72). However, given the robust associations found in the primary analysis 
(Chapter 3; [183]), subsequent pilot study [184], and compelling biological plausibility from 
the mouse model [113], CEBPB deserves further investigation in ageing (in section 7.2.1 I 
note that CEBPB mediates the largest proportion of the association between age and muscle 
strength of any gene in the InCHIANTI study).  
The meta-analysis was performed in two parts; firstly the two FHS generations (which used 
Affymetrix exon arrays) were analysed together, secondly the three cohorts using Illumina-
based arrays (InCHIANTI, RS and SHIP) were meta-analysed together, and finally a meta-
analysis was performed on the summary statistics of these two models; the aim was to 
reduce the heterogeneity in the final meta-analysis by combining cohorts using the same 
array technology first. It is both a strength and a limitation of these studies that cohorts have 
used different array technologies; significantly replicating results are robust to array 
differences, giving confidence to the reported results, but heterogeneity in microarray design 
mean the measures may not be directly comparable, and in some cases genes/transcripts 
are only measured on one array, meaning replication is not possible. Future studies using 
new technologies can address this and discover more novel associations. 
Further investigation is warranted not only into the difference between mice and men 
regarding GDF11 and muscle strength, but also the 115 genes not previously linked to 
muscle strength in the literature. The role of IGF1 in skeletal muscle mitogenesis and 
glucose homeostasis is known [272], but the relation to IGF1R expression in whole blood is 
unclear. More detailed expression data and knowledge of cellular composition and origin 
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would help to shed light on the genes found. The results of complimentary CHARGE 
analyses of genetic and whole blood DNA methylation associations with muscle strength (the 
latter of which I will be coordinating) may provide further mechanistic insight. 
 
7.2.3 Chapter 5 – Cognitive Impairment 
In this analysis of whole blood gene expression and cognitive function in the InCHIANTI 
study I used gene ontologies and gene-set enrichment analysis to investigate inflammatory 
pathways, as well as utilising regression spline models to investigate the associations more 
thoroughly. This transcriptome-wide analysis of gene expression and cognitive function 
(measured using the MMSE criteria for identifying cognitively impaired individuals) found one 
near-significant association between CCR2 and MMSE in a linear regression model.  
There was an already-published lab model of CCR2-deficient mice displaying an accelerated 
Alzheimer’s-like pathology [214]. It was on the strength of the already published evidence 
and the stringent multiple-testing criteria that this study was published. Since publication 
there has been further evidence published – reviewed by ourselves and others [53] – that 
quite convincingly shows (albeit in mice) that bone marrow–derived microglia are CCR2+ and 
can restrict cerebral amyloidosis [273]. We note in Chapter 5 that the association we see in 
blood (CCR2 expression is negatively correlated with MMSE; cognitively impaired individuals 
express more) appears in contrast to the reports in mice. In collaboration with Serge Rivest – 
the principal investigator behind much of the CCR2 work in mice - we published an editorial 
in 2013 addressing this point and suggested that “Increased CCR2 expression in the 
cognitively impaired may be due to an increased demand for macrophage-mediated 
clearance of β-amyloid, caused by impaired phagocytosis by microglia and also the self-
perpetuating nature of the pro-inflammatory state of aging” [53].  
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The importance of the finding that CCR2 expression in peripheral blood was associated with 
cognitive impairment is clear, given the biological literature available; changes in expression 
of CCR2 may reflect differences in underlying cell-type composition, or instead reflect 
differential activation of monocytes, either of which may be interacting with peripheral and 
neuro-inflammation as the blood-brain-barrier becomes less distinct and permeable. Future 
studies need to identify whether CCR2 expression in peripheral blood has predictive value 
for those at highest risk, and whether steps can be taken to ameliorate the changes; here 
evidence from mouse models and human observational studies will be essential once again. 
This study is limited by the lack of follow-up data to help address causality, and by the lack of 
detailed cell-count information to determine the origin of the signal observed; as more data 
becomes available this will be investigated in a future research programme. The MMSE is 
designed to detect cognitive impairment, rather than cognitive ability per se (as it is the loss 
of function that is age-related, the MMSE is still useful), yet it is quite crude; 80% accuracy in 
identifying participants with no impairment vs. any impairment [274]. Future studies should 
use multiple measures of cognitive function and impairment. We plan to extend these 
findings to a longitudinal setting in the InCHIANTI study as more follow-up data of these 
elderly participants becomes available, and seek replication (and/or meta-analysis) with other 
cohorts. 
 
7.2.4 Chapter 6 – Age-related Inflammation 
Here I present the results of an analysis into gene expression transcripts from whole blood in 
the FHS study, with replication in the InCHIANTI study, and whether they statistically mediate 
the association between age and inflammation (interleukin-6, IL-6). This is distinct from the 
analysis of gene-expression transcripts associated with IL-6 that we participated in, which 
found 807 genes significantly associated with IL-6 independent of age [61]. This is a novel 
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analysis method in genomic research into age-related inflammation, and demonstrated that 
only a small number of specific genes mediated the age~IL-6 association.  
Twenty-five of the ninety significant genes in FHS replicated in InCHIANTI, with increasing 
replication as the “effect size” increased (5 of the top 10 genes replicated). I therefore 
focussed on genes mediating >5% of the age~IL-6 association. This analysis provided the 
first evidence that expression of SLC4A10 (a sodium bicarbonate transporter involved in pH 
homeostasis) in whole blood is associated with age-related inflammation, although the 
biology is not clear; mice with disrupted SLC4A10 showed reduced neuronal network activity 
and increased intracellular acidification [275], with other neuronal implications from a human 
patient with cognitive impairment and epilepsy [276]. However, other significant genes 
including IL1B (interleukin-1 beta) and PRF1 (perforin) are known to be involved in the pro-
inflammatory immune response, showing that mediation analysis is a valid analysis method. 
By constructing a mediation model rather than a simple linear regression adjusted for age I 
have discovered a small, distinct subset of IL-6-associated genes that statistically mediate 
the IL-6 association with age. Given the importance of age-related inflammation to ageing 
phenotypes and diseases [60] methods such as these that investigate the interaction 
between inflammation, age, and genes need further use and development to overcome the 
limitations encountered during this project. 
Regarding the mediation analysis methods, the package chosen to perform the resampling to 
determine confidence intervals for the estimates was not designed for multiple-testing 
adjustment; in order to adjust for multiple-testing the confidence intervals were modified from 
the traditional 95% to Bonferroni-adjusted confidence limits. As mentioned in the methods, 
this is a conservative multiple-testing adjustment and may have led to false-negative 
findings. In future analyses we will determine if the method can be modified to compute p-
values so that a Benjamini-Hochberg (or similar) adjustment could be made. Additionally the 
term “mediation” may be misleading in this context as it could imply causality; I stress that no 
causal inferences are drawn, as this is cross-sectional research and the mediation is purely 
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statistical. The only thing distinguishing a mediator and a confounder in this analysis method 
is the conceptual model developed at the start of the project. 
There are also significant limitations when comparing data from two different microarray 
platforms; it is impossible with this data to determine whether the low replication rate (25 of 
90 genes) is due to biological or technical differences between the cohorts (no doubt both 
contribute, but the degree of each is unknown). Future work should focus on dissecting the 
novel genes determined by this analysis (in particular SLC4A10) and determining the reason 
for the low replication rate; whether this difference is biological (cohort differences) or 
technical (differences in RNA handling, or sensitivity between the array platforms). 
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7.3 Limitations 
Studying RNA (and other biochemical markers) in whole blood has clear advantages, in 
particular to provide insights into mechanism (both up- and down-stream effects) and the 
possibility of easy-to-access biomarkers of disease. Yet the limitations must be considered 
when drawing any conclusions from this research. Firstly, a criticism of this research is the 
“whole blood” nature; that the tissue is heterogeneous with regard to its cell composition, and 
that the different subtypes of immune cell will differ in relative proportions between 
individuals, and could be related to the phenotype studied. This is an important 
consideration, and the results are only valid when bearing this in mind; whilst the methods 
adjust for the relative proportion of lymphocytes, neutrophils, monocytes and eosinophils, the 
association observed could be due to the ratio of B- to T-lymphocytes (for instance) also 
being associated with the outcome. This is still an interesting and relevant finding; that 
transcripts and cell-types are associated with ageing phenotypes. Future studies (including 
our own – see the next “Future Research” section) will aim to investigate the mechanisms 
behind gene expression associations, starting with whether the association is independent of 
or related to cell-type, and if the latter from which cell-type the signal originates.  
It is worth noting that as the concentration of cell-types in the sample decreases (e.g. B-cells 
comprise 9% of total lymphocytes in the InCHIANTI baseline data, and lymphocytes make up 
only 30% of total white blood cells) the contribution of that cell-type to the total RNA 
decreases, and a larger effect would therefore be required to have sufficient power to detect 
it in whole blood; therefore the signals we detect will mostly derive from expression in the 
larger fractions of the data, such as neutrophils (~60% of leukocytes in the InCHIANTI data). 
However, if a gene/transcript signal is specific to a particular cellular subtype in the whole 
blood sample, changes in expression (or relative proportion of the cells that are this subtype) 
could still be identified in smaller subsets; this is one reason why investigating genes in the 
BioGPS database [201] can be useful to suggest cellular origins. 
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Another important consideration often overlooked is the assumption that RNA levels 
correspond to protein levels. In an unpublished manuscript in 2012 Dr Nancy Kendrick [277] 
reports that in 4 separate studies examining the relationship between mRNA and protein 
levels the R2 values are below 0.4. The reasons suggested are many, and include post-
transcriptional regulation (e.g. degradation of transcript prior to translation), variations in half-
life of mRNA/protein, and the variety of functions of the proteins themselves, for example 
some proteins are highly stable (such as collagen, a structural protein) whereas others will 
have a much higher and more variable turnover, such as antibodies. Yet the study report by 
Kendrick only studied the amount of protein, let alone that which is active. Protein function 
can be greatly affected by the presence/absence of co-factors, or modifications such as 
acetylation; a recent study by Lozada et al demonstrated that de-acetylation of Werner 
syndrome protein affects it’s binding affinity to DNA structures, directly impacting its DNA 
damage response ability [278]. Therefore the research published in this thesis (RNA 
concentrations statistically associated with phenotypes) must be considered in this context; 
although production of RNA may be associated with a phenotype, for protein-coding 
transcripts this may not correspond directly to differential protein production or activation. 
However, given the complex relationship between RNA and protein (and taking into account 
that many transcripts do not code for proteins but are functional molecules in their own right), 
including not least the effects of alternative splicing and isoform usage, the variability in 
protein activation (be it through phosphorylation or co-factor) and half-life, it still seems a 
valid assumption that increased production of RNA is related to demand for that RNA at that 
time-point. 
Population studies themselves are not without limitations and systematic errors, some of 
which are overcome when seeking independent replication in other cohorts. These include, 
but are not limited to, residual confounders (unaccounted factors that confound relationships 
[279]), learning effects (as participants make repeat visits they may perform better in some 
tests as they get better at them, for example MMSE [280]), selection bias (not everyone in 
the population will participate in a study, for instance particularly unwell or disabled 
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individuals [281]), and, similarly, loss to follow-up (when participants are followed for 
significant periods of time, those who become unwell or disabled may no longer participate) 
[282]. The ideal design for a study in molecular epidemiology would be a large population 
with a good response rate, with DNA, RNA and a host of other biochemical and cell-type (as 
well as general) phenotypes available at baseline, with a number of follow-up visits, including 
links to medical records. In this way cause and effect could be suggested without a number 
of bias’ discussed in this section. 
There are also technical and analytic considerations, in addition to the biological ones. Linear 
regression models make several key assumptions; that the association between the 
dependent and independent variables are linear; that the residuals (error in prediction) are 
normally distributed; and that the variance of the prediction errors are consistent [283]. In 
practical terms when performing large-scale analysis it is optimal to perform the analysis on 
normalised and quality controlled data, and then explore in further depth the output of such 
analyses to assess the validity of the model. If multiple different tests (e.g. non-linear 
regression variants) were performed on each gene expression probe this would increase the 
multiple testing problem dramatically (a challenge inherent when using frequentist-based 
statistics reliant on p-values, where performing a large numbers of parallel tests – such as on 
many gene expression probes - could produce many false-positive results without adjusting 
the p-value threshold [132]). 
Gene ontology enrichment (pathways) analysis also has important considerations. The 
methods for testing enrichment tend not to take into account direction or magnitude of 
association, nor do they weight genes relative to one another or assign particular functions to 
gene interactions (e.g. gene A inhibiting gene B is not taken into account) [284]. Additionally, 
strength of association (one of the key tenets of causality in epidemiology [285]) is not 
always apparent, for instance in Chapter 4 the haematology pathways were the most 
statistically significant but did not contain the largest number of genes associated with 
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muscle strength. However, these methods are still useful for providing additional and 
simplified biological insight to a list of genes, albeit with caveats. 
Finally, microarray data is inherently limited to the specific probes present on the array; not 
only does this mean de novo transcripts will not be measured, but the probes have differing 
binding qualities (affinities) to transcripts, potentially leading to bias. In two chapters there are 
results from two array platforms, which may differ in their expression profile capture. 
Unfortunately it was not possible with this data to compare the two platforms on samples 
from the same individual. To have a truly transcriptome-wide, hypothesis free approach, we 
need a different kind of data, possibly utilising second-generation sequencing approaches 
such as the Illumina RNA-Seq platforms, however this was not within the scope of this 
project and will be addressed by future studies, and of course come with their own bias’ and 
considerations. Many RNAs transcribed by cells are not protein-coding, and the ENCODE 
project is revealing that regulation of transcription of mRNAs and non-coding RNAs is 
complex [286]; multiple levels of data are required to get even a basic understanding of the 
factors involved in regulating transcription and translation.  
Microarrays correlate only moderately to “gold-standard” PCR approaches, both in the 
literature (R=0.5 for Illumina-based microarray and PCR, albeit in mice [287]) and in the 
InCHIANTI study, for example the Illumina probe for CEBPB was significantly correlated 
(pairwise comparison R=0.3, p<0.05) with the PCR data in Chapter 3, but only modestly. 
This could be due to cross-hybridization of probes, low-sensitivity, or measurement of 
different isoforms/transcripts [287]. Additionally there are other potential sources of technical 
variation, including the collection of the RNA (PAXgene tubes used in InCHIANTI to stabilize 
RNA prevent degradation [288]), the choice of normalisation procedures to account for 
systematic technical variability [289] (although much of this is handled by Illumina’s 
“GenomeStudio” there are other choices, including how to account for batch effects, that are 
less clear), the unavailability of a measure of RNA integrity in the InCHIANTI participants 
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(although the PAXgene extraction kits leave very pure samples, with A260/A280 values 
between 1.8 and 2.2, from www.qiagen.com), and the lack of globin reduction in InCHIANTI. 
The alternative splicing of gene transcripts may also be obscured by the use of microarrays; 
work in our group (which I have contributed to) found that expression of specific splicing-
factors associated with age and senescence [80], and that the ratio of isoforms of genes can 
also be age-associated [79]. This is relevant to the microarray probes if, for instance, a 
particular probe only captures one isoform, or if the probe captures all indiscriminately; the 
former would result is a negative/positive association which may not be the whole story if an 
undetected isoform is expressed instead, and the latter would identify a gene where the ratio 
of different isoforms was associated with the phenotype, but not “total expression.” 
Despite the limitations these kinds of studies have value; the opportunity to discover 
biomarkers and gain insight into mechanisms related to ageing in humans is unprecedented, 
and over the last three years the field has been transformed and now many studies can work 
together in large and detailed meta-analyses. However, caution must be used to not “over 
interpret” the data; these studies may be confounded, and make no claims as to the final 
protein abundance. Nor are any causal inferences made; links between mechanism and 
association are hypotheses based on existing knowledge and observations.  
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7.4 Discussion of Thesis 
This thesis reports four data chapters that have explored the relationships between ageing 
phenotypes and molecular markers, specifically gene expression. This includes not only 
transcriptome-wide scans of gene/phenotype associations, but meta-analysis, mediation 
models, gene-set enrichment, pathways, clustering, text-mining, and other bioinformatic 
techniques. The de novo discovery of genes associated with ageing phenotypes in human 
whole blood samples has made an important contribution to the literature, and foundations 
are in place to continue this work on a much larger, collaborative scale, as more diverse 
cohorts are able to replicate and extend these analyses prospectively (future research 
discussed in section 7.5).  
Mouse model experiments have demonstrated that ageing phenotypes such as 
neurodegeneration can be reversed by exposing aged animals to young blood [5] (and vice 
versa). An experiment comparable to the heterochronic parabiosis mice (surgically attached 
so that they share a circulatory environment) in humans is not ethically feasible, so we 
cannot test whether the older tissues can be rejuvenated by exposure to young blood (or 
specific factors therein) and must rely on observational data until suitable model systems are 
generated. In Chapter 4 I examined the relationship between expression of GDF11 – 
supplementation in mice rejuvenates aged muscle [3] – and muscle strength and found that 
there was no association (nominal p>0.05). Although as suggested in that chapter it may be 
that the growth factor pathways are different in humans to mice, equally it could be that 
circulating GDF11 protein is not derived from blood cells; it is currently not known what tissue 
produces circulating GDF11 [3], but examining the BioGPS database of expression in many 
tissues types shows that GDF11 expression is ubiquitous across all assayed cell types, 
including many blood cell types (Figure 7.1). This suggests that if expression of GDF11 in 
whole blood is associated with muscle strength in humans we should have detected it in this 
analysis. Therefore GDF11 is either not expressed by blood cells in humans in relation to 
strength, or alternative circulating factors to GDF11 may drive the ageing of human tissues, 
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and could include the genes identified in Chapter 4 such as insulin-like growth factors. 
Follow-up studies are needed. 
Figure 7.1 | Relative GDF11 expression in different human cell types, data from BioGPS 
GDF11 expression data from BioGPS [201] dataset “GeneAtlas U133A gcrma”  [290] in 
which 79 human tissues were profiled for the relative expression of 15,491 human RefSeq 
genes. 
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It is clear that extensive reviewing of existing literature should be a priority for all such 
studies; for both muscle strength and cognitive function the hypothesis-free approach of 
assessing all available genes found evidence in animal models for mechanistic associations 
with the phenotypes. Novel links between genes and muscle strength and age-related 
inflammation have been discovered and, where possible, suggestions made as to the causal 
pathways. Many other published epidemiological studies of genetic and transcriptomic 
associations do little more than report associations, yet utilising the literature on experiments 
in model organisms and using services such as BioGPS [201] to investigate the relative 
expression of genes in many cell types is of great value when seeking insight into 
mechanism. In particular, it provides evidence for biological plausibility of the statistical 
associations observed in humans, an important component required to draw conclusions 
regarding causality. 
Although subject to limitations (discussed in section 7.3), the conclusions drawn in each 
chapter are based on empirical human observational data combined with experimental data 
from the literature. These studies have taken us further along the road to understanding, and 
have provided direction for future researchers (including myself and others in the group). I 
have presented associations between genes, muscle strength, cognitive function and age-
related inflammation in an elderly human population, and discussed plausible biological 
mechanisms based on existing literature. These studies show that observational studies of 
whole blood in humans add value to the literature; it is becoming increasingly apparent that 
circulating factors can have a huge impact on systems as seemingly disparate as strength 
and cognition [3], [4], and human observational evidence can highlight which pathways 
identified in model organisms are of the highest priority. 
In 2005 it was proposed by John Ioannidis that the majority of publications in the medical 
literature are false [291] - that many positive findings do not translate to the “real world” (the 
paper was in particular focussing on trials and drug discovery, and has subsequently been 
replicated and extended by Bayer Healthcare [292]). Replication and generalizability of 
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findings is therefore a priority, emphasised both by the differences between cohorts in the 
meta-analysis of muscle strength (Chapter 4), and the disparity of the results between the 
microarray platforms in the analysis on inflammation (Chapter 6). 
Follow-on studies not included in this thesis, but which relate to these studies and enhance 
the interpretation, are important, not only for validating observational findings but 
understanding more of the biology. We collaborated with colleagues in the Sport and Health 
Sciences department and found that, in a pilot study of 16 participants, CEBPB expression in 
whole blood increases in response to muscle damage following exercise [184]. This pilot 
shows that it is possible to observe the relationship between CEBPB expression and muscle 
repair over time, which coincided with the time course proposed by Tidball et al [47]. Next, 
studies should investigate whether this CEBPB expression response to exercise-induced 
muscle damage changes with age. Additionally, we collaborated with Rivest et al in an 
editorial discussing the implications of the CCR2 expression association with cognitive 
function in InCHIANTI, and the possible mechanisms [53], as noted in Section 7.2.3. 
I have assessed three ageing phenotypes (muscle strength, cognitive impairments, and 
increased inflammation) in separate manuscripts, yet viewing ageing holistically these are 
interconnected processes; maintenance of muscle strength requires an orchestrated immune 
response, and inflammation is associated with cognitive decline. Throughout the course of 
these projects it has become increasingly apparent that studying whole blood in the context 
of ageing and humans is valuable; not only is the tissue easily accessible and already 
routinely collected, but the immune system and circulating factors are central to many ageing 
processes. Luigi Ferrucci (central to our involvement with the InCHIANTI study) and Claudio 
Franceschi, among others, have been studying this for some time [48], [242], and have 
provided great insight into the associations with age-related diseases and the possible 
evolutionary causes (respectively). In summary, the immune system is optimized to respond 
efficiently to acute infections but does not respond appropriately to long-term chronic 
conditions, such as those in ageing; the latter results in sustained innate immune activation 
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which suppresses the anti-inflammatory response and leads to progressive tissue damage 
[48]. Ferrucci et al found that a number of pro-inflammatory cytokines increase with age and 
are related to cardiovascular risk and morbidity, although the causal direction is unclear 
[242]. This is a central point; although age-related inflammation is damaging to multiple 
tissues and is associated with risk of disease, I show in Chapter 6 that expression of IL6 in 
blood is not positively associated with IL-6 (protein) in elderly individuals. This supports other 
studies suggesting that circulating IL-6 is produced by senescing peripheral tissues [110], 
and further suggests that the innate immune activation may be due to, rather than causing, 
the initial increase in pro-inflammatory cytokines; the inability of the immune system to 
respond with an anti-inflammatory resolution then creates a positive feedback loop as it 
causes even more damage via the pro-inflammatory processes. 
Given the relationship between the immune system, systemic inflammation, ageing, and 
declining function including loss of strength and cognitive ability, determining the 
mechanisms of these interactions and developing therapeutics to postpone age-related 
phenotypes and morbidities are of high importance. Currently it is not known whether 
reducing inflammation could improve health and functioning in elderly people [247]. Studies 
such as those presented in this thesis are of great importance to the wider research field by 
identifying novel genes in age-related phenotypes, and highlighting experimental models of 
particular relevance.  
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7.5 Future Research 
There are clear advantages and limitations to studying RNA levels in the blood, as noted in 
the previous sections. In future research the relationship of specific proteins must also be 
sought. For instance, secreted GDF11 - a cytokine (member of the TGF-β superfamily) - is 
reported as being age-associated (negatively), and supplementation in mice ameliorates the 
age-related dysfunction of skeletal muscle [3]. Yet in the InCHIANTI study, probes for GDF11 
mRNA are not associated with age or muscle strength (p>0.05 in both cases). It could be that 
we are looking in the wrong tissue/cell type, that the age-/muscle-related regulation occurs 
post-transcriptionally, or that the effect was specific to mice and does not directly translate to 
humans. Although mRNA levels are a proxy for demand for proteins, this was not empirically 
tested in these studies and it would be of great benefit in future studies to determine the 
accuracy of this assumption (that mRNA is a proxy for protein); it would also be of great 
benefit to compliment this with sequencing-based approaches to RNA quantification, to 
capture novel and non-coding RNAs too. 
Meta-analysis of gene-expression and muscle-strength associations in the CHARGE 
consortium highlights the variability of gene-expression associations, and the necessity to 
replicate. We are contributing to a wide-range of phenotypes within this consortium, the 
results of which are yet to be published and are not included in this thesis, although they 
broadly fall into this area of research. Within the gene-expression working group analyses 
include inflammation (C-reactive protein, CRP), blood pressure, lipid levels, fasting glucose, 
tobacco exposure, and others. The strength of these studies are increased power and 
confidence in the result; if a gene is found to be associated with a phenotype across diverse 
populations, using different technologies, this is much less likely to be a false-positive; the 
field is now benefitting from many populations having this data and who are willing to 
collaborate on meta-analyses – this is a recent phenomenon, not possible even 3 years ago. 
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Similar approaches are being taken investigating the associations of epigenetic – particularly 
DNA methylation – associations with common diseases of ageing. Within CHARGE the 
epigenetics working groups are investigating multiple ageing phenotypes, including many of 
those listed previously. The InCHIANTI working group, including myself and others, are 
contributing to and will lead some of these analyses. 
Naturally, the next questions once we have established expression and/or epigenetic profiles 
associated with common diseases of ageing in human peripheral blood include (but are 
certainly not limited to);  
1. Do they have any prognostic value?  
2. Are the associations driven by specific immune subtypes? 
3. What are the causal mechanism(s) behind the associations?  
4. Can interventions be developed for the processes indicated by these associations to 
prevent or delay adverse outcomes? 
These questions provide an order to which the answers may arise; as more follow-up data is 
available in cohorts with gene-expression/epigenetic data question 1 becomes more feasible; 
questions 2 and 3 are similar, and ask why the association is observed (if the association is 
due to a specific immune subtype we would then go on to ask what the causal mechanism 
is); and finally if a causal mechanism can be determined, could this be an option for 
treatment/prevention/postponement of disease? 
Many of these questions are the subject of current studies, whereas others will depend on 
the results of these. For instance in InCHIANTI, the participants visited the clinic again in 
2014, 5-years after the gene-expression measurement, so we will soon be able to test the 
predictive nature of whole blood gene expression in an aged population. In the Baltimore 
Longitudinal Study of Aging (BLSA – a project with even more extensive phenotyping than 
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InCHIANTI, to which we will have access courtesy of Professor Melzer’s long-standing 
collaboration with Dr Luigi Ferrucci at the United States National Institute on Aging (NIA)) a 
subset of participants with RNA measurements are also having their immune cell-types 
quantified for ~60 different cell-types, so we can hopefully address (to some degree, at least) 
which cell types are statistically interacting with observed associations with ageing 
phenotypes. 
Follow-on or parallel experiments in model organisms are also a possibility; the Epidemiology 
and RNA groups in Exeter are forging collaborations with the United States NIA mouse 
centre. This will give unique opportunities to not only retrospectively look at what has already 
been done based on our results, but to design longitudinal experiments to test (in multiple 
tissues) the nature of the associations we observe. The translation and synergy between 
mice and human experiments will provide the greatest insight and efficiency to take this 
research forward. 
 
  
 PhD Thesis | Luke Pilling 
185 Chapter 7 – Discussion and Conclusion 
7.6 Conclusion 
Ageing is regarded as declining physiological function with age, accompanied by increased 
susceptibility to age-related diseases. Ageing research aims to improve healthspan in older 
humans. Mouse-model experiments suggest that the ageing process is plastic – that tissues 
retain the capability to rejuvenate – and can be modified to improve healthspan, in particular 
via specific circulating factors; however translation to humans remains unclear.  
In these epidemiological studies I have designed analyses that investigate transcriptome-
wide data derived from whole blood samples from human population study participants, 
aiming to determine biomarkers and gain mechanistic insight. This includes whole-
transcriptome scans to determine gene transcripts associated with age-related phenotypes, 
and includes a meta-analysis of multiple human cohorts, mediation analysis to dissect age-
related inflammation, and pathway-based and clustering methods to gain insight into 
relatedness between genes in terms of function and expression profile.  
I have provided evidence supporting the link between age-related inflammation, loss of 
muscle strength, and loss of cognitive function. I have highlighted links between mouse-
models and human phenotypes, with the potential for these genes to be used as predictive 
markers once follow-up data becomes available. In particular; CCR2-monocytes may be key 
for cognitive ageing and dementia; innate-immune activation is associated with muscle 
strength across a wide age-range; and age-related chronic inflammation is mediated by a 
small number of genes in whole blood, some of which are also related to ageing phenotypes. 
The findings presented in this thesis provide a platform to continue research into molecular 
mechanisms and biomarkers of ageing phenotypes, including longitudinal and epigenetic 
data. I have demonstrated that overlap exists between model organisms and human ageing 
phenotypes and that observational molecular epidemiology is essential to highlight those of 
the greatest relevance. 
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Chapter 8 – Appendix 
 
8.1 Contributions to other projects 
During the course of the PhD I have contributed to a number of related projects within the 
group and in collaboration with others; 
 
8.1.1 mRNA splicing and ageing 
 Holly et al (2013) Changes in splicing factor expression are associated with advancing 
age in man. [80] 
 Holly et al (2014) Splicing Factor 3B1 hypomethylation is associated with altered SF3B1 
transcript expression in older humans. [293] 
 Holly et al (2015) Comparison of senescence-associated miRNAs in primary skin and 
lung fibroblasts [294] 
 
8.1.2 mTOR pathway analysis 
 Harries et al (2012) Advancing age is associated with gene expression changes 
resembling mTOR inhibition: evidence from two human populations. [295] 
 Fellows et al (2012) Age related changes in mTOR-related gene expression in two 
primary human cell lines. [296] 
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8.1.3 CHARGE (and similar) meta-analyses 
 Hek et al (2013) A genome-wide association study of depressive symptoms. [297] 
 Lin et al (2014) Whole Blood Gene Expression and Interleukin-6 Levels. [61] 
 Peters et al (2015) The transcriptional landscape of human age. [76] 
 Huan et al (2015) A Meta-analysis of Gene Expression Signatures of Blood Pressure and 
Hypertension [298] 
 Ibrahim-verbaas et al (2015) GWAS for executive function and processing speed 
suggests involvement of the CADM2 gene [299] 
 
8.1.4 Ecotoxicology 
 Fletcher et al (2013) Associations between PFOA, PFOS and changes in the expression 
of genes involved in cholesterol metabolism in humans. [300] 
 Galloway et al (2015) PFOA and PFOS are associated with reduced expression of the 
parathyroid hormone 2 receptor (PTH2R) gene in women. [301] 
 
8.1.5 Reviews and editorials 
 Pilling et al (2012) Genomics and Successful Aging: Grounds for Renewed Optimism? 
[23] 
 Harries et al (2013) Alzheimer’s pathology: should peripheral monocytes and CCR2 take 
center stage? [53] 
 Melzer et al (2013) Gene Expression Biomarkers and Longevity. [302] 
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8.1.6 Other studies 
 Dutta et al (2013) Uric Acid Measurement Improves Prediction of Cardiovascular 
Mortality in Later Life. [26] 
 Holly et al (2013) Towards a gene expression biomarker set for human biological age. 
[88] 
 Winiarski et al (2014) Clinical Relevance of Increased Endothelial and Mesothelial 
Expression of Proangiogenic Proteases and VEGFA in the Omentum of Patients with 
Metastatic Ovarian High-Grade Serous Carcinoma. [303] 
 Blackwell et al (2014) Changes in CEBPB Expression in Circulating Leukocytes following 
Eccentric Elbow-Flexion Exercise. [184]  
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